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" Every passion of the mind which troubles
mens spirit, either with grief, joy, hope or
anxiety and gets access to the heart, there
makes it to change from its natural constitution
by distemperament, pulsation and the rest..."
Harvey W, 1628
Exercitatio Anatomic de Motu Cordis et Sanguinis
in Animalibus; Francofurti Edition 1628. (Keynes
English Translation, 1928).
HYPOTHESIS
Direct liberation of catecholamines from acutely ischaemic
myocardium acts as a trigger to promote early ventricular
arrhythmias. Altered neurosympathetic activity may be observed by
comparison of local arteriovenous catecholamine differences across
ischaemic and non—ischaemic areas of the open—chest anaesthetised
dog model during coronary artery occlusion under conditions of
varying sympathetic tone. Interaction between the sympathetic
nerve terminal, metabolic disturbances and adrenoceptor activity
is likely in determining the arrhythmogenic action of
catecholamine release during acute ischaemia. This model may
provide increased understanding of the mechanisms of sudden
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Clinical and experimental evidence implicates the sympathetic
nervous system as a possible trigger for lethal ventricular
arrhythmias in ischaemic myocardium. Short term coronary occlusion
in the open chest anaesthetised dog has been used as a model to
study the activity of the sympathetic neuroeffector junction and
its relationship to early ventricular arrhythmias. Regional
sampling of coronary venous effluent on a minute-to-minute basis,
estimation of myocardial blood flow and documentation of
arrhythmias and epicardial activation abnormalities have been
correlated with stimulation and pharmacological manipulation of the
sympathetic nerve terminal to provide a combined biochemical,
neuropharmacological and electrophysiological approach.
Spontaneous release of noradrenaline [NA] from ischaemic
myocardium [I] and non-ischaemic myocardium [NI] is not observed
during a ten minute period of regional ischaemia but does occur
from [I] during early coronary reperfusion. Spontaneous
ventricular fibrillation produces a secondary rise in systemic and
myocardial catecholamines, usually a consequence rather than a cause
of this arrhythmia. Adrenaline [A] extraction across [I] is
enhanced during coronary occlusion and is abolished during early
reperfusion. [NA] release from [I] during graded stimulation of
the left stellate ganglion is maintained during the two early
phases of enhanced vulnerability to arrhythmias but is selectively
inhibited from [I] thereafter. Detrimental effects of sympathetic
stimulation on epicardial activation abnormalities are seen only at
the times of enhanced arrhythmia vulnerability.
Inhibition of neuronal re-uptake (desmethylimipramine) and
attenuation of pre-synaptic alpha-adrenoceptors (yohimbine)
potentiates nerve-stimulated [NA] release from the heart during
regional ischaemia and is arrhythmogenic, intensifying activation
abnormalities and further reducing blood flow to [I]. Spontaneous
[NA] release from the heart during regional ischaemia is, however,
only seen with these agents in combination. Both mechanisms for
atten uation of sympathetic activation appear enhanced in [I]
although the ability of re-uptake blocking drugs to inhibit
enhanced l-H^-NA extraction across [I] is impaired.
Regional intracoronary potassium infusions exert biphasic
effects on nerve-stimulated release of [NA] from the heart, being
inhibitory at low concentration and stimulatory at high
concentration with an increase in coronary vascular resistance.
Both actions may coexist during regional ischaemia. Intracoronary
adenosine infusions potentiate basal [NA] release from the heart
but inhibit release during maximal sympathetic stimulation.
Coronary vascular resistance during sympathetic stimulation is
unchanged by adenosine despite major reduction in basal coronary
vascular tone.
The beneficial actions of pindolol on arrhythmias, epicardial
activation abnormalities, regional myocardial blood flow
distribution and lactate release from [I] are principally secondary
to reduction in heart rate and are substantially abolished by
atrial pacing. This drug, however, reduces blood flow variance
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within [I] and peak [NA] release from [NI] during sympathetic
stimulation.
A potential source of error in the use of radioligands to
quantify myocardial beta-adrenoceptors in crude membrane
preparations is presented. False positive co-operative
interactions may be suggested during 1^25 iodohydroxybenzylpindolol
binding at low concentrations, due to interference by endogenous
catecholamines. Preliminary studies using radioligand binding to
the heart in vivo demonstrates the feasibility of this technique
and changes in adrenoceptor binding during ischaemia. Non-specific
binding limits the sensitivity of this approach.
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INTRODUCTION AND LITERATURE REVIEW
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SUDDEN CARDIAC DEATH: THE PROBLEM
Sudden cardiac death, occuring within the first few minutes of
symptoms of acute myocardial ischaemia or infarction as a result of
coronary heart disease, remains the major therapeutic enigma in
modern medicine. Between 35 and 64 years of age, one death in
three results from the consequences of coronary heart disease
(Gordon and Kannel, 1971) and in North America some 350,000 sudden
cardiac deaths occur annually, accounting for over 50 per cent of
total coronary mortality (Goldstein, 1974). The problem is
particularly prevalent in Scotland where almost 40% of all male
deaths in the 35-64 age group are secondary to ischaemic heart
disease (Fulton et al, 1978). Despite the declining trend in
cardiovascular mortality from the mid 1970's, particularly in North
America, (Thorn and Kannel, 1981), sudden coronary death is likely
to remain for the foreseeable future one of the most important
causes of premature death in the Western World (Epstein and Pisa,
1979) .
Epidemiological data are of value in the identification of
subjects at risk from coronary heart disease but risk profiles
based on conventional indices (cigarette consumption, lipids, blood
pressure, family history, body weight, electrocardiogram) have
consistently failed to predict sudden death compared to other
clinical manifestations of the disease (Vedin et al, 1973; Kannel
et al, 1975; Doyle et al, 1976). It is likely that sudden death
from coronary disease is related more directly to pathological and
metabolic changes in the heart and their consequences, than to the
factors predisposing to these changes.
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Mechanisms
The great majority of sudden deaths result from ventricular
fibrillation, a mechanism first suggested by MacWilliam as early as
1889 and documented electrocardiographically 25 years later
(Halsey, 1915). Holter monitoring during sudden cardiac death has
now confirmed that ventricular fibrillation is the principal
arrhythmia in 80 per cent of patients, usually preceded by varying
periods of ventricular tachycardia (Nikolic et al, 1982). Atypical
ventricular tachycardia (Torsade de Pointes) with an increase in QT
interval immediately prior to the arrest has been documented in up
to 40 per cent of cases (Panidis and Morganroth, 1982; Pratt et al,
1982). Intensive study of the mechanisms of this arrhythmia
strongly supports a central role for single or multiple re-entry
circuits within the heart as the basic electrophysiological process
involved. The concept of circulating excitation in the heart is
not new (Mines, 1913) and has been discussed throughout most of
this century as a possible mechanism for ventricular fibrillation
(Garrey, 1914; Lewis, 1920). In circus movement re-entry, the
initiating impulse encounters an area of unidirectional block and
propagates round the area of block via alternative pathways. If,
as typically occurs during acute myocardial ischaemia, conduction
is slow enough, tissue in the area of block can recover its
excitability and the impulse can propagate retrogradely through
this area emerging as a re-entrant wavefront at its site of origin.
The likelihood of re-entry is therefore enhanced by a lengthy
re-entry pathway, slow conduction velocity and by shortening of
refractoriness. Inhomogeneities in refractoriness between adjacent
cells may create focal areas of undirectional block and further
potentiate the process. Several studies have shown fragmentation
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of extracellular electrograms during acute and chronic ischaemia,
with diastolic bridging between successively conducted beats
(Durrer et al, 1961; Waldo and Kaiser, 1973; Scherlag et al, 1974;
El-Sherif et al, 1975, 1977). This favours re-entrant activity in
the genesis of arrhythmias and highlights heterogeneous activation
patterns in the myocardium during ischaemia.
Recent experimental work has mapped circus movement re-entry
during ventricular tachycardia showing the development of multiple,
often incomplete, circuits of smaller diameter (approximately 0.5
cm) during ventricular fibrillation (Janse et al, 1980). A similar
pattern has been documented in patients with ventricular
tachycardia (Josephson et al, 1978). Such patterns have not been
observed during sinus rhythm or after single ectopic beats. Injury
currents at the border zone between ischaemic and normal tissue may
generate ectopic activity from the non-ischaemic border zone which
may act as the initiator of the re-entrant impulse (Janse and
Kleber, 1981).
Ventricular fibrillation thus results from chaotic
fractionated activity of the heart. Intracellular recordings have
shed little light on mechanisms of pathogenesis partly because
asynchrony of activity is only demonstrable in fibres separated by
10 mm or more (Hogancamp et al, 1959). A critical mass of
myocardium is a prerequisite for sustained fibrillation. Atrial
fibrillation, for example, is not maintained in less than one gram
of tissue (Moe and Abildskov, 1959).
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Anatomical substrates
It is probable that most sudden coronary deaths occur in the
setting of transient myocardial ischaemia rather than evolving
infarction. Thus, the Seattle experience documented acute
transmural myocardial infarction (the development of new Q waves)
in under 20 per cent of patients during hospitalisation following
resuscitation from ventricular fibrillation (Cobb et al, 1980).
Combined data from three counties in Ohio and Michigan revealed a
higher incidence of infarction in such patients (44 per cent)
although still only in the minority (Goldstein et al, 1981).
Post-mortem studies have shown the high prevalence of severe
coronary obstruction of major vessels (Perper et al, 1975;
Reichenback, 1977). Coronary angiography in survivors of
ventricular fibrillation confirms the high prevalence of major
occlusive disease. None of the coronary arterial systems were
affected more frequently than the others, with 56 per cent of 29
Seattle survivors showing greater than 70 per cent stenoses in the
left arterior descending, 61 per cent in the circumflex and 41 per
cent in the right coronary arteries (Cobb et al, 1975). One, two
and three vessel disease was fairly equally distributed among this
group. In a small subgroup of patients with a second episode of
ventricular fibrillation or sudden death, angiography revealed more
extensive coronary disease and increased left ventricular wall
motion abnormalities (Weaver et al, 1976). Most patients dying
suddenly have evidence of a previous episode of myocardial damage
(gross or microscopic), often without prior history of cardiac
disease (Newman et al, 1982). Many morphological studies suggest
that few acute lesions are present in either the myocardium or the
coronary tree (Spain and Brades, 1970; Lie and Titus, 1975;
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Schwartz and Gerritz, 1975; Reichenback et al, 1977). Antemortem
coronary thrombosis is rarely found; no distinctive pattern of
coronary artery involvement has been identified. Although often
depressed, left ventricular ejection fraction may be maintained in
survivors of sudden cardiac death. Using radionuclide angiography,
Ritchie et al (1982) found an ejection fraction of greater than
fifty per cent in one third of 153 survivors of out of hospital
ventricular fibrillation. The mean ejection fraction was 41 per
cent, falling to 38 per cent during exercise. Patients
resuscitated from ventricular fibrillation secondary to myocardial
ischaemia are predisposed to recurrence of the arrhythmia with a 26
per cent mortality at a year and 36 per cent mortality at two
years. The median time for recurrence of the arrhythmia from the
Seattle study was only 20 weeks (Schaffer and Cobb, 1975). It is
also clear that out-of-hospital ventricular fibrillation without
infarction carries a significantly worse prognosis than that
following infarction with a mortality rate three times greater at
two years (Cobb et al, 1975). The poorer prognosis of survivors of
out-of-hospital cardiac arrest compared to survivors of myocardial
infarction has been confirmed by others (Eisenberg et al, 1982).
Prediction
If premonitory symptoms of impending ventricular fibrillation
could be identified, sudden death might be avoided by rapid
transportation of the patient to resuscitation facilities,
preferably a coronary care unit. In two studies up to 40 per cent
of patients had sought medical attention in the weeks prior to
their death, but their symptoms were too vague to have been
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reasonably construed as coronary heart disease (Fulton et al, 1972;
Kuller et al, 1972). The Framingham and Albany studies showed that
few patients reported prodromata in the days and hours prior to
their death (Doyle et al, 1976).
Chronic markers of risk for sudden cardiac death have proved
similarly unreliable. The mere presence of intermittent
ventricular extrasystoles during a one hour period of monitoring
did not increase the likelihood of sudden cardiac death over a
period of three years in 1739 patients with prior myocardial
infarction jhowever advanced grades of ectopy increased the
incidence of sudden death three fold (Ruberman et al, 1976).
Although advanced grades of ventricular ectopy tend to occur in
patients with impaired ventricular function, it is the former
rather than the latter that is the main determinant of the
probability of sudden death in this group (Schulze et al, 1977).
Holter monitoring in survivors of cardiac arrest has confirmed the
high prevalence of ventricular ectopy with two thirds of 144
patients showing complex patterns including bigeminy, trigeminy,
repetitive or multiform ventricular activity. Over half of this
group died from a subsequent arrest (Weaver et al, 1982).
Unfortunately, however, this type of data comes from known high
risk subgroups who form a small proportion of the population as a
whole. Multiple myocardial infarctions, poor left ventricular
function, cardiomegaly and heart failure are all adverse prognostic
factors for cardiovascular mortality but it is not clear that
death, when it comes, is more likely to be sudden in those with
overt myocardial dysfunction (Gordon and Kannel, 1971). Indeed,
the proportion of coronary deaths that are sudden in high risk
groups is approximately 50 per cent, similar to that for the
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general population (Kannel and Thomas, 1982). In almost 25 per
cent of patients, sudden death is the first clinical manifestation
of the disease (Lown, 1979) . Recent aggressive approaches towards
the control of observed and provokable arrhythmias may reduce the
risks of sudden death in selected subgroups (Horowitz et al, 1980;
Ruskin et al, 1981; Graboys et al, 1982), but until the arrhythmia
can be accurately predicted, such measures are unlikely to have a
major impact on the clinical problem as a whole. Clearly, a better
understanding of the mechanisms triggering the arrhythmia is
essential before rational preventative measures can be applied.
SYMPATHETIC NEURAL INFLUENCES IN NON-ISCHAEMIC MYOCARDIUM:
DETERMINANT OF ELECTRICAL STABILITY
The hypothesis that neural factors, initiated locally,
reflexly or from direct activation of higher brain centres, may
trigger electrical instability and predispose the heart to
ventricular arrhythmias is supported by considerable clinical and
experimental evidence.
Sympathetic preganglionic fibres usually leave the spinal cord
via the second, third and fourth thoracic anterior roots and pass
from the stellate and caudal cervical ganglia to the heart (Randall
et al, 1957). Anatomically, many similarities exist between the
sympathetic innervation to the heart in man and that in the dog
(Randall and Armour, 1977). Sympathetic fibres from the right and
left side enter the heart round the adventitia of the great vessels
and the atrial walls and form extensive nerve plexuses throughout
the heart. Their projection corresponds to that of the main
coronary arteries with distribution to surrounding tissue largely
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by subepicardial routes. This has been demonstrated by surgical
epicardiectomy (Szentivanyi et al, 1967) and the application of
phenol to the epicardium (Randall et al, 1968), a compound
producing tissue damage to a depth of approximately 0.25 mm (Kaye
et al, 1968). Interestingly, vagal fibres do not appear to be
disrupted by this manoeuvre (Martins and Zipes, 1980), in keeping
with greater density of acetylcholinesterase staining in
ventricular endocardium than epicardium (Kent et al, 1974).
Adrenergic innervation is particularly rich in the sinoatrial node
and to a lesser extent the atrioventricular node region. The
adrenergic innervation of the ventricle is lower in density than in
the atrium and tends to be less concentrated in the apical compared
to basal portions of the ventricle (Randall and Armour, 1977).
Although central or stellate sympathetic stimulation results in
quite generalised responses across selected regions of the heart,
selective stimulation of small individual cardiac nerves suggests
their highly specific and localised distribution to muscle
segments. In as much as each axon or nerve terminal has the
capacity for independent activity, the system is potentially
capable of becoming disorganised, a factor that would promote
heterogeneity of myocardial conductivity, automaticity and
excitability. Such heterogeneity could lead to fractionation of
electrical impulses through the heart and promote arrhythmias.
Sympathetic activation:
It has been known for many years, indeed since the pioneering
work by Hunt in 1899, that stimulation of the right or left
stellate ganglion exerts quite different functional effects on
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cardiac inotropic, chronotropic and dromotropic responses. On the
right, stimulation of the recurrent cardiac nerve shortens the
ventricular refractory period of the septum and to a lesser extent
the anterior surface of the heart. Stimulation of the cardiac
stellate nerve results in pronounced sinus tachycardia. On the
left, the ventromedial and more particularly the ventrolateral
cardiac nerves considerably shorten the refractory period over the
posterolateral surface of the heart, mainly the left ventricle
(Kralios et al, 1975). Surface ECG recordings show marked
differences in repolarisation phenomena. Left stellate stimulation
m
or right stellate gangl ionectomy increases the T wave amplitude and
causes prolongation of the QT interval. Right stellate stimulation
or left stellate ganglionectomy increases T wave negativity with no
change or a small reduction in QT interval (Rothberger and
Winterberg, 1910; Yanowitz et al, 1966; Kralios et al, 1975).
Inotropic responses to selective cardiac nerve stimulation show
similar regional variability (Randall et al, 1968a; Armour and
Randall, 1975). These studies agree with measurement of
catecholamine levels in the heart following selective right or left
stellectomy (Kimata, 1965) . After right stellectomy, ventricular
noradrenaline decreased most in the right ventricle and to a lesser
extent in the anterior portion of the left ventricle. After left
stellectomy, the greatest decrease in noradrenaline occurred in the
posterolateral portion of the left ventricle. It is probable that
vagus nerve stimulation increases refractoriness in ventricular
myocardium by antagonism of sympathetic activity (Kolman et al,
1976). Electrical stimulation of vagus nerves after stellate
ganglionectomy produces inconsistent effects in anaesthetised dogs
(Martins and Zipes, 1980a). Studies at sites of overlapping
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innervation from the right and left cardiac sympathetic nerves
suggest that the left side is dominant with respect to changes in
refractoriness (Haws and Burgess, 1978).
Similar differences in surface QT interval follow rapid or
prolonged slow infusions of catecholamines. Brief injections of
adrenaline or noradrenaline result in prolongation of the QT
interval, whereas slow infusions over several minutes cause
progressive shortening (Abildskov, 1976).
Since all of these interventions are known to reduce
ventricular recovery time, it is likely that QT interval
prolongation is the result of localised, while QT shortening is the
result of more widespread influences on repolarisation. If the
true time for ventricular repolarisation exceeds that recorded from
a surface ECG, due to cancellation of late recovery, reduction in
recovery time in a localised area of the heart could expose ECG
effects in others, resulting in prolongation of the QT interval.
Abildskov (1976) has provided evidence that ventricular
repolarisation exceeds the duration of the QT interval by showing
an increase in QT duration, exceeding the increase in QRS duration,
following ectopic activation. Late periods of recovery were not
evident after normal excitation. Inhomogeneities in ventricular
repolarisation are a major factor influencing arrhythmia
vulnerability and are increased by left stellate stimulation,
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digitalis glycosides, my-cardial ischaemia and increase in basic
cycle length (Han and Moe, 1964; Han et al, 1966). A 40 per cent
reduction in ventricular fibrillation threshold follows left
stellate stimulation for two minutes with reciprocal changes after
ganglionectomy (Kliks et al, 1975). Spontaneous ventricular
17
arrhythmias (Hageman et al, 1973) and ventricular fibrillaton
(Verrier et al, 1974) may follow isolated left sympathetic
stimulation. In contrast, temporal dispersion of ventricular
recovery is reduced by slow infusion of sympathomimetic amines (Han
and Moe, 1964). This is one explanation for a possible protective
effect of chronic low dose non-pressor noradrenaline infusion on
ventricular fibrillation threshold (Siebens et al, 1953) and on
ventricular arrhythmias and myocardial potassium loss during
coronary occlusion (Regan et al, 1970). As inhomogeneities in
ventricular repolarisation are a factor in both the T wave—form and
arrhythmia vulnerability, analysis of the T wave might be a
promising approach for determining patients at risk from
arrhythmias. Body surface isopotential maps have been used in
preliminary studies to represent dispersion of ventricular recovery
properties with promising early results (Abildskov et al, 1977;
1978; Wyatt et al, 1978; Burgess, 1979).
Electrical stimulation of various areas of the brain can
induce a variety of diverse arrhythmias even in the absence of
demonstrable myocardial ischaemia (Korteweg et al, 1957; Melville
et al, 1963; Abildskov et al, 1970). Changes are most marked with
direct stimulation of areas with known sympathetic connections, the
midbrain, posterior diencephalon and hypothalamus; stimulation of
these results in repolarisation abnormalities similar to those seen
with direct activation of sympathetic nerves to the heart.
Combined vagal and sympathetic activation may be particularly
detrimental (Manning and Cotten, 1962). Verrier et al (1975)
demonstrated a 40 per cent fall in ventricular fibrillation
threshold during stimulation of the posterior hypothalamus, an
effect that persisted despite prevention of the associated
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tachycardia and pressor response. Cervical vagotomy and bilateral
adrenalectomy did not alter the fall in fibrillation threshold but
it was readily prevented by beta-adrenoceptor blockade.
CNS disease:
It is well established that patients with a variety of central
nervous system disease, including stroke, subarachnoid and
intracerebral haemorrhage, trauma, tumours and encephalopathies may
manifest striking abnormalities of ECG waveform, mainly during
repolarisation and may develop ventricular arrhythmias. This
association was first suggested by Byer et al in 1947 and has been
widely documented (Abildskov et al, 1970; Burch, 1978). The
pronounced antiarrhythmic action of sympatholytic treatment was
illustrated by Grossman (1976) who reported a patient with
recurrent ventricular tachycardia in association with a
subarachnoid haemorrhage secondary to rupture of a basilar artery
aneurysm. The arrhythmia developed with prolongation of the
surface QT interval associated with tall symmetrical T waves, was
resistant to lignocaine, phenytoin, procainamide, digoxin,
propranolol and atropine but was immediately abolished following
pharmacological blockade of the left stellate ganglion. T wave
notching in patients with brain lesions may also reflect
asymmetrical alterations in sympathetic tone to the ventricle
(Millar and Abildskov, 1968). It is not clear whether organic
cardiac lesions accompany the ECG abnormalities although petechial
subendocardial haemorrhages have been reported (Koskelo et al,
1964). Myocardial lesions have also been reported following
experimental intracranial haemorrhage in mice (Burch et al, 1967)
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and in animals made hypertensive by stellate ganglion or midbrain
reticular formation stimulation (Kaye et al, 1961; Greenhoot and
Reichenbach, 1969). Seme of the changes are similar to those seen
experimentally after catecholamine infusion (Chappel et al, 1959;
Bloom and Cancilla, 1969).
Psychological factors:
Psychological factors may play a role in cardiac arrhythmias
and sudden cardiac death (Zanchetti and Malliani, 1974; Lynch et
al, 1977). It is probable that the link operates through the
sympathetic nervous system. At constant heart rate, the minimum
current that elicited a repetitive ventricular response in dogs
exposed to an aversive environment was one third that of controls
(Lown et al, 1973). This increase in vulnerability was abolished
following beta-adrenoceptor blockade (Matta et al, 1976).
Exercise:
Activation of sympathetic nerves to the heart through exercise
can trigger arrhythmias, especially if activation is asymmetrical.
Thus Schwartz and Stone (1979) noted exercise induced arrhythmias
in 86 per cent of conscious dogs following right stellate
ganglionectomy in contrast to 8 per cent of control animals and 11
per cent after left stellectomy. An increased incidence of
arrhythmias during exercise was also documented in dogs following
complete cardiac denervation with the exception of the
ventrolateral cardiac nerve, a major input to the left ventricle
(Randall et al, 1978). A tonic coronary vasoconstrictor influence
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is present during exercise (Gwirtz and Stone, 1978; Murray and
Vatner, 1978) and an increase in coronary flow following left
stellectomy indicates its dependence on left sided sympathetic
nerves (Feigl, 1967; Schwartz and Stone, 1977).
Long QT syndrome:
The idiopathic long QT syndrome, in addition to prolongation
of the QT interval is characterised by alteration and or notching
of the T wave, syncopal episodes due to ventricular fibrillation
and sudden death (Schwartz et al, 1975). It was first reported by
Jervell and Lange-Nielson in 1957 in association with congenital
deafness but later Romano et al (1963) and Ward (1964) reported an
otherwise identical syndrome occuring in patients with normal
hearing. Several hundred cases have now been reported (Abildskov,
1979) . Syncope usually begins in early life but may be delayed to
the second or even third decade. Factors precipitating syncopal
episodes include exercise, fear, anxiety and sudden noise, all of
which activate sympathetic nerves to the heart. The usual
mechanism of syncope is ventricular fibrillation. The most
effective therapy for the syndrome involves measures that reduce
neurosympathetic input to the heart such as beta-adrenoceptor
blockade or left stellectomy (Schwartz et al, 1975; Malliani et al,
1980). Several findings suggest that asymmetrical sympathetic
influences on the heart are involved in the pathogenesis of this
unique syndrome (Crampton, 1979) although the exact nature of these
influences is uncertain and could originate centrally, in the
sympathetic nerves or within the myocardium. James et al (1978)
reported evidence of local neuritis and neural degeneration within
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the conducting tissue and ventricular muscle of eight patients who
died suddenly with a history of recurrent syncope. The pattern of
damage of these nerves might dictate the extent of imbalance in
cardiac sympathetic activity. Kralios and Millar (1978) have shown
asymmetrical maturation of cardiac sympathetic nerves in puppies
which, if applicable in man, might provide a basis for regional
sympathetic imbalance and subsequent arrhythmogenesis in later
life. An imbalance between right and left cardiac sympathetic
nerves with left dominance is supported by much experimental
evidence discussed earlier.
SYMPATHETIC INFLUENCES IN ISCHAEMIC MYOCARDIUM:
TRIGGER FOR EARLY ARRHYTHMIAS
Clinical Evidence:
It is now well established that most sudden deaths during
acute myocardial ischaemia or infarction occur within minutes of
the onset of symptoms before the patient has reached hospital
(Kuller 1962; Armstrong et al, 1972; Romo, 1973). In an Edinburgh
community study, 45 per cent of the total deaths within the first
four weeks of myocardial infarction had occurred within the first
hour of the onset of symptoms (Armstrong et al, 1972). Assessment
of autonomic disturbance within this early period has shown the
high prevalence of sympathetic overactivity, evidenced by
tachycardia, transient hypertension or both (Webb et al, 1972). Of
240 patients, only 15 out of 89 (17 per cent) seen within 30
minutes had a normal heart rate and blood pressure when first seen.
Among 151 patients first seen between 30 and 60 minutes, the
incidence of autonomic disturbance was significantly lower at 56
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per cent. Sympathetic overactivity was found more frequently in
patients with anterior infarction and parasympathetic overactivity
more frequently after posterior or inferior infarction.
Sympathetic overactivity was unmasked in some patients following
vagal blockade (Pantridge, 1978). Thus a temporal relationship was
found between prevalence of arrhythmias and autonomic dysfunction
during the critical early vulnerable period.
Although a crude guide to sympathetic nervous system activity
in humans (Esler, 1982), plasma noradrenaline levels have been
uniformly elevated in acute myocardial infarction (Goldstein,
1981). Most data suggests that once the infarct is established,
the level of peripheral sympathoadrenal activation broadly reflects
the extent of myocardial damage and its haemodynamic consequences,
rather than the probability of serious early arrhythmias (Hayashi
et al, 1969; Jequier and Perret, 1979; Nadeau and de Champlain,
1979; Karlsberg et al, 1981). Thus, Karlsberg et al (1981) found a
four-fold rise in plasma noradrenaline and eight-fold rise in
plasma adrenaline in 14 patients with acute infarction, with
peripheral venous sampling a mean of two hours after the onset of
symptoms. No significant differences between anterior and inferior
infarction were observed and no relationship between catecholamine
levels and heart rate, blood pressure or ventricular arrhythmias
was evident. The close relationship between haemodynamic changes
and extent of peripheral sympathetic nervous system activation has
been confirmed experimentally (Karlsberg et al, 1979). Vetter et
al (1974) noted plasma catecholamine levels greater than 1000 pg/ml
in all of four patients sampled within one hour of the onset of
symptoms. Information on cardiac sympathetic activity at the time
of early enhanced vulnerability to arrhythmias was not available,
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although it has been shown that the heart is capable of releasing
noradrenaline later in course of infarction (Mueller et al, 1980).
Earlier studies claimed higher catecholamine levels in patients
with ventricular arrhythmias over the first 24 hours of infarction
(McDonald et al, 1969; Griffiths and Leung, 1971), but the time
scale of these measurements extended well beyond the period of
enhanced vulnerability to primary ventricular fibrillation.
Increased plasma catecholamines do not necessarily imply
increased spillover rates from nerve terminals. For example,
elevation of plasma noradrenaline in older subjects is not due to
an increase in sympathetic tone, but to diminished noradrenaline
plasma clearance (Esler et al, 1981). In addition, over 80 per
cent of noradrenaline released from sympathetic postganglionic
neurones in man is removed by local neuronal uptake or local
metabolism and does not escape into plasma (Silverberg et al,
1978).
Patients admitted to a coronary care unit with chest pain
subsequently shown not to have had a myocardial infarct show lower
initial levels of noradrenaline and rapid reductions towards normal
during hospitalisation (Videbaek et al, 1972). Although a
heterogeneous group, a number of patients in this category will
have had transient myocardial ischaemia and a high risk of
ventricular fibrillation. Thus it is probable that assessment of
peripheral catecholamine concentrations is insufficiently sensitive
for any comment to be made on the relationship between cardiac
sympathetic activity and early arrhythmias during myocardial
ischaemia or early infarction.
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Cardiac reflexes:
There is increasing evidence that excitation of afferent nerve
fibres from the heart, travelling in the cardiac sympathetic
nerves, may have an important role in determining reflex
sympathetic activity to the heart. This is the likely explanation
of tachycardia and hypertension in patients with spontaneous angina
pectoris some minutes before the onset of pain (Littler et al,
1973; Maseri et al, 1978). Myocardial ischaemia excites both vagal
and sympathetic fibres from the heart and elicits a variety of
reflex responses. Brown first reported in 1968 that occlusion of
the left main coronary artery in lightly anaesthetised cats
produced a pseudoaffective response characterised by piloerection,
pupillary dilatation, limb movements, tachycardia and blood
pressure changes. The response was abolished by section of cardiac
afferent sympathetic fibres and was greatly reduced by section of
pericoronary nerves. The cardiac sympathetic sensory endings are
mechanoreceptors (Malliani et al, 1973; Casati et al, 1979), but
their activity can be further enhanced by chemical substances such
as bradykinin (Lombardi et al, 1981) which are released from the
ischaemic heart.
Activation of the afferent limb is followed by increased
efferent discharge of cardiac sympathetics, an excitatory
cardiocardiac reflex (Malliani et al, 1969). This reflex can be
activated within seconds of the onset of myocardial ischaemia and
may play an important role in arrhythmogenesis at this time, since
interruption of the afferent limb by section of the dorsal roots
from the eighth cervical to fifth thoracic segment can
substantially reduce arrhythmias associated with short-lived
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coronary occlusion (Schwartz et al, 1976). It has been suggested
in a preliminary study that efferent neural activation of cardiac
sympathetic nerves after coronary occlusion is patchy, being
increased in some but decreased in others (Lathers et al, 1976).
Selective activation of individual nerves to the heart is a well
recognised arrhythmogenic manoeuvre (D'Agrosa and Flannigan, 1976).
Cardiac sympathetic afferents are also capable of inhibiting
cardiac efferent vagal discharge (Schwartz et al, 1973) and may
thus antagonise vagally-mediated increases in cardiac electrical
stability (Kolman et al, 1975; De Silva et al, 1978). It might be
expected that activation of efferent cardiac sympathetic discharge
following coronary occlusion would be demonstrable in non-ischaemic
as well as ischaemic areas of the heart. Pashkow et al (1977) have
shown increases in myocardial contractile force in non-ischaemic
myocardium following coronary ligation for two minutes, a response
abolished by transection and cannulation of the artery supplying
the non-ischaemic region.
Cardiac sympathetic afferent nerves have also been shown to
have excitatory influences on renal sympathetic nerve activity
during acute ischaemia (Weaver et al, 1981), such a reflex possibly
contributing to inappropriate hypertension at this time. This in
turn may increase myocardial oxygen demands, intensify the area of
ischaemia, and exacerbate myocardial electrical instability through
a cycle of reflex neural discharge.
Cardiac denervation:
In 1936, Cox and Robertson suggested that thoracic
sympathectomy reduced mortality from ventricular fibrillation
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following coronary ligation although statistical evaluation of
their data indicates that mortality rates between control and
denervated groups were not significantly different (Corr and
Gillis, 1978). Cox and Robertson are credited with first advancing
the hypothesis that neural reflexes from the heart might be
deleterious to its function (Malliani et al, 1980). Early studies
on the effect of bilateral stellate ganglionectomy and removal of
chain ganglia showed a variable and at times inconsistent
protection against arrhythmias and mortality during the first few
minutes of myocardial ischaemia (Harris et al. 1951; Milch et al,
1955; Schaal et al, 1969). Depletion of myocardial catecholamines
with reserpine has also shown inconsistent effects on arrhythmias,
including ventricular fibrillation, following coronary occlusion
(Maling et al, 1959; Melville and Varma, 1962; Sommers and
Jennings, 1972). One possible explanation for these inconsistences
lies in the inability of these interventions to achieve complete
cardiac denervation. Thus, residual islets of functioning
adrenergic nerve terminals may actually exacerbate the tendency for
arrhythmia development. Similarly, reserpine rarely causes
complete depletion of catecholamine stores and with levels as
little as five per cent of control, effective neurotransmission can
take place, at least in part through postsynaptic hypersensitivity
(Kalsner and Nickerson, 1969) .
A second explanation for the variable effectiveness of
sympatholytic interventions was suggested by Ebert et al (1970) by
showing that chronic, but not acute cardiac denervation was
protective against early ventricular arrhythmias. These authors
suggested that adequate time must elapse to allow depletion of
catecholamines from the heart before protection is evident. More
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recently, Thomas et al (1981) have supported the concept of a
salutory effect of chronic, but not acute cardiac denervation on
cardiac muscle mechanics during ischaemia. Cardiac contractile
force in the ischaemic area declined by 67 per cent in the control
dogs, by 74 per cent in acutely denervated dogs but by only 22 per
cent in the chronically denervated group (p < 0.001). This data
highlights the importance of direct local interactions between
ischaemic muscle and sympathetic terminals.
Current techniques for surgical denervation of the heart,
mainly developed in Randall's laboratory, allow complete,
verifiable, selective cardiac denervation and have been used to
study possible mechanisms for the cardioprotective effects of this
manoeuvre (Jones et al, 1978; Randall et al, 1980). In studies
where infarct size has been determined, chronically denervated dog
hearts had infarcts some 80 per cent smaller than sham-denervated
controls, whereas in acutely denervated hearts, infarct size was
reduced by only 25 per cent (Jones et al, 1978a). The mechanism
for this protection is uncertain but may in part be related to
reduction in oxygen consumption of chronically denervated heart
tissue (Gregg et al, 1972). Heart rate, a major determinant of
myocardial oxygen consumption, was also reduced by acute and
chronic denervation but perfusion pressure tended to fall also,
making the net balance between oxygen delivery and oxygen demand
difficult to determine.
At similar heart rates, blood pressure and levels of cardiac
work, Barber et al (1980) found significantly lower left
ventricular epicardial and endocardial blood flow (measured by
radiolabelled microspheres) in chronically denervated compared to
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sham-denervated dog hearts. Local ST segment elevation, measured
by epicardial and endocardial plunge electrodes, was less in
denervated hearts in low flow areas following ligation of the left
anterior descending coronary artery and arrhythmias were less
frequent. Collateral perfusion to the ischaemic area was not
modified by denervation in this study, but others have suggested up
to a four fold increase in blood flow in central and peripheral
ischaemic regions after this procedure (Jones et al, 1978b).
Sympathetic stimulation and attenuation:
Central, hypothalamic stimulation during acute myocardial
ischaemia readily exacerbates the tendency for ventricular
fibrillation. Lown and Verrier (1978) noted ventricular
fibrillation in 63 per cent of dogs during coronary artery
occlusion and hypothalamic stimulation, contrasting with a 6 per
cent incidence of fibrillation without hypothalamic stimulation.
Hypothalamic stimulation failed to induce arrhythmias in any
animals without ischaemia.
A similar pattern of enhanced vulnerability to arrhythmias
follows stellate ganglion stimulation during ischaemia, with the
increased incidence of ventricular fibrillation independent of
changes in heart rate and blood pressure (Verrier et al, 1974;
Kliks et al, 1975). Aversive environmental conditioning may also
provoke arrhythmias without direct activation of sympathetic nerves
in dogs following coronary occlusion (Corbalan et al, 1974).
The asymmetrical influences of cardiac sympathetics in
ischaemic myocardium are well documented. Interruption of the left
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stellate ganglion attenuates the arrhythmias, whereas right
stellectomy enhances the frequency of arrhythmias, including
ventricular fibrillation (Schwartz et al, 1976a). Interruption of
sympathetic activity at the level of the dorsal roots of the spinal
cord (Schwartz et al, 1976) or interruption of spinal function from
C4 to T6 (Bhargava et al, 1976) is also protective. Asymmetrical
sympathetic influences may also operate in the myocardium as a
result of previous infarction. Barber et al (1983) recently showed
that experimental infarction can lead to sympathectomy of healthy
myocardium distal to the infarct, presumably as a result of
interruption of epicardial sympathetic nerves which travel beside
the coronary arteries between base and apex (Randall et al, 1968).
Cardiac sympathetic tone may also influence patterns of
coronary blood flow during critical coronary artery stenosis.
Cyclical reductions in flow, characterised by Folts et al, 1976,
and probably mediated via aggregation and disaggregation of
platelets (Sowey et al, 1981; Folts et al, 1982), are enhanced by
stellate ganglion stimulation and adrenaline infusion and
diminished by stellectomy (Raeder et al, 1982).
DETRIMENTAL EFFECTS OF CATECHOLAMINES IN ISCHAEMIC MYOCARDIUM
Electrophvslology:
Local liberation of noradrenaline from nerve terminals in
ischaemic myocardium may potentially trigger arrhythmias through a
variety of different but not mutually exclusive mechanisms.
Catecholamine-enhanced diastolic depolarisation of specialised
ventricular muscle fibres increases normal automaticity (Tsien,
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1974) even in the presence of partial depolarisation (Noble 1975) .
However, diastolic depolarisation can be effectively inhibited by
elevating extracellular potassium concentration to a level likely
to be present in ischaemic myocardium so it is doubtful whether
w
this mechanism operates in vivo (Imanishi and Sura^icz, 1976) .
Triggered after-depolarisations (Cranefield, 1975) may develop
at several levels of transmembrane potential, and their amplitude
is increased by the action of noradrenaline (Hoffman, 1978). As
the amplitude of these oscillatory afterpotentials is partly a
function of cycle length, catecholamines may allow them to reach
threshold levels by increasing heart rate.
Possibly the most important electrophysiological action of
catecholamines in acutely ischaemic myocardium lies in their
ability to promote re-entrant excitation. In the presence of
increased extracellular potassium, the fast inward sodium channel
becomes inactivated and a calcium-dependent slow response action
potential, with an extremely slow conduction time, is generated
(Wit et al, 1972). This will facilitate re-entrant activity within
the heart. Higher levels of potassium increase potassium
conductance and may prevent propagation of the impulse. In the
presence of catecholamines, however, slow response action
potentials may be reactivated (Carmeliet and Vereecke, 1969), with
slow propagation through the ischaemic area and completion of
re-entrant circuits leading to ventricular fibrillation.
Sympathetic neural stimulation may even improve conduction in
ischaemic tissue (Millar et al, 1976) by allowing impulse
propagation through areas previously showing conduction block. The
conducting impulse may then propagate back through previously
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refractory tissue and complete a re-entrant pathway.
Metabolism:
Ultimately, the arrhythmogenic
catecholamine release on ischaemic
neurotransmitter actions on cellular me
1.1) .
Catecholamines stimulate adenylate cyclase activity in the
myocardial cell membrane (reviewed by Drummond and Severson, 1979)
by a molecular mechanism involving interaction with at least three
membrane proteins: the beta^_a(jrenoceptor, the catalytic subunit of
the enzyme and a guanyl nucleotide binding regulatory component
(Schultz and Jakobs, 1981). Elevation of cyclic adenosine 3', 5'
monophosphate (cAMP) results and has been shown in ischaemic
regions prior to malignant arrhythmias in the cat (Com et al,
1978), the baboon and to a lesser degree the dog (Podzuweit et al,
1978). The rise in cAMP is associated with a fall in ventricular
fibrillation threshold (Lubbe et al, 1978). There is considerable
evidence that cAMP influences calcium channels in the sarcolemma;
increased calcium entry into heart cells influences both their
contractile state and electrical activity (Reuter, 1974), and is
involved in the development of both reversible and irreversible
cell injury (Reimer and Jennings, 1981). Although the molecular
mechanisms are poorly understood (Benfey, 1980), it is generally
accepted that an increase in cytoplasmic calcium concentration also
represents the main intracellular signal following activation of
the alpha1_a(irenoceptor> Rapid changes in the activity of cardiac
protein kinase enzymes may follow these intracellular signals
consequences of local
heart muscle depend on
tabolic processes (Figure
32
Figure 1.1 interrelations between neurosympathetic activity and metabolism in acutely
ischaemic myocardium.
(Mewes and Hofmann, 1981) and determine the energy balance of the
ischaemic cell. For example, cAMP dependent activation of
phosphorylase-kinase will activate glycogenolysis and provide
endogenous substrate for ATP production via anaerobic glycolysis.
The increase in contractile force (in normal or peri-ischaemic
muscle) and heart rate following adrenergic stimulation will
increase myocardial oxygen demands and hasten the depletion of
energy reserves. Progressive loss of the cellular pool of high
energy phosphates will thus be accelerated and, at least in more
severely ischaemic muscle, their replacement by glycolytically
produced ATP will be limited because of end-product inhibition of
anaerobic glycolysis by acidosis and lactate production
(phosphofructokinase inhibition) and by a rise in the NADH/NAD
ratio (glyceraldehyde—3-phosphate dehydrogenase inhibition) (Neely
and Morgan, 1974; Rovetto et al, 1975).
A further deleterious action of catecholamines on ischaemic
cell energetics operates through changes in lipid metabolism.
Activation of peripheral lipolysis following acute myocardial
ischaemia increases free fatty acid (FFA) concentrations (Oliver et
al, 1968) and increases their uptake by the myocardium (Vik-Mo et
al, 1979). The latter is principally dependent on the fatty
acid-albumin molar ratio (Miller et al, 1976). This may enhance
myocardial oxygen utilisation without influencing myocardial
mechanics (Mjos 1971), possibly through the cycling of these acids
into and out of the triglyceride pool by ischaemia-induced
esterification to triglyceride and lipolytic breakdown to FFA and
glycerol. The extent of elevation of plasma FFA in man following
acute infarction has been linked both to infarct size and the
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development of serious ventricular arrhythmias (Oliver et al, 1968;
Opie et al, 1911). Reduction in FFA availability to the myocardium
by increasing the albumin-FFA ratio (Miller et al, 1976) or by
antilipolytic drugs (Mjos et al, 1976; Vik-Mo, 1977), decreases
epicardial currents of injury. Inhibition of beta-oxidation in
ischaemic cells promotes the accumulation of triglycerides
(Wartmann et al, 1956; Scheuer and Brachfeld, 1966) which may
increase cellular oxygen requirements and the tendency for
arrhythmias (Brownsey and Brundt, 1977). Enhanced endogenous
lipolysis in ischaemic myocardium is at least partly catecholamine
dependent, as in rats pretreated with reserpine ischaemia failed to
stimulate hormone sensitive lipase activity (Hough and Gevers,
1975) . Accumulation of long chain fatty acyl CoA esters may
inhibit the transport of high energy phosphates across the
mitochondrial membrane (Shung et al, 1975).
PURPOSE OF THESIS
It is a reasonable hypothesis that local and particularly
heterogeneous release of catecholamines in ischaemic myocardium
could act as a trigger for metabolic and electrophysiological
derangements promoting lethal ventricular arrhythmias. Despite
broad-based evidence in support of this contention, a paucity of
direct information is available concerning sympathetic nerve
terminal activity in acute ischaemia and the mechanisms controlling
noradrenaline release and adrenoceptor activation at this time.
This thesis examines spontaneous and nerve-stimulated overflow
of sympathetic neurotransmitters in an animal model of myocardial
ischaemia in vivo at the time of development of the early phase of
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spontaneous ventricular arrhythmias, and relates this overflow to
regional electrophysiology, haemodynamic and some metabolic
abnormalities across ischaemic and non-ischaemic areas of the
heart. The specifity of the model in allowing sampling of
regionally ischaemic and non-ischaemic venous effluent is also
critically evaluated. The role of presynaptic mechanisms
controlling neurotransmitter overflow during ischaemia is assessed
using alpha^-adrenoceptor and neuronal reuptake blocking drugs and
the actions of some ischaemic metabolites evaluated using regional
infusion techniques. Prospects for the prevention of
beta-adrenoceptor mediated detrimental electrophysiological effects
and the role of tonic sympathetic stimulation in ischaemic tissue
are evaluated by analysis of the haemodynamic and
electrophysiological effects of a beta-adrenoceptor blocking drug
with intrinsic sympathomimetic activity. Finally, methodical
aspects of beta-adrenoceptor quantification in vitro using
radioligand binding techniques are studied and their potential
application to adrenoceptor quantification in vivo explored.
It is the aim of this thesis to provide increased basic
knowledge of the complex interrelationships between cardiac
neurosympathetic activity and metabolic and electrophysiological
derangements in acutely ischaemic myocardium at the time of onset
of early ventricular arrhythmias. A direct approach of assessing
neurosympathetic activity, namely regional catecholamine release,
has been adopted. It is hoped that the studies may provide a more
rational therapeutic approach as a basis for the prevention of
sudden cardiac death from coronary heart disease.
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2. MATERIALS AND GENERAL METHODOLOGY
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TBE MODEL
Detailed clinical studies of the mechanisms of ventricular
fibrillation during the first few minutes of myocardial ischaemia
are impractical. The use of an open-chest anaesthetised dog model
of acute myocardial ischaemia is based on the following
considerations.
Firstly, it allows simulation or partial simulation of the
mechanisms of pathogenesis of lethal ventricular arrhythmias in
acute ischaemia that may be applicable to sudden cardiac death in
man (Bigger et al, 1977). The early phase of ventricular
ligation
arrhythmias in the dog following coronary artery/ has been
particularly well characterised
since its description by Harris in 1950. Serious ventricular
arrhythmias, including ventricular fibrillation, are common during
the first 20 minutes of acute ischaemia in this model (Harris phase
1 arrhythmias). After 30 minutes, arrhythmias are rare for several
hours. Two peaks of arrhythmogenesis have now been characterised
during this early period, the first 5-6 minutes after coronary
ligation (phase la) and the second 15-17 minutes after coronary
ligation (phase lb) (Haase and Schiller, 1969; Meesman et al, 1978;
Kaplinsky et al, 1979). Reproducible electrophysiological,
metabolic and haemodynamic changes follow short periods of
ischaemia (10-15 minutes), without the development of myocardial
necr osis (Braunwald and Kloner, 1982) and allow comparison of
control and intervention periods (Kjekshus and Mjos, 1972; Maroko
and Braunwald, 1976; Mjos et al, 1976).
Secondly, the physiology of the neurosympathetic cardiac axis
has been particularly well studied in the dog (Randall, 1977) and
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detailed information is available concerning regional distribution,
function and neuropharmacology of cardiac sympathetic nerves in
this species. Neurosympathetic activity and responsiveness has,
however, been poorly characterised during the early phase of
arrhythmogenesis in acute ischaemia.
Thirdly, the use of an open-chest intact animal permits
integrated reflex, central and peripheral responses to acute
ischaemia to take place, while allowing regional analysis of
metabolic and electrophysiological variables across both ischaemic
and non-ischaemic regions on a minute-to-minute basis. Dog heart
shows similar metabolic and electrophysiological responses to that
of primate (baboon) heart (Opie et al, 1975). Sheep heart has
unusual coronary vasculature, while pig heart is characterised by
lack of intercoronary anastomoses and a conduction system
penetrating to epicardial layers, unlike that in man and in the
dog. Regional venous sampling on a minute-to-minute basis, a
technique widely used in this thesis, is technically difficult in
the rather small cat heart.
The need for anaesthesia constitutes a potential disadvantage
of the open-chest preparation as levels of anaesthesia may
influence myocardial mechanics, oxygen consumption, metabolism and
cardiovascular reflexes and hence may effect changes in ventricular
vulnerability during acute ischaemia (Prys-Roberts, 1980). In all
studies, care was taken to ensure an adequate and even level of
anaesthesia throughout, with maintenance of normal acid-base
balance and normothermia by the use of a heating blanket. Systemic
hypoxia acts as a major trigger for activation of cardiac
sympathetic activity (Woods and Richardson, 1959; Downing, 1966)
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and was avoided by continuous positive pressure ventilation with
room air using a Harvard respirator at a tidal volume and rate
derived from a standard nomogram according to body weight. Neither
respiratory acidosis nor respiratory alkalosis alter the
ventricular fibrillation threshold in dogs (Gerst et al, 1966)
although indirect effects are possible through depression of
myocardial contractility.
Initial studies investigating spontaneous outflow of
myocardial catecholamines in acute ischaemia used a-chloralose in
urethane as the anaesthetic agent with morphine premedication. In
a subsequent series, a-chloralose alone was used to avoid possible
vagotonic effects of morphine (De Silva et al, 1978a) that might
have inhibited nerve terminal catecholamine release (Levy, 1982).
It has been claimed that a-chloralose causes less depression of
cardiovascular reflexes than other intravenous anaesthetics. Tonic
parasympathetic tone may be preserved to a greater degree than with
other agents (Van Citters et al, 1964), a factor that can influence
local electrogram abnormalities during acute ischaemia (Ruffy et
al, 1981).
Pentobarbitone anaesthesia was used for all studies using
sympathetic nerve stimulation and manipulation of nerve terminal
neuropharmacology. It is recognised that vagal tone is low with
barbiturate anaesthesia (Priano et al, 1969) and there is some
evidence that sympathetic tone may be enhanced (Ruffy et al, 1981).
Barbiturate anaesthesia may change ventricular refractoriness
(Laforet et ai, 1957), cardiovascular dynamics (Cox, 1972), and
under certain circumstances may exert significant anti-arrhythmic
effects (Hoffmeister et al, 1958). Dawson et al (1980) compared
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indices of ventricular vulnerability (fibrillation threshold,
single and multiple repetitive extrasystole threshold) in dogs with
and without pentobarbitone anaesthesia. Small but significance
reductions in these parameters were observed in the conscious
state. Fifty-one per cent of the variability in fibrillation
threshold when conscious was explicable by results during prior
anaesthesia, whereas 77 per cent of the variability was explicable
in a control group during two periods of anaesthesia. No detailed
studies are available comparing the effects of barbiturate
anaesthesia on indices of ventricular vulnerability during
ischaemia. The use of each animal as its own control should
minimise experimental error as a consequence of variability in
anaesthetic agent or in levels of anaesthesia.
Local cooling of the heart as a consequence of air exposure
following thoracotomy can alter action potential duration,
refractory periods and conduction times (Hoffman, 1959). Effects
on arrhythmogenesis are more marked if temperature gradients are
generated across the myocardium (Wallace and Mignore, 1966) and are
related to the speed of generation of such gradients. Temperature
differentials may be significant between epicardium and endocardium
and may even be enhanced during ischaemia when reduced coronary
flow diminishes heat transfer.
Significant loss of plasma volume can follow ventilation as a
result of insensible fluid loss and therefore a continuous
intravenous infusion of isotonic saline was used in all
experiments. Additionally, blood losses during surgery were
replaced by saline.
The validity of the technique of assessment of metabolic
changes during myocardial ischaemia from regional arteriovenous
differences requires careful consideration. Although arterial
blood perfuses the ischaemic region via collaterals from
non-occluded vessels, local venous effluent from the ischaemic zone
represents a mixture of venous blood draining both ischaemic and
non-ischaemic myocardium. Furthermore, venous effluent from
ischaemic tissue will be an admixture of contributions from tissue
with varying degrees of hypoperfusion, such that the greater the
degree of ischaemia the less the relative contribution to venous
effluent and the greater the likely dilution with venous effluent
from less severely ischaemic or even non—ischaemic regions.
Regional redistribution of blood following the release of
vasoactive metabolites during the early minutes of ischaemia can
further influence venous admixing with time, irrespective of the
severity of ischaemia. However, striking metabolic changes are
detectable from biochemical analysis of venous effluent draining
ischaemic myocardium. Regional lactate production, potassium
release and enhanced glucose extraction have all been demonstrated
during ischaemia, even if the magnitude of change in coronary
venous effluent in, for example, lactate and potassium is
considerably less than within the central ischaemic zone. A
stricter comparison of ischaemic arteriovenous versus non-ischaemic
arteriovenous substrate differences is achieved by simultaneous
sampling of local venous effluent draining a non-ischaemic area of
myocardium. Under normal conditions, overflow of noradrenaline
from the myocardium is a small fraction of the released
neurotransmitter, probably less than 10 per cent, mainly due to the
activity of neuronal reuptake processes. Changes in
neurosympathetic activity, local blood flow, neuronal reuptake and
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extraneuronal reuptake as a consequence of acute ischaemia
complicate the prediction of noradrenaline output after coronary
occlusion and hence the release from the heart has generally been
expressed as an arteriovenous concentration difference. Detailed
analysis of the validity and assumptions involved with the regional
venous sampling technique is presented on pages 5 5 - 63 .
Assessment of regional myocardial blood flow using
radiolabelled microspheres has the advantage of providing fairly
accurate estimates of regional flow in multiple endocardial and
epicardial tissue sites. General criticisms may be applied to the
microsphere technique (Buckberg et al, 1971). The random
distribution of spheres injected into the arterial circulation
means that precision of regional flow determination is related to
the number of spheres in each tissue sample. The requirement that
there should be at - ':> least 400 spheres per sample dictated the
total number injected. With very low flow, variability in derived
flow secondary to random redistribution of small numbers of spheres
would be increased. Higher doses of microspheres were used for
detailed central and border zone blood flow analyses. Plasma
streaming, preferential sphere distribution and failure of sphere
trapping are minimised by the use of spheres 15 p in diameter :
smaller spheres have a higher incidence of escape through the
vascular bed into the venous circulation and larger spheres may
show preferential regional flow distribution. No haemodynamic
disturbances have been reported in the literature following the
injection of the doses used in this thesis.
RADIOENZYMATIC ASSAY OF PLASMA (AND TISSUE) CATECHOLAMINES
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Principle: The catecholamines noradrenaline [NA], adrenaline [A]
and dopamine [DA] are converted to their 3-0-methylated derivatives
using catechol-O-methyl transferase (COMT) in the presence of a
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The radioactive products normetanephrine (from [NA]), metanephrine
(from [A]) and methoxytyramine (from [DA]) are purified by
selective extraction and separated by thin layer chromatography
(TLC). Normetanephrine and metanephrine are oxidised to vanillin.
This method is modified from Da Prada and Zurcher (1976). It
has advantages of simultaneous determination of [NA], [A] and [DA],
high sensitivity and specificity (within the femtomole range) and
low sample volume.
Extraction of COMT: COOT was purified from rat liver adapting the
procedure of Axelrod and Tomchick (1958). All procedures were
performed on melting ice or at 4°C. Rat liver (100 g : 10 rats)
was homogenised in 400 ml 1.19% KC1, filtered through two layers of
nylon gauze, and the homogenate centrifuged for 10 minutes at 15000
rpm in a refrigerated centrifuge. The fluffy white floating layer
was discarded and the supernatant centrifuged at 24000 rpm (65,000
g) (Beckman ultracentrifuge) for 30 minutes. The pH of the
supernatant was adjusted to 5.0 using 1 M acetic acid, left for 20
minutes and the precipitated proteins spun down (30 minutes, 24000
rpm) and discarded. Ammonium sulphate (16.1 g in 100 ml) was added
slowly with constant stirring and precipitated proteins spun down
(30 minutes, 24000 rpm) after 15 minutes and discarded. More
ammonium sulphate was added (14.8 g in 100 ml) and left for 15
minutes. The precipitate from this stage, containing the COMT, was
packed by centrifugation (30 minutes, 15000 rpm) and the pellet
resuspended in 30 ml 1 mM sodium phosphate buffer (pH 7.0), and
dialysed for 15 hours against the same buffer (51.1 mM NaPO^)
containing 0.1 mM dithiotreitol (DTT) using dialysis tubing
(circumference 48 mm) cleaned three times in 10-^ M EGTA. The
final product was centrifuged (10 min, 15000 rpm) and the clear
supernatant aliquoted into 1 ml cups and deep frozen. The enzyme
is stable for at least three months at -20°C.
Specified Reagents:
•3
(1) H -methyl-S-adenosyl methionine. Radiochemical Centre,
Amersham. Specific activity 10 Ci/mmole (stored -40°C).
(2) HC1 Analar BDH-10125. 37% diluted DDW.
(3) Perchloric acid HC104, Analar BDH. 72% diluted DDW.
(4) Acetic acid ION, Analar BDH. diluted DDW.
(5) NaOH 5N Analar BDH. diluted DDW.
(6) Ammonia 2N Merck 25% diluted DDW.
(7) Tris buffer 2M, Aristar BDH - 45205. pH 9.6.
(8) Borate buffer 1M, Analar BDH - 10058. pH 8.0
(9) Dopamine stock solution (100 fig/ml), Dopamine HC1, Kochlight
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3283.00 in 0.01 N HC1. Stored 4°C. Fresh every 2 months.
(10) Adrenaline stock solution (100 jxg/ml) . L-adrenaline
hydrogen tartrate. Kochlight 9779-60 in 0.01 N HC1. Stored
4°C. Fresh every 2 months.
(11) Noradrenaline stock solution (100 |ig/ml) . L-noradrenal ine
bitartrate. Kochlight 4351-70 in 0.01 N HC1. Stored 4°C.
Fresh every 2 months.
(12) MgCL2 500 mM. Merck. Diluted DDW.
(13) Dithiotreitol (DTT) A grade. Calbiochem.
(14) Enzyme mix: DTT (13) 1 mg
Tris buffer (7) 500 pi
COMT 250 fil
MSC12 (12) 200 |il
SAM (1) 20 nl
970 |il
(15) Carrier solution:
3 methoxytyramine (HC1) (Calbiochem 45426) 30.5 mg
DL metanephrine (HC1) (Calbiochem 44797) 29.6 mg
DL normetanephrine (HC1) (Calbiochem 4911) 30.0 mg
HC1 0.01 N to 25 ml
(16) Sodium tetraphenylborate (TPB) 1.5%, Merck pH 8.0.
Diluted DDW.
(17) TLC tank solvent: Chloroform Merck 80 ml
Ethanol Merck 15 ml
Ethylamine Merck 10 ml
(18) Scintillation solution: Butyl PBD (Ciba) 12.5 g
Toluene (Merck) 2.5 1








Procedure: Plasma (100 jj.1 , frozen immediately after separation
from blood collected into precooled tubes (4°C) containing 10 p
heparin and 1 mg sodium metabisulphate) was deproteinised using 1
vol 0.6 N HCIO^ mixed and centrifuged for 2 minutes. Oxidised
plasma samples were prepared by adding 2 mg NalO^ to 1 ml plasma
and oxidation at 35°C for 10 minutes before deproteinisation as
described above. Tissue samples were weighed, homogenised in 10
vols 0.3 N HCIO^ (containing 5.6 mM EGTA), the homogenate
centrifuged (10 minutes, 15000 rpm) and the supernatant decanted.
The pellet was re-extracted in HC104 solution and centrifuged
before combining the extracts and proceeding as for plasma.
The methylation reaction was undertaken for one hour (35°C),






Deproteinised plasma 100 - - - 100
(Oxidised plasma) - - 100 - -
0.3N HC10
(1 mg/ml Asc Acid)
- 100 - 100 -
Ref Stand (NA, A, DA
60,600 fmol/50 pi
from stock soln.)
- - - 10-50 50
0.01 N HC1 50 50 50 0-40 -
Enzyme mix 100 100 100 100 100
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Extraction of 3-0—methylated products: The reaction was stopped by
placing tubes in an ice-cold bath and adding freshly prepared
borate buffer (8), 3 parts and carrier solution (15) 1 part (200
pi). 100 pi TPB (16) was added and the mixture extracted into 10
ml diethylether by shaking for 5 minutes. After centrifugation (5
minutes, 1500 rpm) the water phase was frozen on dry ice, the ether
phase added to 0.5 ml 0.1N HC1, shaken for 5 minutes and
recentrifuged before freezing the water phase again on dry ice.
The ether phase was discarded and the acid phase (containing the
methylated products) washed with 5 ml butylacetate, shaken for 5
minutes, centrifuged and the water phase frozen. The butylacetate
phase was discarded. The acid phase was evaporated to dryness
under vacuum and the residue dissolved in 100 pi 0.1N HC1.
Amine separation: 50 pi of purified extract was carefully spotted
onto precut 3 x 20 cm, TLC plates (LK5E, Whatman) with a
preadsorbed origin, equilibrated with 105 ml solvent solution and
chromatographed for 1 hour in a solvent tank (approx. 12 plates per
tank). The TLC plates were dried in a stream of cold air and the






Methoxytyramine (Rf value 0.7) was not assayed in tlie studies
described but the method allows this peak to be removed, eluted and
counted directly. Metanephrine (Rf value 0.5) and normetanephrine
(Rf value 0.3) were scraped individually and transferred to liquid
scintillation vials. 1 ml 2N ammonia (6) was added, shaking for 5
minutes and the oxidation stopped by the addition of 50 pi 10%
glycerol solution. The pH was adjusted by the addition of 0.5 ml
10N acetic acid (4) and 10 ml scintillation solution added, shaken
for 10 minutes to extract the oxidised products to the toluene and
counted (Hewlett Packard liquid scintillation spectrometer) .
Typically, blanks and standards (routinely assayed in
triplicate) yielded the following counts per minute:
BLANK 60 fmol 600 fmol
[NA] 30 - 50 100 - 150 1000 - 1200
[A] 30 - 50 150 - 200 1200 - 1500
Oxidised plasma blanks were not routinely processed as
preliminary methodological studies showed similar counts to
acid-blanks.
Each completed experiment was always analysed as part of the
same assay to avoid interassay variability and allow accurate
comparison of catecholamine concentrations before and after an
intervention. The intraassay coefficients of variation for
replicates were 7% for [NA] and 9% for [A]. Linearity of the assay
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for both [NA] and [A] was confirmed over the concentration range
measured in venous and arterial plasma (up to 30 pm/ml, Figure
2.1) .
From a plasma pool stored at -20°C and assayed at intervals
over 400 days, a small but significant trend for decline in
measured catecholamines was evident, amounting to 2.7% per month
for [NA] and 4.5% per month for [A], The interassay coefficient of
variation over this time was 5% for [NA] and 20% for [A].
Experimental samples were analysed within three months of
collection.
LACTATE ASSAY
Lactate concentrations in arterial and venous plasma were
determined fluorimetrically according to the method of Passonneau
(1970). Briefly, 50 pi plasma (diluted 1:50 for non-ischaemic
effluent and 1:100 for ischaemic effluent) is oxidised by lactate
dehydrogenase (45 minutes at 37°C) using nicotinamide adenine
dinucleotide in the presence of HCl-amino-methyl-propanol buffer
and hydrazine hydrate. The resulting reduced nucleotide
fluorescence is determined using an Aminco fluorimeter with
appropriate blank corrections and read against the standard curve
(2, 4, 6, 8, 10 mmol/1).
REGIONAL MYOCARDIAL BLOOD FLOW DETERMINATION
Regional myocardial blood flow was determined by the injection
of radioactively labelled microspheres through a left atrial
cannula with subsequent analysis of radioactivity in myocardial
slices modified from the method of Utley et al (1974).
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N A
y - 2. 5 x 10"3x + 0.31 (r= 0. 993)
JL I
200 400 600 800 1000 1200 1400 1600
f mol
y - 4.2 x 10"3x + 0. 06 ( r= 0. 998)
X
200 400 600 800 1000 1200 1400 1600
f mol
Figure 2.1 Linearity of radioenzymatic assay for l-noradrenaline (NA) and
l-adrenaline (A) as free base.
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Prior to injection 1.5 x 10^ (or for detailed mapping studies
8 x 10^) microspheres, 15 jam in diameter, labelled with Co^,
Sn-^3 or Sr^^, were suspended in 10 per cent dextran and sonicated
for 10 minutes to disperse aggregates before being drawn into a
syringe containing 0.1 ml 5% Tween 80 (to prevent reaggregation).
The suspension was diluted with 10 per cent dextran to give a final
concentration of Tween 80 of less than 0.5 per cent. Microspheres
were continually agitated by hand before injection. Ten seconds
before injection, withdrawal of a reference blood flow sample from
the descending aorta was commenced at constant rate (9 ml per
minute) into a pre-weighed heparinised syringe and continued for
exactly two minutes. Microspheres were injected into the left
atrium over 10 seconds at predetermined times with respect to
coronary occlusion, detailed in individual experimental protocols.
After completion of each experiment, the heart was excised and
stored overnight at 4°C to facilitate its dissection. An
anatomical diagram of coronary anatomy, site of ligation and area
of cyanosis was drawn immediately before excision. The free wall
of the left ventricle was removed, dissected free of epicardial
fat, major blood vessels and papillary muscle and divided into
approximately twenty biopsies of relatively constant geometry,
including the entire ischaemic area. Samples were further divided
into endocardial and epicardial halves and weighed separately. For
more detailed blood flow mapping studies using the higher dose of
microspheres, the free left ventricular wall was divided into
approximately eighty biopsies which were further separated into
endocardial and epicardial halves before being weighed (100 - 250
mg) •
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Radioactivity in each biopsy, and total radioactivity in the
reference blood flow sample were determined initially using a
two-channel gamma counter (Wallac, LKB-Wallac, Finland) and
subsequently using a multichannel gamma counter (Compugamma,
LKB-Wallac, Finland) with appropriate windows and energy peak
crossover and decay corrections.
Regional myocardial blood flow was calculated for each biopsy
from the formula:
CM
RMBF = x RBF (ml/min/g)
CR
where CM = radioactivity (cpm/g wet weight) in tissue sample
CR = total cpm in reference blood sample
RBF = reference blood flow (ml/min) derived from
withdrawal time and volume of blood in
reference syringe.
Reproducibility studies have confirmed no systematic
differences in measured regional flow with the isotopes used and no
significant errors attributable to geometric factors or decay
during counting (Riemersma, 1979) . Results were calculated using a
computer programme and presented as 1) endocardial blood flow, 2)
epicardial blood flow and 3) the endocardial-epicardial blood flow
ratio.
During experiments infusing ischaemic metabolites without
coronary occlusion, continuous measurement of regional (left
anterior descending and circumflex) blood flow was carried out
using an electromagnetic flowmeter (Skalar Instruments), with 1.5,
2 or 2.5 mm probes, according to vessel diameter. Great care was
taken during the experiment to maintain the probe at right angles
to the artery and to minimise movement artefact between vessel and
probe. Reproducible changes in blood flow could be achieved
following left stellate ganglion stimulation at all frequencies.
This technique was used only during the regional infusion of
metabolites without coronary occlusion.
REGIONAL EPIGARDIAL ACTIVATION TIMES
A 5 x 4 cm flexible multielectrode grid was sutured to the
epicardium over the free left ventricular wall across the ischaemic
area created by coronary occlusion. This grid provided mapping of
the epicardial activation sequence within the ischaemic zone by
electronic multiplexing of unipolar electrograms from the 80 point
grid. Each electrode was approximately one mm in diameter,
separated by 5 mm and grouped in an 8 x 10 array. Signals from
each electrode site were passed to a lead selection unit allowing
selection of any individual electrogram with respect to the Wilson
central terminal. A switch on the lead selection unit allowed the
sequential selection of six groups of 14 electrograms
(approximately four complexes per group) which were recorded on
magnetic tape (4-channel recorder) after passage through a
3-channel multiplexing device coding 5 signals per channel with a
sampling frequency of less than 3 as. Regional epicardial
activation time was calculated at each electrode site by replay of
the multiplexed signals through a purpose built demultiplexer
(Department of Medical Physics, University of Edinburgh) and
amplifier and display of individual electrograms on a 3-channel
recorder (Mingograf, Siemens Elema) . Local conduction delay was
derived from the midpoint of the intrinsic deflection of individual
electrograms, compared to the earliest ventricular activation from
an electrode in the non-ischaemic area (after Russell et al, 1982).
Conduction delay at each electrode could be reliably measured
to the nearest 4 ms (paper speed 250 or 500 mm/sec) and conduction
delay maps were constructed at intervals during ischaemia,
immediately after low and high frequency left stellate ganglion
stimulation and during coronary reperfusion. Electrograms without
a clear cut intrinsic deflection, or those with poor quality
signals were not included in the analysis. Occasionally, with
activation delays greater than 60 ms, the QRS complex became
slurred with multiple negative deflections. Under these
circumstances, measurements were taken to the midpoint of the major
negative deflection of the electrogram, the time most likely to
coincide with the upstroke of the local cardiac action potential.
The recording and analytical apparatus are shown diagramatically in
Figure 2.2.
REGIONAL SAMPLING FROM ISCHAEMIG EFFLUENT
As discussed earlier, regional sampling of ischaemic coronary
venous effluent from an ischaemic area depends on equilibration
between coronary venous blood and that perfusing the ischaemic
territory. This, in turn, is dependent upon the extent to which
arterial collaterals from the LAD (proximal to the site of
occlusion) and from the circumflex coronary artery perfuse
ischaemic or non-ischaemic tissue before draining to the venous
sampling site. Clearly the lower the flow in the central ischaemic
area, the greater is the potential contribution of non-equilibrated
blood to the local coronary venous effluent, either as drainage
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Figure 2.2 Measurement of regional activation time. A flexible multi-electrode
grid over the free left ventricular wall and ischaemic area allows sequential
recording of individual electrograms at all sites over a few seconds using a multi¬
plexing device (see text).
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from a non-ischaemic area or from arteriovenous shunts.
In practice, the contribution of the LAD to perfusion of the
ischaemic region can be considered to be nil, since the LAD has
generally been occluded proximal to the origin of the first septal
perforator branch. At steady state, therefore, the input and
output from the territory of drainage of the coronary vein is the
same and may be defined as:
flow LV x [V] = flow LAD x [A] + flow x^x [a] + flow x2x [A] (1)
where flow LV and flow LAD represent local venous and left anterior
descending c oronary arterial flow respectively, [V] and [A]
represent local venous and coronary arterial concentrations
respectively of a tracer not extracted or metabolised by the heart;
flow x^ represents the contribution of collateral nutritional flow
from the circumflex artery to local venous flow i.e. that component
that has equilibrated with the region of interest; and flow x^
represents the contribution of non-nutritional flow from a
non-ischaemic area to local venous flow i.e. that component that
has not equilibrated with the region of interest.
During ischaemia as a result of LAD occlusion, flow LAD = 0.
Thus, substituting in equation (1), and rearranging
flow LV' = (flow x'x + flow x'2) [A] (2)
[V]
where flow LV', flow x'^ an(j flow x'2 represent the flows defined
above during LAD ligation. [A3 should be similar to concentrations
in the coronary sinus [CS] if the tracer is at steady state and if
extraction or metabolism of the tracer is not modified by coronary
occlusion. If the circumflex coronary artery is the major
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contributor to local venous flow during ischaemia, then [A], [CS]
and [LV] should become similar at steady state.
The contributions of nutritional and non-nutritional flow to
total venous flow may be derived from the following three
principles:
(1) Nutritional flow in the ischaemic area can be measured
conventionally using radiolabelled microspheres.
(2) Total venous flow (nutritional and non-nutritional) may be
measured directly in an epicardial coronary vein.
(3) Retrograde coronary venous infusion of microspheres can
define the territory of drainage of the local vein from
which total nutritional flow can be derived (from (1),
above) .
Source of collateral perfusion in ischaemic area and origins of
ischaemic effluent
Preliminary experiments evaluated three extravascular space
markers; technetium (Tc 99m) ^ I^l-kippuj-apg and Xenon. The
collection and handling of Xenon in plasma samples proved
difficult. i!31—hippurate was extracted to a minor degree across
the heart (< 10 per cent) but steady state was achieved within 5
minutes. Tc^m extraction averaged 1 per cent across the anterior
myocardium and 3 per cent across the circumflex region (coefficient
of variation 6 per cent for each), neither significantly different
from zero.
In further experiments the effect of retrograde venous
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perfusion (in vitro) on labelling of the venous territory with
microspheres was evaluated using 25 cm and 75 cm water perfusion
pressure. The epicardial area labelled was similar at both
perfusion pressures in two studies using paired microsphere
injections, although endocardial labelling was 20 per cent greater
at the higher pressure. In view of this, the higher pressure was
used. At 75 cm water, no significant loss of arterially injected
microspheres (wedged in the capillary bed) was observed.
Myocardial tissue containing 2 per cent of the total venous
injection or greater was arbitrarily designated as part of the
territory draining into the local vein.
The studies with ischaemia were performed in open-chest
pentobarbitone anaesthetised dogs prepared as described in Chapter
3. The LAD was dissected for occlusion and a venous sampling
catheter was placed in the centre of the LAD territory. For this
study, a large bore (5FG) portex cannula was used and tied directly
into the local coronary vein [LV] occluding its lumen. A lateral
catheter towards the coronary sinus [CS] was also inserted
conventionally. Circumflex coronary artery flow was measured using
an electromagnetic flow probe, and this vessel perfused from the
left carotid artery at measured flow as illustrated in figure 2.3.
Flow was kept constant through the experiment. Tc^9m or
1 3 1
I J-L-hippurate was infused at constant rate proximal to the
coronary perfusion pump and blood sampled just prior to the
circumflex artery [A] . Tracer concentrations (cpm/ml) at [A], [LV]
and [CS] sampling sites were measured at minute intervals over 20
minutes, ten minutes before and ten minutes during LAD occlusion.
Flow in the local venous territory was measured directly by timing
blood draining from the [LV] catheter, used as a syphon.
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Figure 2.3 Validation of local venous sampling.- experimental prep¬
aration. The circumflex coronary artery was perfused at constant
flow from the carotid artery and labelled selectively using tecnetium
(Tc) 99m. Nutritional flow was measured from intraatrial microsphere
injection and local venous (LV) flow measured directly (see text).
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Nutritional blood flow was determined 5 minutes after LAD occlusion
using intraatrial microspheres as described earlier.
At the end of each experiment, the heart was carefully excised
and supported in a cradle. Microspheres (20-50,000) were infused
into the local venous catheter and flushed over 10 minutes at
constant pressure (75 cm H^q). The free left ventricular wall was
then prepared as described previously and cut into 36 biopsies
including the whole of the LAD territory. Each biopsy was further
divided into endocardial and epicardial regions by midline
dissection and counted. Biopsies containing greater than 2 per
cent of the venous tracer (from in-vitro labelling) were designated
as part of the region drained by the local vein and mean
nutritional flow and then determined as described previously.
As shown in Figure 2.4 in a representative experiment, tracer
levels in [LV] increased rapidly following LAD occlusion and were
not significantly different from [CS] concentrations during acute
ischaemia. In this study, therefore, the circumflex coronary was
the source of blood flow to the ischaemic region. If the LAD or
right coronary had contributed significantly, the concentrations in
the [LV] would have remained below those in the [CS]. In two other
experiments, [LV] concentrations averaged 80 per cent of [CS]
concentrations during ischaemia.
Using this model, mean nutritional flow in the region of
interest (as defined above) in three experiments was 1.3, 1.0 and
0.9 ml/min for territories of 4.3, 2.3 and 3.8 g wet weight
respectively. Venous flow, averaged over 2-8 minutes of ischaemia,
which included the period of microsphere injection, was 2.0, 1.2
and 1.5 ml/min. Nutritional flow averaged 65, 83 and 60 per cent
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Minutes
Figure 2.4 Effects of LAD occlusion on anterior (LV) and
lateral (CS) venous concentrations of l131-hippurate during
infusion into the circumflex coronary artery. See text for
details. Data from one experiment
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of total venous flow in [LV].
Thus, in this model, despite several assumptions, the bulk of
coronary venous effluent has indeed perfused the ischaemic region
created by LAD occlusion. The use of regional venous sampling can
therefore be considered to reflect qualitatively changes in
metabolites in the ischaemic area. It is likely, however, that
hormone and metabolite spillover into coronary venous effluent will
occur to a greater extent from moderately ischaemic rather than
severely ischaemic regions, although this has not been quantified.
On the other hand, however, a small contribution to local venous
effluent from non-ischaemic or non-equilibrated areas precludes the
use of this technique to quantify output from the ischaemic region.
For this reason, results in this thesis have generally been
expressed in terms of arteriovenous concentration differences
rather than output, although regional flow has been measured in all
experiments.
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3 SPONTANEOUS CATECHOLAMINE RELEASE FROM
ACUTELY ISCHAEMIC MYOCARDIUM
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It is generally accepted that increased liberation of
catecholamines in the heart follows the onset of myocardial
ischaemia or infarction. Indeed, few authors appear to consider
that the question requires detailed discussion or debate (Hoffman,
1978). However, although the evidence favouring activation of
efferent neurosympathetic activity to the heart following acute
ischaemia is considerable, much of it is indirect and dependent on
observations following pharmacological or surgical manipulation of
the cardiac neurosympathetic axis, or on observation of end organ
responses rather than the activity of the nerve terminal itself.
In keeping with the clinical evidence summarised in Chapter 1,
arterial catecholamine levels rise soon after the onset of
experimental coronary occlusion. Staszewska-Barczak and
Ceremuzynski (1968) observed a progressive rise in arterial
adrenaline over the first 15 minutes of coronary ligation in a
majority of anaesthetised dogs, with secretion rates up to 8
pg/min. Arterial noradrenaline levels rose infrequently. Once
elevated, arterial catecholamine levels remained constant over a
3-4 hour period, contrasting with the periodicity of spontaneous
arrhythmias over this period in this model. Nevertheless, these
authors observed a relationship between adrenaline release and
spontaneous arrhythmias (Ceremuzynski et al, 1969), and established
that adrenaline release occurred from the adrenal medulla as a
result of reflex stimulation from cardiac receptors in the centre
of and at the periphery of the evolving infarct. This reflex
involved vagal efferent as well as extra-vagal pathways and
required intact supraspinal structures (Staszewska-Barczak, 1971).
The source of the infrequently observed increase in noradrenaline
was not identified.
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The noradrenaline content of infarcted heart muscle has
decreased to less than 40 per cent of control by 24 hours and
rapidly declines towards zero thereafter (Gudbjarnason, 1972). The
rate of decline in tissue catecholamine content during the
reversible phase of acute ischaemia has not been assessed. Muntz
et al (1981) noted no significant reduction in tissue catecholamine
content one and three hours after LAD ligation in dogs, but after
three hours these authors noted a significant reduction in
catecholamine fluorescence within sympathetic nerves, suggesting
that catecholamines were redistributed within ischaemic myocardium
at this time. Russell et al (1961) noted a small reduction in
infarcted tissue noradrenaline content (from 0.83 + 0.32 to 0.64
+ 0.16 pg/g wet weight) one hour after coronary artery ligation
in the dog. No significant reduction in noradrenaline content in
rat ventricular myocardium was noted 30 minutes after left coronary
artery ligation (Abrahamsson et al, 1982). In non-infarcted
myocardium, a progressive decline in noradrenaline content was
observed over the first two weeks following coronary ligation, with
a gradual recovery of normal tissue levels over a further four
weeks (Gudbjarnason et al, 1971). Neither time course bears a
close relationship to spontaneous arrhythmias in this model. As
measurement of tissue catecholamines does not distinguish between
intraneuronal (stored) and extraneuronal (released)
neurotransmitter, such studies are unlikely to define nerve
terminal activity.
A reduced threshold for ventricular arrhythmias after
catecholamine infusion during experimental infarction has been
known for over 20 years (Maling and Moran, 1957; Winbury et al,
1962; Cha et al, 1970), with a time course rather similar to
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depletion of noradrenaline in the infarct zone. These studies
avoided to a large extent the early phase of arrhythmias (Harris,
Phase I) by using a two-stage coronary ligation procedure (Harris,
1950) and therefore cannot provide information on sensitivity to
catecholamines during acute ischaemia (ligation for 10-20 minutes)
as opposed to infarction (ligation beyond 24 hours).
Catecholamine perfusion of isolated hearts produces several
metabolic and ultrastructural abnormalities similar to acute
ischaemia. Thus, depletion of tissue ATP and glycogen,
accumulation of lactate, leakage of creatinine phosphokinase and
aspartate aminotransferase have been demonstrated with myofibrillar
abnormalities and mitochondrial rounding, enlargement and altered
electron density (Williamson, 1964, 1966; Waldenstrom et al, 1978).
In general, the concentrations of catecholamines used for such
studies have been approximately two to three orders of magnitude
higher than those seen under physiological conditions. However,
local myocardial concentrations round the nerve terminal may be
many times greater than in plasma, particularly if neurosympathetic
activity has been stimulated by ischaemia, and removal mechanisms
impaired. Similar harmful metabolic effects of endogenous
catecholamines on the development of hypoxic myocardial cell damage
in the rat have been shown by Gauduel et al (1979) .
The purpose of the present study was to observe on a minute to
minute basis catecholamine concentrations in arterial and in
coronary venous blood draining ischaemic and non-ischaemic
myocardium during experimental acute coronary ligation before, at
the onset of, and following spontaneous ventricular arrhythmias
including ventricular fibrillation. Tritiated noradrenaline is
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rapidly taken up by the dog heart and equilibrates with the
intraneuronal stored neurotransmitter pool (Chidsey et al, 1963;
Fillon et al, 1971). The first demonstration of labelled
noradrenaline release with nerve stimulation was made by Hertting
and Axelrod in 1961. Since then, exogenous adrenergic transmitter
release from the heart has been correlated with a variety of
physiological and pathophysiological responses in the dog model in
vivo (Gaffney et al, 1963; Harrison et al, 1963; Yamaguchi et al,
1976). Release of prelabelled noradrenaline from the myocardium
into the coronary sinus increases following intracoronary tryamine
and left stellate ganglion stimulation (Yamaguchi et al, 1973).
,• I Bronk et al. 19 3G ]
Catecholamine release from the heart occurs at phy^ological ; nerve
stimulation frequencies (1-3 Hz) despite intact uptake mechanisms,
suggesting that the venous catecholamine content is a reflection of
changing levels at the nerve terminal (Yamaguchi et al, 1975).
This increased production is independent of haemodynamic changes
(Siegel et al, 1961). The studies reported in this thesis are
therefore based on the assumption that changes in nerve terminal
catecholamine release from alterations in efferent sympathetic
activity or from local myocardial influences on the nerve terminal
itself are reflected by corresponding changes in venous
catecholamine content.
METHODS
Operative and Sampling Methods
After an overnight fast, adult mongrel dogs (10-24 kg) of
either sex were anaesthetised with 50 mg/kg intravenous
alpha-chloralose in urethane (25%) thirty minutes after
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premedication with 2 mg/kg intramuscular morphine (Series I).
Maintenance anaesthesia was achieved by constant intravenous
infusion of 5 mg/kg/hour alpha-chloralose in urethane. For Series
II, morphine premedication was omitted and anaesthesia induced by
100 mg/kg alpha-chloralose alone as a slow intravenous infusion.
Maintenance was achieved by 10 mg/kg/hour alpha-chloralose.
Following endotracheal intubation, animals were ventilated on room
air using a positive pressure Harvard respirator at 15 cycles per
minute and appropriate tidal volume.
The operative procedures were as follows: sampling, infusion
and monitoring catheters (Portex 3FG, 6FG and 8FG respectively)
were inserted into both right and left femoral vessels, and the
heart was exposed through a left lateral thoracotomy (fifth
interspace) and suspended in a pericardial cradle. The left
anterior descending coronary artery (LAD) was isolated within 3 cm
of its origin and a loose ligature placed round it to facilate
occlusion using a Mayfield intracranial arterial clip. Great care
was taken during the dissection to minimise injury to pericoronary
nerves which were readily visualised. Two further catheters (3FG)
were inserted into epicardial coronary veins, one antegradely
towards the centre of the LAD territory and the other retrogradely
into a vein draining circumflex territory effluent towards the
coronary sinus. These catheters were similar to the arterial
sampling catheter except for two side holes, cut into the side of
the catheter within 2 cm of its tip to facilate sampling at low
flow rates. During insertion, the catheters were continuously
flushed with saline to prevent clotting and when in position were
sutured to the epicardium and filled with heparin(1000 iu/ml). A
left atrial catheter (3FG) was inserted via the atrial appendage
63
for microsphere injections.
For intracoronary arterial infusions
(morphine-chloralose-urethane anaesthesia), a small (approx 1-1.5mm
external-diameter) side branch of the proximal LAD was isolated as
it crossed the root of the pulmonary artery towards the right
ventricle. Occasionally, this vessel proved too small and
therefore the first small proximal LAD branch to the right or left
of the septum was used. A Portex catheter (1FG) was heparinised
and inserted such that its tip lay just at the point of bifurcation
of the vessel from the LAD but without projecting into the lumen of
the parent vessel. For technical reasons, this procedure was
unsuccessful in three animals, who were subsequently assigned to
the main experimental protocol. The experimental preparation is
shown in Figure 3.1.
In four experiments (morphine-chloralose-urethane
anaesthesia), the left fifth rib was resected, the lung retracted
and the anterior and posterior ansa subclavia from the left
stellate ganglian dissected free from fat and subcutaneous tissue
and attached to a silver bipolar stimulating electrode for
stimulation using a Grass model S48 stimulator. No coronary
dissection was performed for these studies but coronary venous
sampling catheters were inserted as described above.
In each experiment following completion of surgery, the
preparation was heparinised (100 u/kg) and allowed to recover for
30 minutes or until haemodynamically stable. Arterial blood
pressure (Elcomatic 751 transducer), heart rate and the surface ECG
were recorded continuously on a Devices recorder. Ventricular
fibrillation during coronary occlusion was managed by removal of
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Figure 3.1 Experimental preparation. Sampling catheters
in a local vein in the centre of the LAD territory (1, tip
arrowed ) and laterally draining towards the coronary sinus
(2) allow partial separation of ischaemic and non-ischaemic
effluent Infusion catheters in a small side branch of the
LAD (3) and in the left atrium (4) are also shown. A loose
ligature is round the LAD at the site of occlusion.
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the occlusion clip and DC defibrillation (10-20 joules) repeated as
necessary.
Series I:
The effect of coronary occlusion on arterial and cardiac
venous catecholamines was initially studied in 12 experiments
(Series I). Thirty minutes after completion of surgery, and prior
to coronary artery occlusion coronary venous effluent was sampled
continuously for ten minutes from the local vein in the LAD
territory using a calibrated Watson-Marlow roller pump at a flow
rate of 1 ml/min). Arterial samples were collected from the aorta
at five minute intervals.
Coronary venous and arterial sampling were then continued
during a ten minute period of LAD occlusion and for ten minutes of
reperfusion following abrupt rele ase of the occlusion clip.
Regional myocardial blood flow was estimated by microsphere
injection 5 minutes after LAD occlusion (Figure 3.2a). One
experiment was subsequently excluded from statistical analysis
because of excessive variability in depth of anaesthesia and
correspondingly high basal catecholamine levels.
Handling of prelabelled noradrenaline by iscbaemic myocardium
The effect of coronary occlusion on the efflux of
3
dl H-noradrenaline and its metabolites from the ischaemic area was
studied in five experiments. Prior to coronary occlusion, 25 jiCi
3
dl H-noradrenaline was infused into the LAD over ten minutes, the
infusion being completed 15 minutes before the start of sampling.
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Figure 3.2 Experimental protocols; spontaneous catecholamine overflow
during acute i-chaemia.
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Local venous and arterial samples were collected as in Series I for
10 minute periods before, during and after LAD occlusion (Figure
3.2b) and plasma (100 pi) counted directly in a liquid
scintillation spectrometer. In four of these experiments, the
catecholamine content of venous and arterial samples was also
determined enzymatically, forming part of Series I. The object of
these experiments was to determine whether catecholamines released
from sympathetic nerve terminals during acute ischaemia were
metabolised prior to their efflux into coronary venous effluent.
Series II:
The basic experimental design in this series of 16 experiments
using a-chloralose anaesthesia was similar with the addition of
continuous sampling from arterial and coronary sinus catheters
(Figure 3.2c). This anaesthetic agent was used alone to avoid
possible vagotonic effects of morphine.
Validation of detection of catecholamine release from the heart:
In two studies without LAD occlusion 1-noradrenaline dissolved
in isotonic saline containing 1% ascorbic acid was infused into the
LAD territory in physiological doses (5, 10 and 15 ng/kg/min), each
over five minutes with continuous sampling of local venous effluent
for five minutes before, during and for five minutes after the
infusion (6 experiments). Intracoronary tyramine (5 pg/kg/min)
was infused for 15 minutes with continuous local venous sampling
for ten minutes before, during and for five minutes after the
infusion.
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The anterior and posterior ansa subclavia from the left
stellate ganglion were stimulated for one minute periods at
supramaximal voltage (8v) using square wave pulses (4 msec) at 8
Hz. Continuous sampling of local venous, coronary sinus and
arterial plasma before, during and after sympathetic stimulation
was undertaken in four experiments.
All plasma samples were analysed for adrenaline ([A]) and
noradrenaline ([NA]) as described in Chapter 2. Substantially
reduced local venous flow during ischaemia usually decreased the
sample volume from the ischaemic area to 500 pi or less.
Occasionally, adequate volumes were not obtained over one minute
and collection was therefore continued for two minutes before
proceeding to the next sample. Plasma lactate was analysed in
selected pre-occlusion samples and at intervals during occlusion
and reperfusion. Samples obtained following resuscitation were not
included in the overall statistical analysis.
Trends in arterial catecholamine concentrations with time were
evaluated where appropriate with a linear regression co-efficient
and least squares method of analysis. Variability in levels before
or during coronary occlusion was evaluated by analysis of variance
and computed modified t-statistic. Students t-test for paired data
was used to calculate probability values on arteriovenous
differences and on the combined results from before, during and
after coronary occlusion periods where no differences were observed
within each of these periods. Changes in peak myocardial
catecholamine release during coronary reperfusion were analysed by
comparing levels immediately before to those immediately after


























































*P<0.02wrtpre-release+<0.05bas llev l Table3.1:Spontaneouscatecholaminecon entrationsbef r ,duri gderLADclusi nf tenminutes(=11,S riesI).
mean + standard error of the mean. A five per cent level of
confidence was considered significant.
RESULTS
SERIES I
Mean data for plasma catecholamines over two one-minute
sampling periods out of the ten minute sampling periods before,
during and after coronary occlusion are given in Table 3.1 and
shown graphically on a minute-to-minute basis in Figures 3.3 and
3.4. The changes in [NA] and [A] (compared to basal levels)
during and after LAD occlusion are given in table 3-la.
Release of small amounts of [NA] from the heart was observed
during the preocclusion period but no substantial or significant
changes in concentration followed coronary occlusion, although
increased variability in levels in ischaemic venous effluent was
observed (Figure 3.3). Increased [NA] concentrations in ischaemic
effluent were, however, observed during coronary reperfusion,
reaching a peak within the first minute of release of the occlusion
clip and declining rapidly towards pre-release levels thereafter.
Arterial [NA] increased progressively, levels approximately
doubling during the sampling period (p < 0.005). A significant
increase in regional [NA] release from the control period was
observed for the first two minutes of reperfusion only (Figure
3.5) .
In contrast, venous [A] levels were lower than arterial levels
during the control period (Figure 3.4). Ischaemia caused an
immediate three fold rise in arterial [A] (p < 0.05 compared to

























































Figure 3.3 Arterial (open circles) and local venous (closed circles)
noradrenaline (NA) responses to ten minutes LAD occlusion and reper-
fusion (Series 1, mean ±SEM).
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5 1 0 15 20 25 Minutes
Figure 3.4 Arterial (open circles) and local venous (closed circles)
adrenaline (A) responses to ten minutes LAD occlusion and reperfusion
(Series I, mean ± SEM).
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significantly enhanced extraction of [A] across the ischaemic area
(Figure 3.5). Reperfusion increased venous [A] and abolished
extraction for 4-5 minutes, a time course rather similar to the
period of reactive hyperaemia. It was not possible to know whether
actual release of [A] from the heart occurred at this time without
more frequent measurement of arterial levels.
Arrhythmias:
Frequent ventricular premature bea ts (> 10/minute) and/or
self terminating ventricular tachycardia occurred in three
experiments which form part of the data detailed above. As shown
in Figure 3.6, patterns of arterial and venous catecholamines and
in particular, levels immediately preceding the arrhythmias, did
not differ substantially in these experiments, from the group as a
whole. Reperfusion-induced release of [NA] was seen in two of the
three studies, in one of which (Figure 3.6b) release was delayed
for four minutes after removal of the occlusion clip. In this
experiment, a similar delay in the appearance of reactive
hyperaemia was noted, suggesting that mechanical factors at the
occlusion site or possibly vasospasm may have delayed the washout
phase associated with reperfusion. A small but statistically
significant increase in local venous [NA] with coronary occlusion
was noted in one study (Figure 3.6c) during frequent ventricular
premature beats without fibrillation (control [NA] 0.7 + 0.05
pmol/ml; occlusion [NA] (during VPB's) 1.6 + 0.05 pmol/ml, p <
0.01). Arterial [NA] remained low during this study but transient
increases in arterial levels during the phase of arrhythmias were
not excluded.
Spontaneous ventricular fibrillation occurred in three
80
T\ OCCLUSION REPERFUSION
* p < 0.05 wrt control
** p < 0.01 wrt control
Figure 3.5 Noradrenaline (NA) release from and adrenaline (A)
extraction across ischaemic myocardium (2, 6, 10 min)and on
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Figure 3.6 Arterial (open circles) and localvenous (closed circles)
catecholamine responses during ischaemia complicated by frequent
ventricular premature beats (VPB)orself terminating ventricular
tachycardia (VT). Three experiments.
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experiments once during LAD occlusion and twice within the first
few seconds of reperfusion. Local venous [NA] increased
significantly, immediately before spontaneous ventricular
fibrillation (Figure 3.7a). Arterial [NA] was also increased when
first measured following defibrillation and both levels returned to
preocclusion values over five minutes. Haemodynamically
significant ventricular tachycardia occurred prior to spontaneous
ventricular fibrillation. Reperfusion induced ventricular
fibrillation (Figure 3.7b) did not modify the pattern of [NA]
release and abolished [A] extraction associated with this manoevre
in the absence of the arrhythmia.
Metabolites:
3
Prelabelling of the ischaemic territory with H-noradrenaline
■
did not reveal consistent efflux of [NA] or its metabolites from
the ischaemic area (Figure 3.8a). Trend analysis of the decrease
in counts over time did not reveal statistically significant
differences between the occlusion and preocclusion periods (pooled
results). Two studies, however, did suggest some increase in
radioactivity in ischaemic effluent, the first immediately
preceding spontaneous ventricular fibrillaton (Figure 3.8b) and the
second during the development of ventricular premature hearts
(Figure 3.8c). In both of these experiments, arterial counts
declined normally, indicating absence of generalised sympathetic
activation over this time.
SERIES II
The overall pattern of [NA] and [A] responses to acute
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Figure 3. 7 Arterial (open circles) and local venous (closed circles)
catecholamine responses during spontaneous ventricular fibrillation
during coronary occlusion (A) and on reperfusion (B). Vertical
lines show defibrillation.
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10 20 10 20 Minutes
Figure3.8 ^H-NA in arterial (open circles), local venous (closed circles) and
coronary sinus (triangles)effluent. A- mean data (4 experiments). B- ventric¬




8' 10' 2' 4' 6' 8' 10' 2' 4' 6'
[NA](pmol/ml)
Art x 1.6 1.7 1.6 1.5 2.1 1.7 2.0 1.7 1.9 2.3
SEM 0.2 0.3 0.3 0.3 0.5 0.3 0.4 0.2 0.3 0.9
LV x 2.1 1.8 2.2 1.9 2.7 2.5 2.4 3.0 2.1 2.4
SEM 0.4 0.4 0.4 0.4 0.7 0.5 0.4 0.4 0.3 0.6
CS x 1.9 1.8 2.0 2.0 1.6 2.2 1.8 1.9 2.3 2.6
SEM 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.5 0.4 0.3
[A](pmol/ml)
Art I 0.6 0.7 0.8 0.7 1.1 1.0 1.1 1.1 1.6 1.4
SEM 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.4 0.4
LV I 0.4 0.3 0.5 0.7 0.7 0.6 0.5 1.2 1.5 1.2
SEM 0.1 0.1 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.4
CS I 0.5 0.5 0.5 0.5 0.5 0.8 0.7 0.8 0.7 0.7
SEM 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3
TABLE 3.2: Spontaneous catecholamine concentrations before, during and





Art "x 0.1 0.5
SEM 0.2 0.4
LV T 0.0 -0.1
SEM 0.4 0.3
CS T 0.1 0.1
SEM 0.3 0.4
[A](pmol/ml)
Art x 0.2 0.5
SEM 0.3 0.3
LV Y 0.2 0.4
SEM 0.3 0.4
















p < 0.05 wrt basal level
TABLE 3.2a: Changes in catecholamine concentrations during and
after LAD occlusion for ten minutes (n = 16; Series II).
Data from Table 3.2.
ischaemia and reperfusion were similar to Series I (Tables 3.2 and 3-2a).
Arterial [NA] tended to increase gradually during the sampling
period (basal 1.6 + 0.2 pmol/ml; reperfusion 2.0 + 0.3 pmol/ml; p
< 0.05) with a more obvious rise in arterial [A] during ischaemia
and reperfuson (basal 0.6 + 0.2 pmol/ml; ischaemia 0.9 + 0.2
pmol/ml; reperfusion 1.4 pmol/ml, p < 0.05). Release of small
amounts of [NA] from the heart was not significantly modified by
regional ischaemia, and although release was maintained from the
ischaemic area more than the non-ischaemic area during LAD
occlusion (Figure 3.9), this difference did not achieve statistical
significance at a 5 per cent level of confidence (0.05 < p < 0.1).
As before, [NA] release specifically from the previously ichaemic
area was readily seen during the first two minutes of reperfusion.
Adrenaline extraction across the heart was maintained during the
ischaemic period, but was abolished during early reperfusion,
indeed minor release of [A] from the previously ischaemic area was
evident at this time (Figure 3.9).
No systematic differences between basal catecholamine
concentrations (preocclusion) were observed between Series I and
II, arterial [A] levels being slightly greater in the
morphine-chloralose-urethane series, while basal [NA] levels were
greater in the chloralose series (Table 3.1 and 3.2).
As with Series I, spontaneous ventricular ectopic beats (5
experiments) generally did not modify or follow changes in
catecholamine release from the heart, although a minor increase in
local venous [NA] followed coronary occlusion and ventricular
ectopic beats in one experiment. Minute-to-minute sampling of


















* p < 0.05 wrt control
**p< 0.005 wrt control
Figure 3.9 Catecholamine release from and extraction across
ischaemic (open bars) and non-ischaemic (shaded bars) myocardium
before and during coronary occlusion (2, 4-8, 10 min) and on
reperfusion (2, 6 min). Data from table 3.2.
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Art x 2.7 2.9 2.7 2.7 2.3 4.6
SEM 0.6 0.8 0.6 0.7 0.8 1.6
LV x 2.4 3.7 4.5+ 9.4+ 2.9 17.9++
SEM 0.4 1.1 1.2 3.1 1.0 4.5
[A](pmol/ml)
Art x 1.0 0.9 1.3 1.6 1.7 2.1
SEM 0.5 0.6 0.5 0.6 0.9 1.0
LV x 0.4 0.5 0.5 0.5 0.7 1.1
SEM 0.2 0.3 0.2 0.3 0.4 0.4
+
p < 0.05 ++ p < 0.005 wrt control.
Table 3.3: Arterial and venous catecholamine response to
intracoronary 1-noradrenaline and tyramine (n = 6 )
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fibrillation followed or resulted in a catecholamine surge.
Ventricular fibrillation during LAD occlusion occurred in three
experiments. A representative example, corrected for delay in the
sampling lines (Figure 3.10), demonstrated that increments in [NA]
concentrations at all sampling sites occurred immediately following
the arrhythmia rather than before it developed. In this example,
no warning tachyarrhythmia developed. It is probable therefore,
that generalised sympathetic activation occurred secondary to the
loss of effective circulation and/or defibrillation, and was not an
antecedent to the arrhythmia.
Validation of detection of catecholamine release
The sensitivity of the model in detecting release of [NA] from
the heart was tested in three ways. Firstly, intracoronary
infusions of 1-noradrenaline at three physiological doses (5, 10,
15 ng/kg/min) was readily detectable in local venous effluent (mean
data Table 3.3; example Figure 3.11a). This dose range had no
measurable haemodynamic effect. Secondly, intracoronary tyramine
(5 pg/kg/min) over 15 minutes resulted in massive myocardial [NA]
release (mean data Table 3.3; example Figure 3.11b) and in one
study caused spontaneous ventricular fibrillation. Thirdly,
stimulation of the left stellate ganglion at 15 minute intervals,
for four one-minute periods readily induced cardiac [NA] overflow
(Figure 3.12). No significant differences in peak [NA] release
were identified although considerable inter-individual variability
in [NA] responses was observed.
Lactate Production
Release of lactate into ischaemic venous effluent was observed
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Minutes
Figure 3.10 Arterial (open circles), local venous (closed circles)
and coronary sinus (triangles) NA before and after spontaneous




Figure 3.11 Arterial (open circles) and local venous (closed circles)
NA responses to intracoronary noradrenaline (A) and tyramine (B).
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Figure 3.12 Myocardial NA release before (open bars) and immediately after
(shaded bars) four one-minute periods of left stellate ganglion stimulation (8v;
4msecs) at 8Hz (n=4).
93
in all studies with coronary occlusion (mean arteriovenous
difference 0.4 + 0.2 mM/1 preocclusion and -4.3 + 1.2 mii/1 during
ischaemia: p < 0.001; n = 27). An example is shown in Figure 3.13.
Lactate release was confined to the ischaemic territory, except
during reperfusion when some release into the coronary sinus was
evident.
Haemodvnamic Data
The ischaemic territory (flow less than 50% control) averaged
38+6 per cent of the free left ventricular wall in Series I and
40+5 per cent of the free wall in Series II (p = NS). Mean flow
within the ischaemic and non-ischaemic areas for both series is
shown in Figure 3.14. Flow reduction to the endocardium (23 + 4
ml/min/100 g Series I; 22+4 ml/min/100 g Series II) was
significantly greater than to the epicardium (33 + 6 ml/min/100 g
Series I; 34+5 ml/min/100 g Series II; p < 0.025).
Reconstruction of flow maps from each experiment confirmed that the
tip of the local venous sampling catheter lay well within the
low-flow ischaemic zone.
Changes in mean heart rate and blood pressure during coronary
occlusion did not achieve statistical significance in Series I (HR
139 + 6 beats/min before and 141 + 7 beats/min during ischaemia;
BP 122 + 9 mmHg before and 120 + 8 mmHg during ischaemia). In
Series II, however, heart rate increased significantly from 149 +
5 beats/minute before to 154 + 5 beats/minute during ischaemia (p
< 0.01). Blood pressure did not change (128 + 6 mmHg before and
126 + 6 mmHg during ischaemia).
%
Figure 3.13 Arterial (open circles), local venous (closed circles) and
coronary sinus (triangles) lactate during coronary occlusion and
reperfusion.
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Series I Series II Series I Series II
NON-ISCHAEMIC ISCHAEMIC
Figure 3.14 Regional myocardial blood flow (RMBF) to normal and
ischaemic areas (Series land II).
DISCUSSION
On theoretical grounds, loss of amine content from infarcting
myocardium is readily understood on the basis of known phenomena
influencing nerve terminal catecholamine storage. Thus, retention
of [NA] within storage vesicles depends on aerobic production of
ATP (Bogdanski and Blaszkowski 1975) The amine reuptake pump is
linked to the Na+-K+-ATPase system, is energy dependent (Wakade and
Furchgott, 1968) and is susceptible to inhibition by, for example,
increased extracellular potassium or acidosis. Depolarisation of
the neuronal membrane inhibits the amine pump and facilitates
neurotransmitter diffusion into venous effluent (Lorenz and
Vanhoutte, 1975; Verhaeghe et al, 1978). The major intraneuronal
degradation enzyme for [NA] , monoamine oxidase, requires intact
mitochondrial function (Vanhoutte, 1978), but is not ATP dependent.
It is not therefore surprising that myocardial catecholamine levels
decline after coronary ligation. The crucial question relevant to
the results presented in this chapter is whether these phenomena,
applicable to irreversibly damaged tissue, apply equally to the
very early arrythmogenic phase associated with reversible ischaemic
injury. It is probable that they do not.
Massive release of myocardial catecholamines does not occur
within minutes of LAD ligation in the open chest anaesthetised dog.
Endogenous [NA] release is readily demonstrable during
intracoronary tyramine infusion and cardiac sympathetic nerve
stimulation in the absence of coronary occlusion. As the highly
sensitive radiochemical method of analysis detects release of
physiological quantities of neurotransmitter from the heart, it is
therefore most unlikely that massive release from nerve terminals
S7
has been missed even though lymphatic drainage and direct drainage
to the ventricular cavity via Thebesian vessels may be enhanced by
ischaemia. In this respect, the results stand in sharp contrast to
the early studies of Wollenberger and Shahab,(1965), Shahab and
Wollenberger,(1967) and Shahab et al,(1969; 1971) in the isolated
rat and rabbit heart and in the dog heart in vivo. This group
showed loss of an estimated 25 per cent of the total [NA] content
of rabbit heart after three to four minutes of arrested perfusion
and reperfusion, coinciding with release of lactate from this
preparation. Subsequently, in the dog heart, occlusion of the left
anterior descending coronary artery for between two and three
minutes caused massive release of [NA] (up to 750 ng/min) into the
great cardiac vein again coinciding temporally with lactate release
at this site. The major part of the release, however, appeared to
coincide with the reperfusion rather than the occlusion period.
The extent of catecholamine release from the heart after very short
periods of ischaemia, reported by Shahab and co-workers, has not
been confirmed by several more recent studies, mainly using more
sensitive and specific assay methods (Rogg and Bucher 1979;
Marshall and Parratt, 1980). In the current study, lactate release
during acute ischaemia was maximal during occlusion (Figure 3.13)
contrasting with [NA] release that was most easily demonstrated
during early reperfusion (Figure 3.3). This suggests that
catecholamine release associated with coronary reperfusion is
specific to this manoeuvre and not merely washout of catecholamines
released during the ischaemic period.
Absence of massive [NA] release during acute ischaemia should
not imply absence of enhanced neurosympathetic activity at the
nerve terminal over this time. In both studies with ventricular
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arrhythmias, prelabelling of the ischaemic territory with
3
H-noradrenaline showed a specific increase in counts in ischaemic
effluent immediately preceding spontaneous ventricular fibrillation
(Figure 3.8b) or during spontaneous ventricular premature beats
(Figure 3.8c). This trend for increased release of the parent
amine and/or its metabolites, however, did not achieve statistical
significance for the grouped results (Figure 3.8a). Release of
[NA] into ischaemic effluent was also seen in 2/8 studies with
spontaneous ventricular arrhythmias, short of fibrillation. It
seems probable, however, that most of the increase in local venous
catecholamines with ventricular fibrillation resulted from
generalised sympathetic activation at this time, either secondary
to circulatory arrest or as a consequence of electrical stimulation
of the heart during defibrillation (Blinks, 1966; Euler 1980,
1980a). The rise in [NA] and [A] following defibrillation occurred
at all sampling sites (Figure 3.10).
One possible explanation for the apparent absence of major
[NA] release from the heart during early ischaemia may lie in
enhanced amine reuptake, metabolism and negative feedback operating
at the nerve terminal. The powerful reuptake mechanism for
example, accounts for the removal of at least two-thirds of
released neurotransmitter (Folkow et al, 1967), and was active in
the study reported here, evidenced by peak venous [NA]
concentrations during steady state intracoronary 1-noradrenaline
infusion of less than half that predicted by assuming an average
LAD flow. With reduced blood flow in the ischaemic area, the
diffusion gradient between the extracellular and intravascular
space will be diminished and hence removal of neurotransmitter by
this mechanism reduced. It is quite possible that reduction in
9S
neurotransmitter diffusion from the synaptic cleft is offset by
enhanced neuronal reuptake. An evaluation of the importance of
neuronal reuptake and presynaptic negative feedback in controlling
release of [NA] from ischaemic myocardium is presented in Chapter
5.
Recent studies into [NA] efflux from the heart during acute
ischaemia as opposed to the earlier studies of Wollenberger and
Shahab have shown either modest release (Lammerant et al, 1966;
Dutta and Booker, 1970; Hirsche et al, 1980) or no release
(Marshall and Parratt, 1980; McGrath et al, 1981) of the
neurotransmitter at the time of early ventricular arrhythmias.
None of these studies as in the present study have related regional
catecholamine release to arrhythmias on a minute-to-minute basis.
Hirsche et al (1980) noted a small increase (approximately 50%) in
coronary sinus [NA] at the time of early ventricular arrhythmias
(Phase la) but no increments in venous [NA] between 10 and 30
minutes after coronary ligation in the pig. McGrath et al (1981)
failed to detect an increase in coronary sinus [NA] during LAD
ligation in five anaesthetised dogs, although both the site of
occlusion and coronary venous lactate concentrations during
occlusion in this study suggested a small area of mild ischaemia.
The increase in arterial [A] during coronary occlusion is in
keeping with the studies of Ceremuzynski and co-workers from the
late 1960's and early 1970's, showing enhanced [A] excretion from
the adrenal medulla within minutes of coronary occlusion on the
basis of a reflex originating from the ischaemic area. Increased
[A] extraction selectively across the ischaemic area in the
experiments reported here was an unexpected finding and supports
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the view that uptake processes are active in the ischaemic area at
this time. Extraction was rapidly abolished for several minutes by
coronary reperfusion (Figure 3.5 and 3.9). One explanation for
these findings is that flow is a major determinant of [A] uptake by
the heart. Low flow (ischaemia) increases uptake, provided of
course that uptake (neuronal and extraneuronal) mechanisms are
intact, whereas high flow (reactive hyperaemia) reduces uptake.
Reperfus ion-induced release of [A] extracted during the immediately
preceding ischaemia, may also have contributed to the rise in local
venous [A] at this time.
The importance of reperfus ion-induced [NA] release in the
genesis of reperfusion arrhythmias has not been widely
investigated. Indeed, until the recent demonstration of the
potential importance of vasospasm in the genesis of reversible and
irreversible ischaemic injury in man (Berndt et al, 1977; Oliva and
Breckenridge, 1977; Maseri et al, 1978), reperfusion had not been
considered as a likely mechanism of arrhythmogenesis. Taking flow
into account, the observed small reperfusion-induced overflow of
[NA] from the previously ischaemic area represents a several-fold
increase in [NA] output, sustained for a maximum of two minutes. ^
Although reperfusion-induced [NA] overflow was noted only during
the first two minutes, [NA] output from the previously ischaemic
area may have persisted for a longer period because of the dilu-
tional effect of reactive hyperaemia on the [NA] concentration
in local venous effluent.
reperfusion arrhythmias have suggested that instantaneous
arrhythmias occurring within the first minute of reperfusion are
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associated with heterogeneous recovery and fractionation of
activation across the heart, rather similar to (and correlated
with) the antecedent period of arrhythmias during coronary ligation
(Levites et al, 1975; Kaplinsky et al, 1981). In contrast, the
second less common phase of delayed ventricular arrhythmias (rarely
progressing to fibrillation) occuring two to seven minutes after
coronary reperfusion develops when electrical activity has become
synchronous (Kaplinsky et al, 1981) and enhanced [NA] release from
the heart has subsided. The cause of [NA] release on reperfusion
is speculative. Increased transmembrane calcium flux, certainly
important in reperfusion-induced cellular injury in myocytes (Walen
et al, 1974) may result in calcium overload of the neuroplasm and
excessive exocytotic release of stored [NA]. Alternatively,
enhanced local [A] concentrations may act as promotors of [NA]
release through activation of presynaptic beta receptors (Langer,
1978). Adrenergic mechanisms have been implicated in reperfusion
arrhythmias, alpha- but not beta-adrenoceptor antagonists being
effective in their suppression (Corr and Gillis 1978; Sheridan et
al, 1980).
Catecholamine fluorescence of ischaemic and infarcting
myocardium has not shown consistency with regard to the rate of
decrease in nerve terminal fluorescence after coronary ligation.
Paessens and Borchard (1980) showed some reduction in fluorescence
two to four hours after coronary occlusion with areas completely
devoid of fluorescence only after 12-24 hours. Abrahamsson et al
(1982) showed reductions in fluorescence in the central ischaemic
area of rat heart after 2 1/2 hours. At 30 minutes, small areas of
reduced fluorescence were visible but the [NA] content of
sham-operated animals was also diminished at this time suggesting a
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non-specific effect. A similar time course of depletion over some
hours has been reported in the dog (Vasku et al, 1978). In
contrast, Hirsche et al (1981) have suggested extremely rapid
reductions in nerve terminal catecholamine content after LAD
occlusion in the pig model, substantial reductions in fluorescence
being detected after three to four minutes of ischaemia. This
depletion was readily prevented by lignocaine and prostacyclin.
The reasons for such variability in results is unclear but species
differences and differences in the processing of ischaemic tissue
may be important. The influence of acidosis, hyperkalaemia and
other metabolic changes typical of ischaemia on the technique of
fluorescence histochemistry has been poorly defined.
No biologically important differences between the effects of
morphine/chloralose/urethane and chloralose anaesthesia on
catecholamine responses were oberved. The slightly increased heart
rate and blood pressure with chloralose alone, and the small
further increase in heart rate after coronary occlusion with this
agent, probably reflect absence of the vagotonic influence of
morphine (De Silva et al, 1978a). Activation of parasympathetic
activity antagonises cardiac sympathetic responses directly and
through inhibition of nerve terminal [NA] release via a peripheral
muscarinic mechanism (Lavallee et al, 1978, 1980). This may also
explain the somewhat lower basal [NA] levels in arterial and venous
plasma in Series I (with morphine) compared to Series II
(chloralose alone). Ventricular arrhythmias tended to occur more
frequently in Series II (50 per cent) than in Series I (36 per
cent) but differences did not achieve statistical significance.
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4 TIME-DEPENDENCY OF NEUROSYMPATHETIC RESPONSIVENESS:
RELATIONSHIP TO EARLY ARRHYTHMIAS
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The purpose of this study was to assess regional catecholamine
release from the heart and electrophysiological responses during
direct stimulation of efferent cardiac sympathetic nerves at
intervals after coronary occlusion. Over the past two decades,
there has been an explosion of interest and information concerning
factors that modulate peripheral release of sympathetic
neurotransmitter at the nerve terminal (Shepherd and Vanhoutte,
1981). Much of the work, however, has been in vitro and in tissues
other than the heart. It is possible, nonetheless, that
neurohumoral or metabolic changes in ischaemic myocardium might, at
least in the short term, inhibit or depress nerve terminal
responses to enhanced efferent neural discharge and hence explain
absence of major catecholamine release from the heart (Chapter 3).
A moderate degree of acidosis (for example a reduction in pH
from 7.4 to 7.1) is without effect on the basal tension or
responsiveness of isolated cutaneous veins to increasing
concentrations of [NA] , but does depress the response to
sympathetic stimulation (Tobian et al, 1959; Vanhoutte et al,
1968), possibly by reducing calcium entry into the nerve terminal
and inhibiting exocytotic release of neurotransmitter (Verbeuren et
al, 1978). An increase in local potassium concentration can have
at least three actions on the nerve terminal. At concentrations
below 20 mmol/1, inhibition of [NA] release in response to nerve
stimulation is observed, but neuronal reuptake is also reduced.
With higher concentrations, the neurotransmitter is liberated
directly (Kirpekar et al, 1972; Lorenz and Vanhoutte, 1975).
Similarly, adenosine, adenine nucleotides, histamine and
5-hydroxtryptamine have all been shown to inhibit [NA] release in
response to nerve stimulation (Verkaeghe et al, 1977; McGrath and
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Shepherd, 1978; De Mey et al, 1979). Activation of presynaptic
alpha adrenoceptors may limit [NA] release via a local negative
feedback loop (Langer.1978; Starke,1978), an aspect discussed
further in Chapter 5. Acetylcholine release from vagal efferents
may also have an inhibitory effect (Vanhoutte,1974). Arachidonic
acid metabolites synthesised in the heart and released during acute
ischaemia may attenuate adrenergic transmitter release (Wennmalm,
1978; Khan and Malik, 1982) while peptides such as angiotensin II
may have a facilitatory role (Lanier and Malik, 1983).
Stimulation of the ansa subclavia from the right and left
stellate ganglion in the dog activates most of the efferent
sympathetic nerves to the heart. Nerves from the left side provide
the major sympathetic input to the left ventricle. Noradrenaline
overflow into the coronary sinus and contractile responses of the
left ventricle are significantly greater with left compared to
right sided stimulation. Chronotropic responses, however, are much
less, reflecting the major sympathetic input to the sinus node from
the cardiac stellate nerve, a branch from the right stellate
ganglion (Levy and Blattberg, 1977). It has recently been
suggested that heart rate per se may influence the dissipation of
released neurotransmitter into venous effluent, especially if
reuptake processes are impaired (Levy,1982). Cardiac responses to
prolonged trains of sympathetic stimuli are maximal and remain
constant over 1-2 minutes but thereafter decline at high rates of
stimulaton (Levy and Blattberg, 1976). Left stellate ganglion
stimulation for one-minute periods at both low (1 Hz) and high (10
Hz) frequency was therefore selected for these investigations.
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METHODS: PROTOCOLS
Studies were performed on adult mongrel dogs (10 - 25 kg) of
either sex anaesthetised with pentobarbitone (25 mg/kg
intravenously for induction; 4 mg/kg/hr for maintenance) and
ventilated on room air using a Harvard respirator. After placement
of infusion and sampling catheters in both femoral vessels, and an
aortic catheter for monitoring blood pressure, a left lateral
thoracotomy was performed, the left fifth rib resected and the
heart suspended in a pericardial cradle. After lung retraction,
good visualisation of the left stellate ganglion was achieved. The
anterior and posterior ansa subclavia from this ganglion were
carefully dissected free from pleura, fat and subcutaneous tissue
and stimulated using a bipolar silver hook electrode attached to a
Grass Model S48 stimulator. Square wave pulses (4 ms duration) at
supramaximal voltage (8 - 10 v) and varying frequency (1 - 20 Hz)
were used. After a test stimulation over 30 seconds at 10 Hz to
confirm an appropriate inotropic and chronotropic response -
usually a 20 - 40 per cent increase in mean blood pressure, widened
pulse pressure and increase in heart rate of 10 - 20 beats/minute,
associated in 70 per cent of studies with the development of nodal
rhythm - the heart was paced continuously from the left atrium
throughout each experiment at a rate of 5 - 10 beats/minute faster
than the peak chronotropic response observed. The paced rate
varied overall between 150 and 192 beats/minute in different
experiments but was kept constant for each study.
The left anterior descending coronary artery (LAD) was
isolated within 2 cms of its origin distal to the first septal
perforator for coronary occlusion using a Mayfield occlusion clip.
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As described in Chapter 3, venous catheters were inserted
retrogradely into the centre of the LAD territory and antegradely
on the posterolateral surface of the heart, draining towards the
coronary sinus. The left atrium was catheterised via the appendage
and the animal heparinised (100 u/kg) after completion of surgery.
At least 30 minutes elapsed between completion of surgery and
sample collection. In control studies without ischaemia, 1 ml
samples were taken simultaneously over 15 seconds from arterial and
both cardiac venous sampling sites at minute intervals for two
minutes before, after and during the final 15 seconds of one minute
periods of ansa stimulation at varying frequency.
In Group I, minute-to-minute changes in catecholamine and
lactate levels at arterial and both cardiac venous sampling sites
were measured as above, before, during and after ansa stimulation
for one minute at 1 and 10 Hz in the absence of ischaemia and at
either low or high frequency during two successive ten minute
periods of LAD occlusion followed by reperfusion (Figure 4.1a).
Stimulation was commenced exactly four minutes after coronary
occlusion in each period to allow sympathetic activation during the
phase of maximum liklihood of spontaneous arrhythmias. At least 15
minutes recovery was allowed after the control ansa stimulation
before ischaemia and at least one hour recovery was allowed between
the first and second occlusion. Regional myocardial blood flow was
measured by microsphere injection three minutes after the second
occlusion and again one minute after reperfusion. Ventricular
fibrillation was managed by internal DC defibrillation after
removal of the coronary occlusion clip. In view of the changes in
catecholamines resulting from ventricular fibrillation (described
10a
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Figure 4.1 Experimental protocols. Time-dependency of neurosympathetic responsive¬
ness. In Group 1 (A), during two ten-minute periods of LAD occlusion, the ansa was
stimulated for one minute at 1 and 10 Hz respectively before and four minutes after
occlusion. Minute-to-minute changes in catecholamines in ischaemic (I) and non-
ischaemic (NI) effluent were assessed (arrowsl In Group 11 (B), activation delay and
catecholamine overflow were assessed during a single 75 minute period of LAD occlusion
and reperfusion. Sympathetic stimulation was undertaken at 5, 17, 30 and 60 minutes
after the onset of ischaemia.
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in Chapter 3), all samples collected after this arrhythmia were
excluded from the analysis. The anterior local venous catheter was
positioned within the centre of the LAD perfusion territory, thus
draining venous blood from predominantly ischaemic myocardium (I)
during coronary occlusion. The posterolateral venous catheter
towards the coronary sinus drained non-ischaemic myocardium (NI)
from the area of perfusion of the circumflex coronary artery.
In Group II, LAD occlusion was continued for 75 minutes before
reperfusion and myocardial catecholamine and lactate overflow from
ischaemic and non-ischaemic areas assessed during four successive
periods of low and high frequency ansa stimulation: twice at the
times of peak incidence of spontaneous arrhythmias 5 and 17 minutes
after occlusion (Harris phase la and lb respectively), and twice
when arrhythmias are relatively rare 30 and 60 minutes after
occlusion (Figure 4.1b). Ventricular fibrillation was documented
in three experiments during ansa stimulation at 5 minutes and once
during stimulation at 17 minutes. Arrhythmias were not observed
during stimulation at 30 or 60 minutes. Defibrillation without
removal of the coronary occlusion clip restored sinus rhythm in two
out of the three episodes of fibrillation at 5 minutes and in the
episode at 17 minutes. As the studies in Chapter 3 showed that
catecholamine levels return to pre-fibrillation values within five
minutes of the restoration of stable sinus rhythm, data from these
experiments was included in the overall analysis, with the
exception of the first five minutes after defibrillation. Regional
myocardial blood flow was assessed three minutes after occlusion.
Epicardial activation delay across the ischaemic region was mapped
immediately before ansa stimulation, immediately after each
one-minute period of high frequency stimulation and one and three
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minutes after coronary reperfusion (Figure 4.1b). Mean activation
delay in the ischaemic area was derived from electrodes showing
local activation times equal to or greater than 40 msecs at any
period after coronary occlusion.
All samples were collected into precooled tubes (4°C)
containing heparin and sodium metabisulphite. Plasma was
immediately separated and frozen for subsequent analysis as
described previously.
Changes in peak myocardial catecholamine and lactate overflow
and blood pressure following single periods of ansa stimulation and
coronary reperfusion were analysed by comparing levels immediately
before with those during nerve stimulation or reperfusion using
Student's t-test for pair differences. Trends in myocardial
catecholamine overflow during sequential periods of ansa
stimulation and with time were evaluated by analysis of variance
and computed modified t-statistic. Non-parametric ranking methods
(Wilcoxon test for pair differences) were used for analysis of
epicardial activation delays before and after nerve stimulation.
Data are expressed as mean + standard error of the mean with a
five per cent level of confidence considered statistically
significant.
RESULTS
In the non-ischaemic state, stimulation of the ansa for one
in
minute resulted , frequency-dependent release of [NA] into both
anterior and lateral cardiac veins with peak release between 10 and
20 Hz (Figure 4.2). Release was greater from the lateral
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Figure 4. 2 Frequency - response curves (semi-log scale) and reproducibility of
regional myocardial NA release in response to sympathetic stimulation. Release
was greater from the lateral compared to the anterior surface of the heart (n =7,
upper panel). Repeated ansa stimulation showed no evidence of tachyphylaxis or
reduction in overflow with LAD dissection during a three hour period.
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10 Hz 13.4 + 1.9 pmol/nl circumflex; 10.2 + 2.0 pmol/ml LAD; p <
0.05) , possibly reflecting different densities of sympathetic
innervation from the left stellate ganglion in these areas.
For subsequent experiments, as indicated above 1 and 10 Hz
stimulation was selected for analysis of the catecholamine
response. Repeated stimulation of the ansa at these frequencies on
seven successive occasions resulted in reproducible myocardial [NA]
release from both sites with no evidence of tachyphylaxis over a
three hour period (Figure 4.2). When dissection of the LAD
(without occlusion) was carried out after the third period of
stimulation this did not modify peak [NA] relase during four
subsequent stimulations, suggesting that the dissection itself did
not impair the functional responsiveness of the sympathetic nerves
over this time.
Group I— Effect of ischaemia on stimulation—induced [NA] release
The pattern of [NA] response to ansa stimulation was not
significantly modified by two ten-minute periods of LAD occlusion
in seven experiments (Group I). Arterial [NA] increased gradually
over the periods of ischaemia (basal [NA] 1.7 + 0.4 pmol/ml; [NA]
after second occlusion 3.3 + 0.7 pmol/ml [p < 0.05}), but [NA]
release from I and NI areas was not significantly different from
that prior to ischaemia (Table 4.1). Peak release at 1 Hz from the
anterior local vein was 1.1 + 0.8 pmol/ml basal and 2.2 + 1.9
pmol/ml during ischaemia; at 10 Hz release was 7.5 + 4.3 pmol/ml
basal and 7.8 + 5.0 pmol/ml during ischaemia, p = NS. Similarly,
[NA] release from the non-ischaemic lateral surface of the heart
was not modified by LAD occlusion (Table 4.1). Myocardial [NA]
FIRST SECOND
BASAL OCCLUSION OCCLUSION REPERFUSION
Cont 1Hz 10Hz 2' 1Hz 2' 10Hz 1' 3'
[NA](pmol/ml)
Art x 1.7 1.7 2.4 2.0 2.5 3.2 3.3 3.9 3.1
SEM 0.4 0.4 0.6 0.6 0.7 0.6 0.7 1.6 1.4
LV I 2.0 2.8 9.9 3.4 4.7 3.1 11.0 5.1 3.9
SEM 0.4 0.4 3.5 1.0 1.8 0.6 3.8 1.9 1.7
CS x 2.5 4.1 13.8 2.9 3.9 3.6 16.5 3.0 2.8
SEM 0.4 0.5 5.4 0.8 0.7 0.9 5.0 2.0 1.9
](pmol/ml)
Art x 0.6 0.7 0.5 0.6 0.7 1.8 3.0 5.7 4.7
SEM 0.3 0.4 0.3 0.3 0.5 1.1 2.3 4.8 3.7
LV x 0.2 0.4 1.1 0.4 0.4 0.5 1.2 4.1 3.7
SEM 0.1 0.1 0.7 0.1 0.1 0.3 0.7 3.5 3.1
CS x 0.2 0.4 0.7 0.3 0.3 0.4 0.8 1.7 1.8
SEM 0.1 0.2 0.4 0.1 0.1 0.1 0.4 1.2 1.5
Table 4.1: Myocardial catecholamine responses to low and high
frequency sympathetic nerve stimulation before and during
coronary occlusion and to reperfusion (Group I, n = 7).
Seperfusion data combined from first and second occlusions.
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release from ischaemic and non-ischaemic territories is shown in
Figure 4.3.
Arterial [A] also increased progressively during the two
periods of ischaemia with further increase on reperfusion (Table
4.1). Myocardial [A] extraction was maintained during occlusion,
ansa stimulation and reperfusion although extraction was
significantly less and output of [A] (derived from mean endocardial
and epicardial blood flows shown in Table 4.2) significantly
greater from I compared to NI during reperfusion ([A] extraction
across I 28 + 8 per cent and output 11.0 + 6.1 pmol/min/g one
minute after reperfusion: [A] extraction across NI 70 + 18 per
cent and output 1.3 + 2.1 pmol/min/g at the same time: p < 0.01).
The ischaemic area (flow < 50 per cent of normal myocardium)
involved 27+4 per cent of the epicardium and 31+4 per cent of
the endocardium of the free left ventricular wall. Lactate
production was restricted to the ischaemic area where mean blood
flow decreased to 30 per cent and 18 per cent of flow in the
non-ischaemic epicardium and endocardium respectively (Table 4.2).
Reperfusion induced a small but significant spontaneous
release of [NA] from the ischaemic area (1.2 + 1.1 pmol/ml, Table
4.1 and Figure 4.3). This represented an approximately 30 fold
increase in mean [NA] output from I (from 0.5 + 0.4 pmol/min/g
four minutes after occlusion to 16.2 + 3.6 pmol/min/g one minute
after reperfusion) while output from non-ischaemic myocardium was
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Figure 4.3 Noradrenaline release from I and NI myocardium with ansa





























Table 4.2: Regional blood flow and lactate extraction across
ischaemic and non-iscbaemic myocardium during 10 minutes
LAD occlusion and one minute after reperfusion
(Group I, n = 7).
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Group II— Effect of ischaemia duration on stimulation—induced [NA]
release
In contrast to responses during a ten minute period of
ischaemia, catecholamine release and changes in epicardial
activation delay varied with ansa stimulation at intervals during
75 minutes of ischaemia. Peak [NA] in I and NI effluent was
similar 5 and 17 minutes after LAD occlusion but levels were
significantly less in I at 30 and 60 minutes (Figure 4.4a),
corresponding with a reduction in [NA] release of approximately
eighty per cent from this area (Figure 4.5a). [NA] responses from
non-ischaemic effluent (Figure 4.4b) and [NA] release from this
area (Figure 4.5b) were not modified by coronary occlusion.
Reperfusion induced substantial release of [NA] from the previously
ischaemic area and lesser release from non-ischaemic tissue (Figure
4.4) .
As shown in Figure 4.6, a progressive increase in arterial [A]
was maintained during the 75 minute occlusion and on reperfusion.
[A] increased from 1.0 + 0.3 pmol/ml prior to occlusion to 1.9 +
0.5 pmol/ml during ischaemia (p < 0.05) with a further increase to
2.8 + 0.8 pmol/ml during the first five minutes of reperfusion.
Although levels of [A] in venous effluent remained constant during
occlusion, extraction across I increased from 0.7 + 0.2 to 1.5 +
0.6 pmol/ml (p < 0.02). Extraction across I, however, decreased
significantly (1.0 + 0.5 pmol/ml; p < 0.05) during reperfusion.
Changes in epicardial activation delay within the ischaemic
area before and after ansa stimulation (Table 4.3) showed
significant differences dependent on the duration of coronary
occlusion. Stimulation after five minutes of ischaemia increased
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ll ll ll ll ANSA Stimulation (Hz)
Minutes
* p< 0.05 wrt responses at 5 and 17 min
** p< 0.01 wrt pre-reperfusion NA
Figure 4.4 Noradrenaline responses in arterial (open circles), local venous
(closed circles, A) and coronary sinus (triangles, B) plasma with ansa stimul¬










5 min 17 min 30 min
* p < 0.05 wrt release at 5 and 17 min
60 min
Figure 4.5 Noradrenaline release from ischaemic (A) and non-ischaemic (B)
myocardium with ansa stimulation. Data from Figure 4.4.
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Figure 4.6 Adrenaline responses in arterial (open circles), local venous (closed circle?
A) and coronary sinus (triangles, B) plasma during LAD occlusion and on reperfusion
(Group 11, n=9).
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activation delay from 44+6 msecs to 56 + 6 msecs (p < 0.05) and
after 17 minutes activation delay also increased from 41 + 4 to 50
+ 5 msecs (p < 0.05). In contrast, activation abnormalities were
unchanged with ansa stimulation after 30 or 60 minutes of
ischaemia, with a small but statistically non-significant reduction
in activation times at these two periods. Conduction abnormalities
regressed rapidly on coronary reperfusion. The change in
activation time following ansa stimulation at 5, 17, 30 and 60
minutes of ischaemia is shown for each experiment in Figure 4.7.
The temporal variability in this marker of electrophysiological
abnormality is evident.
An index of the effect of ansa stimulation on epicardial
conduction in ischaemic myocardium was derived from comparison of
the product of mean activation delay across the ischaemic area and
number of electrodes within the ischaemic area before and after
sympathetic stimulation. As shown in Figure 4.8, this product was
related to myocardial [NA] release at each early period of ansa
stimulation. Release 5 and 17 minutes after coronary occlusion was
associated with an increase in the epicardial activation delay
index in 17 of the 18 periods of ansa stimulation. In contrast,
stimulation at 30 and 60 minutes resulted in a minor increase in
activation delay index on eight occasions and a decrease on ten
occasions. Catecholamine release was correspondingly diminished at
these times.
Lactate extraction was maintained across the non-ischaemic
myocardium during LAD occlusion and reperfusion (Table 4.4). Ansa
stimulation increased lactate release from ischaemic myocardium 5,





IN ISCHAEMIA AREA (msecs)
PRE SNS POST SNS
5 min x 44 56
SEM 6 6
17 min x 41 50
SEM 4 5
30 min x 42 40
SEM 3 3
60 min x 41 38
SEM 4 3
74 min x 37
SEM 3
Reperfusion lmin x 32
SEM 3
Reperfusion 3min x 28
SEM 2
Table 4.3: Mean epicardial activation delay in the ischaemic area
and responses to sympathetic stimulation (SNS) during
coronary occlusion and on reperfusion (n = 9). The
number of electrodes within the ischaemic area (see
Methods for definition) varied between 5 and 56 (mean 31)
for individual experiments.
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Figure 4.7 Changes in regional epicardial activation times with ansa stimulation
(10 Hz for one minute) 5, 17, 30, and 60 minutes after LAD occlusion. Data from
nine individual experiments.
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Figure 4.8 Changes in epicardial activation delay index (mean delay x no electrodes
in ischaemic area) and NA overflow from the ischaemic area during ansa stimulation
5 and 17 minutes (closed circles) and 30 and 60 minutes ( open circles) after coronary
occlusion.
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release). The increase in lactate release at 60 minutes occurred
despite absence of significant [NA] release from ischaemic
myocardium at this time.
Blood pressure immediately before and during ansa stimulation
was not modified by coronary occlusion (Table 4.4). Mean blood
flow (measured three minutes after LAD occlusion) within the
ischaemic area was reduced to 18+7 ml/min/100 g in endocardium
and 26+9 ml/min/100 g in epicardium. Flow in the non-ischaemic
endocardium and epicardium was 107 + 6 ml/min/100 g and 110 + 11
ml/min/100 g respectively.
DISCUSSION
This study has assessed temporal variability in [NA] and [A]
release from ischaemic and non-ischaemic areas of myocardium and
shown that local neurotransmission is maintained over the first
twenty minutes of regional ischaemia but selectively inhibited in
the ischaemic region thereafter. Furthermore, evidence for a
detrimental effect of sympathetic stimulation on local epicardial
activation abnormalities within the ischaemic area is demonstrable
only during nerve stimulation five and seventeen minutes after LAD
ligation, the times of maximum likelihood of spontaneous
arrhythmias in this model (Kaplinsky et al, 1979). At these two
early periods of enhanced vulnerability, a crude relationship is
evident between the extent of local [NA] release during sympathetic
stimulation, and the resulting increase in local activation times.
Assuming that flow within the ischaemic region remains relatively
constant with time (at least over 75 minutes), the reduction in
peak [NA] levels in ischaemic venous effluent following sympathetic
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DURATION OF MYOCARDIAL LACTATE BLOOD PRESSURE
ISCHAEMIA EXTRACTION (%) (mmHg)
I NI
Basal x +31 +41 122
SEM 10 12 16
5 min x -93 +46 120
SEM 29 11 14
SNS I -246 +19
SEM 40 17
17 min x -153 +18 116
SEM 31 13 9
SNS x -229 +14 142
SEM 30 12 17
30 min x -127 +19 113
SEM 37 9 13
SNS x -197 +15 139
SEM 42 12 12
60 min x -142 +32 109
SEM 26 14 9
SNS x -200 +30 138
SEM 37 16 12
74 min x -125 +27 106
SEM 19 18 10
Reperfusion x -75 +6 107
SEM 29 10 13
Table 4.4: Myocardial lactate extraction (art - yen x 100) and
art
blood presssure responses before and during LAD
occlusion, sympathetic stimulation (SNS) and on
reperfusion (Group II; n = 11).
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stimulation after 30 minutes of occlusion represents an eighty per
cent inhibition of [NA] release from the heart in comparison to
responses at five and seventeen minutes. Basal [NA] levels do not
change with coronary occlusion beyond thirty minutes suggesting
that extraction is unaltered at this time. Enhanced extraction of
[A] across ischaemic myocardium is maintained throughout the longer
occlusion. It is likely that the contribution to ischaemic
effleunt from collaterals that have not perfused ischaemic tissue
is small as the dissociation between catecholamine release from
anterior (ischaemic) and lateral (non-ischaemic) surfaces of the
heart was readily apparent after thirty minutes. Furthermore,
lactate release was confined to ischaemic effluent.
Although continuous stimulation of cardiac sympathetic nerves
for periods of six to ten minutes has been reported to cause
depletion of myocardial catecholamines (Pindok et al, 1981) and
reduction in peak myocardial [NA] overflow (Levy and Blattberg,
1976) sequential one minute periods of stimulation result in
reproducible, frequency dependent [NA] overflow from both anterior
and lateral surfaces of the heart without evidence of
tachyphylaxis. Thus, despite large interindividual differences in
peak [NA] overflow, this technique provides a reliable means of
assessing the functional responses of the neurosympathetic axis in
both ischaemic and non-ischaemic areas of myocardium. No
significant reduction in local venous [NA] release was observed
following dissection of the coronary artery, showing that this
manoeuvre does not result in regional cardiac denervation, one
theoretical explanation for absence of spontaneous neiirotransmitter
release during ischaemia. The model also provides a means for
testing drug and metabolite influences on the nerve terminal
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(Yamaguchi et al, 1977; Chapters 5 and 6).
Although the mechanism of regional impairment of
neurotransmission after thirty minutes coronary occlusion has not
been elucidated, it is unlikely to have been secondary to depletion
of neurotransmitter from the nerve terminal as [NA] levels decline
following coronary occlusion at a rate between three and ten per
cent per hour (Mathes and Gudbjarnason, 1971; Serrano et al, 1974),
too slow to influence responses by thirty minutes. Histochemical
evidence of peripheral sympathetic denervation is not detectable
until between two and six hours of ischaemia (Terravainen and
Makitie, 1976; Muntz et al, 1981). Furthermore, massive release of
neurotransmitter during reperfusion (Figure 4.4) argues against
depletion of nerve terminal stores by ischaemia of this duration.
Lactate release, by contrast, decreased rapidly during reperfusion
suggesting that neurotransmitter release at this time was from
preformed stores and not merely a part of the reperfus ion-induced
washout of ischaemic metabolites. It is most likely that
accumulation of one or several metabolites inhibits
neurotransmission either at the level of the nerve terminal or more
proximally as nerve fibres pass through ischaemic tissue. Vagal
tone may potentially inhibit [NA] release through a peripheral
muscarinic mechanism (Levy and Blattberg, 1976, 1979; Lavallee et
al, 1980) but has little effect on the spontaneous release of [NA]
and [A] from ischaemic myocardium (Williford et al, 1983). Vagal
tone, however, is low during barbiturate anaesthesia (Priano et al,
1969) is preferentially enhanced by stimulation of mechanoreceptors
along the inferior, rather than the anterior surface of the heart
(Thoren, 1979) and is unlikely to be selectively active in
inhibiting catecholamine release specifically from the ischaemic
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area after thirty minutes.
The findings of this study agree well with data from Martins
et al (1980) who showed dissociation between the effects of left
stellate ganglion stimulation and systemic noradrenaline infusion
on regional myocardial shortening thirty minutes after coronary
occlusion. Systolic expansion of the ischaemic territory of the
left ventricle was decreased during the catecholamine infusion (at
a dose producing a similar increase in blood pressure to
sympathetic stimulation) while systolic expansion was unaltered by
stellate stimulation. Responses before thirty minutes of ischaemia
and catecholamine release from the heart were not assessed.
Although these two techniques of cardiac activation are not
directly comparable, the results suggested impaired
neurotransmission within the ischaemic region at this time.
Similar abnormalities in sympathetic nerve function have been shown
in a preliminary report by Cuiffo et al (1983) after twenty-five
minutes of coronary occlusion and reperfusion.
Coronary reperfusion after occlusion for ten or seventy-five
minutes is associated with substantial neurotransmitter release
from the ischaemic area. As the regional venous sampling technique
cannot completely separate ischaemic and non-ischaemic effluent,
particularly during the reactive hyperaemia associated with
coronary reperfusion, it is not possible to determine with
certainty the origin of the small reperfusion-induced release of
[NA] into the lateral (non-ischaemic) vein after the longer
occlusion. It is likely, however, that a significant portion of
this overflow represents spillover from the ischaemic area.
Theoretically, [NA] release on reperfusion may result from washout
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of neurotransmitter released from an extraneuronal compartment
during the period of ischaemia or from release directly associated
with reperfusion. The latter process is likely to predominate
because of the similar time course of rise and fall in levels of
[NA] in ischaemic and non-ischaemic effluent following sympathetic
stimulation. If released neurotransmitter did not reach the
vascular bed in the ischaemic area, then the time course for [NA]
release from this area should have been longer and the maximum
concentrations lower than in the absence of ischaemia or in
conparison to the response in the non-ischaemic area. Extraction
of [A] decreased during reperfusion, compatable with either a
reduction in myocardial [A] uptake, possibly secondary to
hyperaemia, or coexisting release of [A] at this time.
It is probable that the fundamental electrophysiological
mechanisms of the two early phases of arrhythmogenesis are
different. It is now generally accepted that the earlier phase la
arrhythmias are reentrant in origin, although circus movements may
under certain circumstances be generated by regional flow of injury
current between ischaemic and non-ischaemic areas (Janse et al,
1980). Several studies have demonstrated fractionation and
fragmentation of surface and intramural activation (Boineau and
Cox, 1973; Scherlag et al, 1974; Russell et al, 1979; Janse and
Kleber, 1981) and other phenomena associated with reentry. Spatial
heterogeneity of activation may be a further marker for
arrhythmogenesis at this time (Russell et al, 1983). In contrast,
diastolic bridging activity associated with reentry is absent
during phase lb arrhythmias and responses to pharmacological
interventions may be different. Phase lb arrhythmias are,
apparently, more effectively suppressed by calcium antagonists
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(Parratt, 1982) and less effectively suppressed by
beta-adrenoceptor blockade (Menken et al, 1979) than phase la
arrhythmias. Epicardial activation delay has been shown to be less
during phase lb than phase la arrhythmias in this and in a previous
study (Kaplinsky et al, 1979). However, the present study has
demonstrated that neurosympathetic responsiveness is maintained
during both early phases of arrhythmias. Clearly, the
electrophysiological consequences of catecholamine release in
ischaemic myocardium are critically dependent on the duration of
ischaemia. Metabolic and ionic shifts such as potassium
concentration, pH, redox state, glycolytic activity and
accumulation of toxic metabolites such as lysophosphatides or fatty
acyl carnitine can all contribute to depression of conduction in
ischaemic myocardium and may be modified by catecholamine release.
Temporal variability in neurosympathetic activity across the
myocardium may have important implications in the treatment and
prevention of arrhythmias following acute ischaemia in man. If
similar phases of early arrhythmias operate, and if adrenoceptor
modulation in ischaemic tissue is a prerequisite for an
antiarrhythmic action of a sympatholytic drug (suppositions that
remain to be proved), then efficacy will depend on delivery to
ischaemic tissue before the development of impaired
neurotransmission and low risk of lethal arrhythmias. Conversely,
if such drugs act primarily on non-ischaemic myocardium, then
efficacy will be independent of the duration of ischaemia. In view
of the marked time-dependence of the appearance of spontaneous
arrhythmias in the dog and many other animal models, it is probable
that ischaemic tissue is the primary target for drug action.
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This study has provided a link between catecholamine release
from the heart and the electrophysiological responses of ischaemic
tissue to sympathetic stimulation and highlighted temporal
variability in neurosynaptic activation during the first hour of
ischaemia. Further studies will be necessary to clarify the
metabolic determinants of impaired neurotransmisson after thirty
minutes and the causes and pathophysiological consequences of
myocardial catecholamine release associated with coronary
reperfusion.
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5 PRESYNAPTIC CONTROL OF CATECHOLAMINE RELEASE:
INFLUENCE OF REUPTAKE AND ALPHA ADRENOCEPTOR BLOCKADE
The importance of both active and passive mechanisms in the
disposition of [NA] released from adrenergic nerve terminals has
been recognised for many years. The neuronal cell membrane
possesses a powerful amine reuptake pump, capable under basal
conditions of the removal of approximately three quarters of
arterial [NA] in a single circulation through the heart (Chidsey et
al, 1963), and therefore in close apposition to the vascular
compartment. Following reuptake, the neurotransmitter may be
conserved within storage vesicles or deaminated by
intramitochondrial monoamine oxidase, both processes requiring ATP.
Alternatively, myocytes and vascular smooth muscle cells actively
take up [NA] which, once in the cytoplasm, is inactivated mainly
through O-methylation to normetanephine (Chidsey et al, 1963;
Kalsner 1975, 1976; Verbeuren et al, 1977).
The importance of reuptake and enzymatic degradation in the
removal of released neurotransmitter is undoubtedly modified both
by changes in sympathetic activation and changes in passive removal
mechanisms. Tyramine for example, increases four fold the release
of [NA] from the isolated canine heart while increases in
normetanephrine release are minor (Chidsey et al, 1963), suggesting
that the capacity of enzymatic processes to inactivate
catecholamines may be limited. It is also likely that blood flow
per se is a determinant of neurotransmitter removal by reuptake,
enzymatic degradation, or passive diffusion into the vascular
compartment. The studies in Chapter 3, for example, showed
enhanced extraction of [A] across ischaemic myocardium during
coronary occlusion, and reduced extraction on reperfusion,
compatible with [A] removal being dependent on circulation time.
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More recently, evidence has become available of the presence
of adrenoceptors on the outer surface of the adrenergic nerve
terminal membrane. These adrenoceptors are capable of acting as
powerful local modulators of catecholamine release from nerve
terminals. In 1957, Brown and Gillespie first reported (although
they did not appreciate the significance of their report) that
phenoxybenzamine, an alpha-adrenoceptor blocking drug, increased
the stimulation induced overflow of [NA] in the perfused cat
spleen. In 1971, four independent reports from three continents
were published each suggesting that [NA] release was locally
regulated by a negative feedback mechanism (Farnebo and Bamberger,
1971; Kirpekar and Puig, 1971; Langer et al, 1971; Starke, 1971).
Two types of experimental evidence supported this contention;
firstly, augmentation of release by alpha-adrenoceptor antagonists
in excess of that observed by preventing uptake into nerves or
muscle cells, and secondly, diminished release of neurotransmitter
by the administration of alpha-adrenoceptor agonists. Rank order
potencies of alpha-adrenoceptor agonists in inhibiting adrenergic
neurotransmitter release (presynaptic action) or constricting
vascular smooth muscle (postsynaptic action) have shown ratios up
to 300, methoxamine and phenylephrine favouring the postsynaptic
(alpha 1) receptor whereas clonidine, oxymetazoline and tramazoline
are more active at the presynaptic (alpha 2) site. More recently,
postsynaptic alpha adrenoceptors with characteristics of the alpha
2 subtype have also been recognised in certain tissues (Drew and
Whiting, 1979; Starke and Langer, 1979), although their
physiological significance is less certain.
The release of [NA] from cardiac tissues may also be changed
by drugs with affinity for the beta-adrenoceptor. In general,
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agonists increase whereas antagonists reduce nerve-stimulation
induced neurotransmitter release (Aaler-Graschinsky and Langer,
1975), although the latter action in particular is controversial
(Majewski et al, 1980, 1981). The role of presynaptic
beta-adrenoceptors in modulating [NA] release from ischaemic
n^ocardium is not considered further in this chapter.
Absence of spontaneous catecholamine overflow from the heart
(Chapter 3) despite apparently normal neurosympathetic activity at
the time of early ventricular arrhythmias implies (Chapter 4) an
important role for local modulators of catecholamine release in
acutely ischaemic myocardium, the modulators acting to limit
neurotransmitter overflow into ischaemic effluent. The studies
presented in this chapter have therefore investigated the
influences of an alpha 2 adrenoceptor antagonist (yohimbine) and
two reuptake inhibitors (viloxazine and desmethylimipramine), on
spontaneous and nerve stimulated catecholamine overflow and on
arrhythmias during acute ischaemia.
Methods, Protocols
Adult mongrel dogs of either sex were anaesthetized with
pentobarbitone (25 mg/kg intravenously for induction; 4 mg/kg/hr
for maintenance) and prepared surgically as described in Chapter 4
with the addition of a second left atrial cannula for those
experiments requiring labelling of the heart with
3
1- H-noradrenaline. Myocardial catecholamine and lactate
extraction and regional overflow were measured before and during
ten or twelve minute periods of LAD ligation and on reperfusion
before and in the presence of the reuptake inhibitors and alpha 2
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adrenoceptor antagonist both singly and in combination. In
addition, graded stimulation of the left stellate ganglion was
performed before and during coronary occlusion in the experiments
investigating yohimbine and desmethylimipramine, and regional
epicardial activation times were measured before and immediately
after each period of high frequency ansa stimulation.
Group I: Yohimbine
A test occlusion was performed initially to determine the area
of ischaemia and patterns of electrophysiological abnormality.
Minute-to-minute changes in plasma catecholamines across ischaemic
and non-ischaemic areas of myocardium were measured in nine
experiments during a twelve minute period of coronary occlusion and
for two minutes of reperfusion (Figure 5.1). The anterior and
posterior ansa from the left stellate ganglion were stimulated for
one minute (as described previously) at low (1 Hz) and at high (10
Hz) frequency four and six minutes respectively following coronary
occlusion. Blood samples (up to 1 ml) for catecholamine analysis
were withdrawn simultaneously from arterial and venous sampling
sites over 15—30 seconds at the times shown in Figure 5.1a. Full
analysis was possible with 200 pi. Regional myocardial blood flow
was measured three minutes after occlusion and conduction delay was
measured prior to coronary occlusion, at three minutes after
occlusion and immediately after low and high frequency ansa
stimulation. Ventricular fibrillation was managed by internal DC
defibrillation (10 joules) after removal of the coronary occlusion
clip. All samples obtained after spontaneous venticular
fibrillation were excluded from the analysis.
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Figure 5.1 Experimental protocols. In Groups I, 11 and 111 (A), regional
catecholamine overflow and electrophysiological responses were evaluated
during a twelve minute LAD occlusion and on reperfusion before and after
administration of desmethylimipramine and yohimbine. In Group IV (B),
regional noradrenaline extraction was measured during a ten minute LAD
occlusion and on reperfusion before and after viloxazine by prelabelling
the heart with l-H3-noradrenaline, 75piCi for the first (control) and 175pCi
for the second (viloxazine) occlusion.
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in the presence of yohimbine (1 mg/kg i.v. bolus; 0.2 mg/kg/hr
infusion) as the hydrochloride salt, commenced 30 minutes prior to
the second occlusion. Previous studies from our laboratory have
shown that patterns of electrophysiological abnormality are
reproducible for the second and subsequent occlusions (Russell et
al, 1979), thus allowing comparison of the effect of drug
interventions in the same experimental preparation. The dose of
yohimbine was selected following evaluation of responses at three
doses in the absence of coronary occlusion (Table 5.1). [NA]
release at 1 Hz stimulation increased after low-dose yohimbine
(0.25 mg/kg), but no further increments were apparent with
increasing yohimbine dose. At 10 Hz stimulation, overflow was
further potentiated by the 1.0 mg/kg dose but not by the 3.0 mg/kg
dose. As a result of these preliminary observations, 1.0 mg/kg
yohimbine was selected for study during myocardial ischaemia.
Group II: De smethylimipramine
The same protocol as above was used for six experiments before
and after intravenous desmethylimipramine 2.5 mg/kg bolus and 1
mg/kg/hr maintenance infusion.
Group III: Yohimbine/desmethylimipramine
The effects of both drugs in combination at the dosages
detailed above were evaluated in seven experiments during a third
twelve minute period of ischaemia with a similar protocol of
sampling and sympathetic stimulation. Regional blood flow
measurements were not undertaken in this group. The same
experimental preparation as Group I was used for these studies





(negative A-V difference; pmol/1; n = 3)





















+ P < 0.01 compared to control
Table 5.1: Effects of yohimbine on myocardial NA release (mean +
SEM) without ischaemia. The left stellate ganglion was
stimulated at low (1 Hz) and high (10 Hz) frequency for
one minute. The mean NA concentration was determined in
arterial and local venous plasma before and over two
minutes after ansa stimulation.
U1
undertaken because of haemod3rnamic deterioration in the preparation
associated with excessive blood loss and a low haematocrit.
Grout) IV
For this series, the influence of the specific neuronal
reuptake blocking agent viloxazine (ICI Pharmaceuticals, England)
3
on regional myocardial H-noradrenaline extraction was evaluated in
twelve experiments. Following basal sampling over five minutes,
myocardial labelling was achieved by a left atrial bolus injection
3
of 15 pCi 1-H -noradrenaline (Amersham International, England;
Ref. TRE584, Spec Act 30-50 Ci/mmol) dissolved in fresh 1% ascorbic
acid followed by a continuous atrial infusion of 60 pCi over
twenty minutes (Figure 5.IB). The total dose infused was approx.
2 nmol per dog. The infusion was designed to keep arterial
3
H -noradrenaline levels constant. No attempt was made to separate
radioactive metabolites of noradrenaline from the parent amine. A
ten minute period of LAD occlusion was performed five minutes after
the bolus injection with minute-to-minute regional sampling
throughout the occlusion and for five minutes on reperfusion.
Regional myocardial blood flow was determined four minutes after
occlusion. After a thirty minute recovery period, intravenous
viloxazine at two doses [5 mg/kg (n = 6) or 25 mg/kg (n = 3) bolus
and 1 mg/kg/hr or 5 mg/kg/hr maintenance infusion respectively] was
given. In a second group of controls (n = 3), isotonic saline was
infused. Thirty minutes after drug or saline administration, a
second period of continuous sampling was commenced over five
minutes to quantify residual radioactivity. A second intraatrial
3
bolus injection of 35 ;iCi 1-H noradrenaline was given followed by
a continuous infusion of 140 fiCi over twenty minutes. The higher
U2
dose of radioactivity (which had no demonstrable haeinodynamic
effect) was required to minimise the influence of residual
radioactivity on measurement of myocardial noradrenaline extraction
during the second occlusion. Coronary occlusion, reperfusion and
regional blood flow estimation were performed as for the first
period of ischaemia.
Changes in catecholamine and lactate concentrations following
drug administration were evaluated by analysis of variance and
computed modified t-statistic for pair differences. Non parametric
methods (Wilcoxon test for pair differences) were used for analysis
of changes in blood flow and surface electrophysiology. Data are
expressed as mean + standard error of the mean with a five per
cent level of confidence considered statistically significant.
RESULTS
Group I ~ Yohimbine
Catecholamines:
Mean [NA] concentrations at arterial and at ischaemic and
non-ischaemic venous sampling sites during coronary occlusion and
reperfusion are shown in Figure 5.2. Under control conditions,
[NA] levels were unchanged at all sampling sites during coronary
occlusion but a small reperfusion-induced rise in [NA] was observed
from the previously ischaemic area as noted previously. Basal
levels of [NA] were slightly increased after yohimbine, but the
rise during left ansa stimulation was more marked, particularly in
the ischaemic effluent, where the peak [NA] level at 10 Hz
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Figure 5.2 Plasma noradrenaline (NA) concentration in arterial and
in non-ischaemic and ischaemic venous effluent during coronary
occlusion and reperfusion (mean + SEM; N=9); effects of yohimbine.
The blocks indicate low and high frequency ansa stimulation.
1U
< 0.005). The increase in [NA] in ischaemic effluent associated
with reperfusion was similarly enhanced. Expressed as the negative
arteriovenous difference, [NA] release from ischaemic myocardium
was not detectable three or eleven minutes after coronary occlusion
(Figure 5.3) but was significantly potentiated both with
sympathetic stimulation and on reperfusion.
Extraction of [A] was maintained across both ischaemic and
non-ischaemic myocardium and was not influenced by coronary
occlusion or ansa stimulation (Figure 5.4). Coronary reperfusion
resulted in a significant rise in [A] in ischaemic effluent (from
0.5 + 0.2 pmol/ml one minute before to 1.1 + 0.4 pmol/ml one
minute after reperfusion (p < 0.05)). A smaller rise in [A] from
non-ischaemic effluent during reperfusion was not statistically
significant. Following yohimbine, arterial [A] rose 2-3 fold and
extraction across the heart increased from 45 to 64 per cent.
Enhanced extraction of [A] was maintained at both sampling sites
during coronary occlusion with a rise in venous [A] during coronary
reperfusion, compatible with release of [A] from the heart at this
time.
Lactate:
Myocardial lactate production across ischaemic myocardium
occurred throughout coronary occlusion and was increased (p < 0.05)
during sympathetic stimulation (Figure 5.5). Net extraction of
lactate was maintained across non-ischaemic myocardium, although
extraction tended to fall during coronary occlusion, suggesting
either a minor contribution from ischaemic effluent at this



















* p<0.05 wrt control
**p< 0.005 wrt control
Figure 5.3 Myocardial noradrenaline (NA) release from and extraction across
ischaemic myocardium during coronary occlusion and reperfusion before, during
and after ansa stimulation. Data shown before and after yohimbine administration
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Figure5.4 Plasma adrenaline (A) concentrations duringcoronary occlusion
and reperfusion (mean ± SEM, n=9). Effects of yohimbine.
U7
* p < 0.05 wrt control
** p < 0.05 wrt extraction at 3, 9 mins.
Figure 5. 5 The effects of yohimbine on myocardial lactate
extraction (mean ± SEM; n =9). Data shown for samples with¬
drawn before occlusion, three and nine minutes after occlusion
and immediately after high frequency ansa stimulation,
(extraction (%) = X 100 )
U8
area. Yohimbine reduced myocardial lactate extraction before
coronary occlusion (p < 0.05) but did not modify the pattern of
lactate release from the heart during coronary occlusion and
sympathetic stimulation.
Eae&Bodyn&Btics:
Blood flow to non-ischaemic myocardium was not significantl3'
affected by yohimbine. Endocardial flow fell by 9 per cent from 90
+ 14 to 82 + 14 ml/min/100 g, while in the epicardium flow was
reduced by 6 per cent from 89 + 11 to 83 + 15 ml/min/100 g.
Neither change was statistically significant. In contrast,
ischaemic endocardial flow decreased by 24 per cent from 27+2 to
20 + 11 ml/min/100 g (p < 0.01) and ischaemic epicardial flow
decreased 36 per cent from 43 + 17 to 28 + 14 ml/min/100 g (p <
0.01). In keeping with some post synaptic alpha-adrenoceptor
blockade, mean arterial blood pressure fell from 108 + 8 to 84 +
7 mmHg (p < 0.01) after yohimbine. The increment in mean blood
pressure with ansa stimulation at both low (4+4 mmHg control; 9
+ 7 mmHg yohimbine) and high (14 + 16 mmHg control; 19+8 mmHg
yohimbine) frequency stimulation was not significantly affected.
Electrophysiology:
Spontaneous ventricular fibrillation occurred twice during
control occlusions (22 per cent) and five times after yohimbine (56
per cent). In keeping with this tendency for an increased
incidence of spontaneous ventricular fibrillation the mean duration
of coronary occlusion without ventricular fibrillation decreased
H9
after yohimbine from 10+1 to 8+1 minutes (p < 0.05).
Regional epicardial activation abnormalities after coronary
occlusion were intensified by yohimbine. For each experiment, the
mean conduction delay was compared at electrodes within the central
ischaemic zone. Three minutes after coronary occlusion, yohimbine
increased activation delay by 26 per cent from 41 + 2 to 54 + 5
ms (p < 0.01). At low and high frequency ansa stimulation,
activation delay increased by 24 and 22 per cent respectively (from
51 + 3 ms before yohimbine to 67 +7 ms after yohimbine at 1 Hz,
and from 57 + 4 ms before yohimbine to 73 + 10 ms after yohimbine
at 10 Hz [p < 0.01]). The ischaemic zone activation delays are
summarised for each experiment in Table 5.2.
Patterns of activation abnormality from one experiment are
illustrated in Figure 5.6. Prior to coronary occlusion most local
activation times were less than 30 ms. After three minutes of
ischaemia, both the area and magnitude of the conduction
abnormalities that developed across the ischaemic area were
increased by yohimbine (Figure 5.6a). Sympathetic nerve
stimulation induced a further increase in local activation times
during the control occlusion but no site showed delay in excess of
60 ms. After yohimbine, however, approximately 10 per cent of
sites showed delay greater than 60 ms. Profiles of conduction
changes across the ischaemic zone from the same experiment (Figure
5.6b) showed an increase in the magnitude and variability in
activation delay in the ischaemic zone. These changes in
activation times are in keeping with an increase in spontaneous
arrhythmias. In the example shown, spontaneous ventricular
fibrillation occurred two minutes after high frequency ansa
150
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Figure 5.6 A Patterns of epicardial activation delay. Activation delay is plotted
against number of electrodes with that delay for one experiment Data are shown
before and after yohimbine prior to and three minutes after coronary occlusion
and during ansa stimulation. B Profiles of activation delay across the ischaemic
zone from the same experiment Data are shown from five rows of ten electrodes
traversing the epicardium (ie 50 sites), recorded three minutes after coronary
occlusion.
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stimulaton with yohimbine but fibrillation did not occur with the
control occlusion.
Group II — de sine thyl imipramine
The changes in regional myocardial catecholamine release,
blood flow and lactate production after neuronal reuptake blockade
were qualitatively similar to those following alpha^-adrenoceptor
inhibition.
Catecholamines:
[NA] release from the heart with ansa stimulation was
potentiated across both ischaemic and non-ischaemic areas (Figure
5.7). Spontaneous [NA] release was not observed despite reuptake
blockade. Expressed as the percentage increase in myocardial [NA]
release following desmethylimipramine, it can be seen from figure
5.8 that at low frequency sympathetic stimulation and during
reperfusion, the enhancement of release was greater across
ischaemic compared to non-ischaemic myocardium. This suggests that
neuronal reuptake was enhanced in ischaemic myocardium prior to
drug administration.
Basal arterial [A] increased five fold following
desmethylimipramine (from 0.3 + 0.1 to 1.5 + 0.7 pmol/ml; p <
0.02) , the values rising parallel with those of the control period
during ischaemia and reperfusion (Figure 5.9). Extraction of [A]
was also maintained across both ischaemic and non-ischaemic
myocardium during coronary occlusion with reuptake blockade,
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Figure 5. 7 Plasma noradrenaline (NA) concentrations in arterial and
in non-ischaemic and ischaemic venous effluent during coronary
occlusion and reperfusion (mean ± SEM; n=6); effects of desmethyl¬
imipramine.
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*p<0.05 wrt non-ischaemic region
Figure 5.8 Increment in myocardial NA release from non-ischaemic
(shaded bars) and ischaemic (open bars) myocardium following neuronal
reuptake blockade with desmethylimipramine. Responses shown during
low and high frequency ansa stimulation and during the first three
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Figure 5.9 Plasma adrenaline (A) concentrations during coronary
occlusion and reperfusion (mean ± SEM; n=6); effects of desmethyl¬
imipramine.
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with desmethylimipramine. Reperfusion rapidly reduced [A]
extraction across the previously ischaemic area, with minor and
statistically insignificant release of [A] after one minute. No
such release was observed during the control occlusion.
Lactate:
Myocardial lactate production across ischaemic myocardium
occurred throughout occlusion with a statistically non-significant
trend for increased production during sympathetic stimulation
(figure 5.10). As noted after yohimbine (see Figure 5.5),
extraction tended to fall across non-ischaemic myocardium during
the period of coronary occlusion following reuptake blockade but
the trend did not achieve statistical significance.
Haeaodynuics:
Blood flow to non-ischaemic myocardium fell significantly
after desmethylimipramine. Endocardial flow fell by 35 per cent
from 115 + 32 to 74 + 32 ml/min/100 g (p < 0.02), while
epicardial flow fell by 29 per cent from 114 + 40 to 82 + 40
ml/min/100 g (p < 0.05). An even greater reduction in flow was
observed in the area of ischaemia, endocardial flow decreasing by
44 per cent from 35 + 13 to 20 + 15 ml/min/100 g and epicardial
flow decreasing by 35 per cent from 44 + 17 to 20 + 25 ml/min/100
g (p < 0.02) . During coronary occlusion, mean arterial blood
pressure and pulse pressure did not change after reuptake blockade
(108 + 8 and 35+9 mmHg control; 104 + 18 and 32 + 13 mmHg





























Figure 5.10 The effects of desmethylimipramine on myocardial
lactate extraction (mean + SEM; n=6). Data shown for samples
withdrawn before occlusion, three and nine minutes after





frequency ansa stimulation were similar (10 + 11 minEg control; 9
+ 15 mmEg desmethylimipramine), with high frequency the increment
was larger after reuptake blockade (28 + 16 mmEg control; 46 + 21
mmEg desmethylimipramine; p < 0.05), possibly reflecting more
intense myocardial catecholamine stimulation (Figure 5.7) at this
time.
Electrophysiology:
Spontaneous ventricular fibrillation occurred once during
control occlusions (17 per cent) and three times during occlusions
after desmethylimipramine (50 per cent). The mean duration of
coronary occlusion before fibrillation occured decreased with
desmethylimipramine from 11 + 1 to 9 + 1 minutes (0.05 < p <
0.1) .
Group III— Yohimbine — desmethylimipramine
Catecholamines:
In combination, yohimbine and desmethylimipramine resulted in
marked increases in [NA] at all sampling sites (Figure 5.11),
significantly greater than with either drug alone (Figures 5.2 and
5.7). Basal arterial [NA] rose 15 fold from 1.4 to 22.1 pmol/ml,
although no significant spontaneous [NA] release from the heart was
observed. During coronary occlusion, however, spontaneous release
of [NA] from both ischaemic and non-ischaemic areas was observed,
in contrast to control responses and that with yohimbine or
desmethylimipramine alone (Figure 5.12). Release of [NA] during



























Figure 5.11 Plasma NA (circles) and A (squares) concentrations in
arterial and in non-ischaemic and ischaemic venous effluent during
coronary occlusion and reperfusion (mean + SEM; n=7); effects of
yohimbine and desmethylimipramine (DMI) in combination. Control
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* p < 0.03 wrt control
**p<0.02 wrt control
Figure 5.12 Spontaneous myocardial NA release/extraction from ischaemic
and non-ischaemic areas during coronary occlusion and on reperfusion.
Combined data from Groups I, II, and III.
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ischaemic area, although the rapid rise in arterial [NA] at this
time may have limited the accuracy of this observation. No further
potentiation of enhanced reperfusion-induced overflow of [NA] from
the ischaemic area was observed as a result of the drug
combination. Surprisingly, increases in myocardial [NA] overflow
with ansa stimulation were modest, especially from the ischaemic
area (Figure 5.11). However, as spontaneous catecholamine release
was observed prior to sympathetic stimulation, and as plasma levels
of [NA] were so high, it may be that the capacity of the nerve
terminals to release further transmitter as a result of additional
direct nerve stimulation was limited. Despite this, however,
epicardial activation abnormalities increased considerably during
ansa stimulation with the drug combination (vide infra; Figure
5.14) .
Arterial [A] was further increased with combined reuptake and
alpha^adrenoceptor blockade (Figure 5.11) but the increase (1.5 +
0.1 pmol/ml control; 3.7 +1.8 pmol/ml yohimbine/DMI) was less
than that for [NA]. Extraction of [A] across the heart was
maintained with the yohimbine/DMI combination both before (47 per
cent control; 40 per cent yohimbine/DMI [p = NS]) and during (33
per cent control; 41 per cent yohimbine/DMI [p = NS]) coronary
occlusion and was abolished during reperfusion. Spontaneous
release of [A] was not observed.
Lactate:
As shown previously for both yohimbine and
desmethylimipramine, myocardial lactate production occurred
throughout the period of coronary occlusion and was restricted to
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the ischaemic territory (Figure 5.13). Basal lactate extraction
was reduced by yohimbine/DMI and production enhanced during maximal
ansa stimulation and prior to reperfusion. Basal arterial lactate
concentration increased from 1.2 + 0.2 mmol/1 to 2.1 + 0.5 mmol/1
(p < 0.05) with the drug combination.
Haeaodynamics:
The small reduction in mean arterial blood pressure noted
after yohimbine was maintained with the addition of
desmethylimipramine (108 + 9 mmHg control; 86+5 mmHg
yohimbine/DMI [p < 0.05]). The increase in mean pressure at low
frequency ansa stimulation was unaffected (4+4 mmHg control; 3
+ 4 mmHg yohimbine/DMI) while at high frequency, the increase was
diminished (15 + 13 mmHg control; 8+5 mmHg yohimbine/DMI [p <
0.05]).
Electropliysiology:
Spontaneous ventricular fibrillation occurred once during
control occlusions (14 per cent) and four times after yohimbine/DMI
(57 per cent). The mean duration of coronary occlusion without
ventricular fibrillation fell from 11+1 to 7+1 minutes (p <
0.05) with the drug combination.
Regional epicardial activation abnormalities after coronary
occlusion were further intensified with combined
reuptake/alpha^-adrenoceptor blockade (Figure 5.14). At three
minutes, mean activation delay increased by 59 per cent from 42 +
2 to 67 + 6 msecs (p < 0.01). At low frequency ansa stimulation,
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* p < 0.05 wrt control
Figure 5.13 The effects of yohimbine/desmethylimipramine
on myocardial lactate extraction (mean ± SEM; n=7).
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CONTROL YOHIMBINE/ DMI
Figure 5 14 Mean epicardial activation* delay before and after sym -
pathetic stimulation within the central ischaemic area (n= 7); effects
of yohimbine/desmethylimipramine. Ventricular fibrillation developed
during high frequency ansa stimulation in two studies after yohimbine/
DMI.
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activation delaj' increased from 48 + 3 to 77 + B msecs (p < 0.01)
and at high frequency stimulation, activation delay increased from
56 + 5 to 87 + 9 msecs (p < 0.01) .
Patterns of activation abnormality from one representative
experiment are illustrated in Figure 5.15. Both the absolute
levels and heterogeneity of activation times have been
substantially increased by yohimbine/DMI, in keeping with an
increase in spontaneous arrhythmias.
Group IV - Viloxazine
Noradrenaline extraction:
3
Before ischaemia, 1- H-NA extraction was similar across the
anterior and lateral surfaces of the heart (42 + 6 and 44+8 per
cent respectively) . During coronary occlusion, extraction
increased across the ischaemic area (51 + 7 per cent; p < 0.05)
but remained unchanged across the non-ischaemic area (47 + 6 per
cent) as shown in Table 5.3. Viloxazine resulted in a significant
3
reduction in myocardial 1- H-NA extraction across both territories
(51 +7 to 39 + 5 per cent ischaemic; 47+6 to 26 + 5 per cent
non-ischaemic; Table 5.3) but the percentage reduction in
extraction was significantly greater across the non-ischaemic (45
+ 8 per cent) compared to the ischaemic (20 + 4 per cent) area.
3
Thus, despite enhanced 1- H-NA extraction across ischaemic
myocardium, neuronal reuptake blockade with this drug results in a
relatively small reduction in extraction at this site. It appears
that this phenomenon of reduced activity of neuronal reuptake
blocking drugs in ischaemic myocardium is not specific for
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Figure 5.15 Patterns of epicardial activation delay; effects of yohimbine/
DM I. A. Activation delay is plotted against number of electrodes with that
delay before occlusion, three minutes after occlusion and during ansa
stimulation. B. Profiles of activation delay across the ischaemic zone
(same experiment). Data taken from five rows of ten electrodes across the
epicardium (50 sites) recorded immediately after ansa stimulation (10 Hz).
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EXPERIMENT MYOCARDIAL 1-3H-NORADRENALINE EXTRACTION (%)
ISCHAEMIC NON—ISCHAEMIC
CONTROL VILOXAZINE CONTROL VILOXAZINE
1 61 45 51 39
2 53 42 61 30
3 75 — 57 —
4 46 45 49 26
5 72 65 74 46
6 68 45 58 32
7 41 35 37 9
8 21 18 19 6
9 21 18 18 16
+ ++
Mean + SEM 51+7 39+5 47+6 26 +5
CONTROL I CONTROL II CONTROL I CONTROL
10 42 47 47 41
11 68 73 85 89
12 64 49 58 53
Mean + SEM 58+8 56 + 9 63 + 12 61 + 14
+
p < 0.02 wrt control ++P < 0.001 wrt control
Table 5.3: The effect of low dose (expts 1-6) and high dose
(expts 7-9) viloxazine on extraction of 1-H3
noradrenaline across ischaemic and non-ischaemic
myocardium. Mean extraction shown for each area during
coronary occlusion. Expts 10—12 controls.
158
protocol, the percentage reduction in myocardial 1- H-NA extraction
after desmethylimipramine (2.5 mg/kg) was similarly greater across
the non-ischaemic (48 + 10 per cent) compared to the ischaemic (34
+ 11 per cent) territory.
An example of the effect of high dose viloxazine on myocardial
3
1- H-NA extraction is shown in Figure 5.16. During the control
occlusion (Figure 5.16a), extraction was increased slightly across
the ischaemic compared to the non-ischaemic area with selective
abolition of extraction across the ischaemic area on reperfusion
(due to [NA] release). Arteriovenous differences were
substantially reduced (although not abolished) by viloxazine
(Figure 5.16b) but during coronary occlusion, extraction across the
ischaemic area was greater than that across the non-ischaemic area.
Reperfusion-induced noradrenaline release was readily observed from
the previously ischaemic territory.
Lactate:
Lactate production during coronary occlusion was restricted to
the ischaemic area. No significant differences in lactate release
were noted between control occlusions and those after viloxazine.
Before occlusion, lactate extraction was 37 + 10 per cent before
and 32+6 per cent after viloxazine. Extraction fell to -156 +
40 per cent during the control occlusion and -117 + 38 per cent
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Figure 5.16 Myocardial NA extraction during continuous labelling
with i-^H-NA; effects of viloxazine (expt. 7).
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Haessodyuan i c s:
As with desmethylimipramine, blood flow to non-ischaemic
myocardium fell after viloxazine. Endocardial flow fell by 26 per
cent from 105 +11 to 78+7 ml/min/100 g while epicardial flow
fell by 25 per cent from 94 + 8 to 71+7 ml/min/100 g (p < 0.05
for both) . The reduction in flow to the ischaemic area following
viloxazine was similar, endocardial flow decreasing by 27 per cent
from 30+7 to 22 + 4 ml/min/100 g and epicardial flow decreasing
by 23 per cent from 40 + 10 to 31 + 8 ml/min/100 g (0.05 < p <
0.1). Mean arterial blood pressure fell from 103 + 12 to 90 + 9
mmHg after reuptake blockade.
Electrophysiology:
As noted previously for both yohimbine and desmethylimipramine
singly and in combination, ventricular arrhs'thmias were more
prevalent after reuptake blockade with viloxazine. Spontaneous
ventricular fibrillation occurred twice during the control
occlusion (22 per cent) and on four occasions (44 per cent) after
viloxazine. The mean duration of coronary occlusion prior to
ventricular fibrillation fell from 9 + 1 to 7 + 1 minutes (0.05 <
p < 0.1) .
The incidence of ventricular arrhythmias and duration of
occlusion without ventricular fibrillation are summarised for each
experimental group in Figure 5.17. The control data have been
derived from all studies before drug administration The trend for
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Figure 5.17 Percent incidence of ventricular tachycardia/ectopics
(open histograms) or ventricular fibrillation (closed histograms)
and duration of occlusion before ventricular fibrillation (closed
circles); influence of presynaptic adrenoceptor modulation,
control n=31; Gp I yohimbine n=9; Gp II desmethylimipramine




These studies indicate the importance of presynaptic
adrenergic mechanisms in controlling catecholamine overflow from
ischaemic and non-ischaemic myocardium and determining
electrophysiological abnormalities during coronary occlusion.
Furthermore, a relationship has been shown between the extent of
potentiation of myocardial catecholamine release as a result of
drug administration and epicardial activation abnormalities and
spontaneous ventricular arrhythmias, such that the greater the
potentiation of [NA] release, the greater the likelihood of
arrhythmogenesis.
An alpha-adrenoceptor blocking agent with selectivity for the
alpha^subtype, such as yohimbine, acts preferentially at the
presynaptic level to block alpha-adrenoceptor-mediated negative
feedback and thus increases local [NA] release (Tanaka and Starke,
1980). Although presynaptic alpha^-adrenoceptor antagonists may
reduce the early mortality from ventricular fibrillation during
both circumflex (Manning and Caudwell, 1947) and LAD coronary
occlusion (Sheridan et al, 1980), it is probable that the major
influence of sympathetic stimulation on vulnerability to
ventricular arrhythmias is mediated by beta-adrenoceptors (Malliani
et al, 1980). Beta-adrenoceptor blockade substantially reduces
enhanced vulnerability to ventricular arrhythmias associated with
stellate ganglion stimulation, hypothalamic stimulation and
catecholamine infusion (Lown et al, 1977). Thus, enhanced regional
catecholamine release, secondary to presynaptic alpha^-adrenoceptor
blockade may be arrhythmogenic from increased beta-adrenoceptor
stimulation, despite some postsynaptic alpha^-adrenoceptor
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blockade, evidenced in the yohimbine studies by a small fall in
systolic blood pressure. Yohimbine increased arrhythmias and
conduction abnormalities, and reduced blood flow to the ischaemic
area during LAD occlusion in the anaesthetised dog model. Although
some alpha—adrenoceptor blocking agents can modify [NA] release
centrally, inhibit neuronal reuptake, and exhibit quinidine like
effects on canine Purkinje fibres (Rosen et al, 1971), it is
unlikely that yohimbine would have such activity in the dose
selected for this study.
It is probable that a component of the increase in arterial
catecholamines after yohimbine was secondary to a reflex increase
in sympathetic tone from the fall in systemic blood pressure. This
may be the explanation for the rise in arterial [A] with this drug
(Figure 5.4), a factor that, theoretically, may further potentiate
release of [NA] by activation of presynaptic beta-adrenoceptors.
However, the rise in arterial [NA] was small compared to increases
in myocardial [NA] release with sympathetic stimulation (Figure
5.3), the latter a direct assessment of the blocking action of
yohimbine on nerve terminal adrenoceptors in the heart.
Furthermore, it is myocardial, rather than systemic catecholamine
release that is particularly associated with malignant arrhythmias
(Hoffman, 1978). The three-fold increase in [NA] release with ansa
stimulation after yohimbine demonstrates the activity of nerve
terminal feedback mechanisms in acutely ischaemic myocardium.
Indeed, [NA] release was increased more across the ischaemic (168
per cent rise) than across the non-ischaemic (86 per cent rise)
territory. The [NA] concentration at the synaptic cleft is not
readily predictable but will be many times greater than the change
in ischaemic effluent.
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Yohimbine increased both the severity and heterogeneity of
epicardial activation abnormalities across the ischaemic area
before and during sympathetic stimulation. Marked regional
disparities in activation delay may result from temporal dispersion
of epicardial activation with adjacent areas showing variable
recovery of conduction, a situation predisposing to re-entry (Wit
et al, 1974). Increased local [NA] concentrations may be
arrhythmogenic through enhancement of slow-response action
potentials, provocation of after-depolarisation or other mechanisms
facilitating re-entry (Hoffman, 1978).
The selective reduction in RMBF to the ischaemic area with
yohimbine would be compatible with an increase in coronary vascular
resistance with this drug, although coronary perfusion pressure
would have decreased with the fall in arterial blood pressure.
Autoregulation presumably prevented a reduction in blood flow to
the non-ischaemic area. After reuptake blockade with
desmethylimipramine, however, RMBF was significantly reduced to
both the non—ischaemic and particularly the ischaemic area, despite
absence of change in blood pressure. It is quite possible,
therefore, that increased myocardial [NA] release after either
alpha^-adrenoceptor blockade or reuptake blockade may increase
coronary vascular tone through post-synaptic alpha^—adrenoceptor
activation and prevent maximal vasodilation secondary to
accumulation of ischaemic vasodilator metabolites. Tonic
alpha-adrenoceptor vasoconstrictor tone has been demonstrated in
the normal coronary circulation (Feigl, 1975; Kelley and Feigl,
1978; Orlick et al, 1978; Murray and Vatner, 1979)- although
controversy remains (Chilian et al, 1981)- and in the presence of a
fixed coronary stenosis (Buffington and Feigl, 1981). Indeed, in
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the presence of a severe circumflex coronary artery stenosis,
Heusch and Deussen (1983) showed lactate production, arrhythmias
and an increase in coronary vascular resistance distal to the
stenosis as a result of cardiac sympathetic nerve stimulation. A
reduction in coronarjr vascular resistance followed sympathetic
stimulation when there was moderate or no circumflex stenosis. The
increase in corona^' vascular resistance was prevented by
phentolamine. Stimulation of cardiac sympathetic nerves may also
limit epicardial blood flow during maximal adenosine-induced
metabolic vasodilatation (Johannsen et al, 1982). The reported
here study supports the concept of alpha-adrenoceptor mediated
coronary vasoconstriction as an inducer or intensifier of
myocardial ischaemia distal to a severe corona^ obstruction.
A direct effect of yohimbine or desmethylimipramine on
coronary vasomotor tone cannot be excluded but is unlikely in view
of their known pharmacological activity.
The potentiation of myocardial catecholamine overflow by
desmethylimipramine was rather similar to that with yohimbine,
although the rise in arterial [NA] was less marked. The latter
observation may be explicable by absence of change in blood
pressure with desmethylimipramine and hence no reflex increase in
central neurosympathetic outflow. Expressed as the increase in
myocardial [NA] release as a result of reuptake blockade with
desmethylimipramine, it can be seen from Figure 5.8 that, at low
frequency ansa stimulation, there is greater release across the
ischaemic than the non-ischaemic area. This observation may be
explained either by more effective reuptake blockade in the
ischaemic area or enhanced reuptake activity at this site prior to
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drug administration and hence greater drug efficacy. As shown in
the viloxazine studies (Table 5.3) and in three studies with
3
desmethylimipramine, extraction of 1- H-NA was less effectively
reduced across the ischaemic, compared to the non-ischaemic area.
Thus, despite less effective inhibition of neuronal reuptake, [NA]
release was potentiated more across the ischaemic than the
non-ischaemic area, strongly favouring enhanced reuptake at the
former site i.e. before desmethylimipramine or viloxazine were
given. No such differences were evident during high frequency ansa
stimulation, possibly because factors other than neuronal reuptake,
such as diffusion, washout or extraneuronal uptake may have
determined removal of released neurotransmitter at such high and
unphysiological concentrations. The activity of neuronal reuptake
in limiting [NA] overflow from isolated perfused rat heart has
recently been demonstrated (Schomig et al, 1983). Enhanced
neuronal reuptake in acutely ischaemic myocardium and enhanced
presynaptic negative feedback may be an explanation for absence of
spontaneous [NA] overflow from the heart.
Flow itself is an important determinant of reuptake. A
reduction in flow will reduce the concentration gradient between
the juxtasynaptic and vascular spaces and hence reduce removal of
released neurotransmitter by diffusion, allowing enhanced local
reuptake, provided such processes remain active. In the isolated
rat heart, [NA] extraction is enhanced during severe ischaemia (0.1
ml/min) but not with milder reductions in flow (3.0 ml/min)
(Riemersma and Jynge, unpublished data). During low flow
ischaemia, (0.05 ml/min/g beyond ten minutes) Dietz et al (1982)
noted a three-fold increase in [NA] release from isolated perfused
rat hearts during reperfusion in the presence of 100 pM cocaine.
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With no flow ischaemia, no such potentiation of [NA] release with
uptake blockade was evident. Thus, complete cessation of flow may
inhibit neuronal reuptake, an energy dependent process. It has
also been suggested that the massaging action of the heart may aid
diffusion of released neurotransmitter into the blood stream (Levy
1982). This mechanism will be reduced or absent in the ischaemic
territory. The control studies in group IV revealed enhanced
3
extraction of 1- H-NA across the ischaemic territory during
coronary occlusion. Increased extraction at this site was
maintained after viloxazine, despite, as shown in Table 5.3,
reduced efficacy of this reuptake blocker in ischaemic myocardium.
The importance of extraneuronal uptake in removal of released
[NA] has not been assessed in these studies although catecholamine
metabolites may have contributed to tritium efflux in group IV. It
is likely, however, that extraneuronal uptake is much less
important than neuronal uptake in removing released
neurotransmitter from sympathetic nerve terminals, since
extraneuronal uptake blockade has little influence on the magnitude
and duration of the chronotropic and inotropic response to
sympathetic stimulation (Matsuda et al, 1979). In contrast,
neuronal uptake blockade has a pronounced effect on the duration of
the chronotropic and to a lesser extent the inotropic response
(Koerker and Moran, 1971; Levy and Blattberg, 1978; Matsuda et al,
1980).
Both yohimbine and desmethylimipramine potentiated
reperfusion-induced [NA] release from the ischaemic area. As
discussed in Chapters 3 and 4, it seems more likely that this
release is specific to reperfusion per se, rather than washout of
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[NA] released during the period of ischaemia and if this is so, it
is probable that the transmitter is being released from nerve
terminals in the ischaemic zone. Reperfusion-induced ventricular
fibrillation occurred twice as frequently after reuptake or
alpha-adrenoceptor blockade as in control studies.
Given in combination, yohimbine and desmethy1imipramine caused
marked increases in basal catecholamine concentrations at all
sampling sites. Release of [NA] from the heart was not observed,
under basal conditions. At both three and eleven minutes after
coronary occlusion, however, spontaneous release of [NA] from
ischaemic and non-ischaemic areas was observed, contrasting with
responses to either drug given alone and to the control occlusion.
Even under these conditions of combined alpha^-adrenoceptor and
neuronal reuptake blockade, the increase in myocardial [NA] release
as a result of coronary occlusion, while statistically significant,
represented a modest rise over substantially elevated arterial
levels (Figures 5.11 and 5.12). Using this model, therefore,
spontaneous release of [NA] from the heart during coronary
occlusion can be unmasked only by attenuation of neuronal reuptake
and alpha^-adrenoceptor mediated negative feedback mechanisms.
Neither agent caused spontaneous release of [NA] from the heart
when used alone, presumably because of the efficacy of the
alternative mechanisms for reducing [NA] spillover from the
synaptic cleft, an effect recently shown by Enero (1983) for
changes in rat atrial rate during sympathetic stimulation. The
modest increase in myocardial [NA] release following ansa
stimulation in the studies reported here may also partly reflect
nerve fatigue as a result of intense drug-induced nerve terminal
activity.
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It is, perhaps, not surprising that epicardial activation
abnormalities across the ischaemic area were further intensified bjr
the drug combination (Figures 5.14), compared to yohimbine alone
(Table 5.2). These findings are in keeping with the hypothesis
that enhanced local myocardial catecholamine turnover increases
electrophysiological abnormalities resulting from acute ischaemia
and predisposes to arrhythmias based on re-entry.
3
Diminished activity (assessed by the reduction in 1- H-NA
extraction) of both reuptake inhibitors in ischaemic as opposed to
non-ischaemic myocardium was an unexpected finding. Drug delivery
to both areas should have been the same. The mechanism by which
diminished activity of reuptake blockers occurs in ischaemic tissue
is unknown but may involve impaired access or binding to its
receptor, or the presence of metabolites that impair signal
transformation processes. The effect of calcium channel blockers
on developed tension in cat papillary muscle, for example, alters
significantly with change in pH (Briscoe and Smith, 1982). A
relationship between the differential efficacy of reuptake
inhibitory drugs in ischaemic and non-ischaemic myocardium
(i.e. the difference in extraction across each area) and the
likelihood of arrhythmias during coronary occlusion following
viloxazine was suggested by the finding of a greater difference in
regional extraction (48 + 19 per cent; n = 5), in those
experiments where arrhythmias were more severe or occurred earlier,
than in those where arrhythmias did not increase (18 + 12 per
cent; n = 3; p < 0.05). Differential efficacy of reuptake
inhibitory drugs across the heart will create a [NA] concentration
gradient between ischaemic and non-ischaemic areas and may enhance
the likelihood of arrhythmia production.
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Extraction of [A] was maintained across both ischaemic and
non-ischaemic areas and was not significantly reduced by yohimbine
or DMI singly and in combination, suggesting that extraction is not
dependent on either neuronal uptake or alpha0-adrenoceptor
mechanisms. It is probable that extraction of [A] across the heart
is predominantly extraneuronal, a process known to have a higher
affinity for [A] compared to [NA] (Iverson, 1967).
Energy-dependent neuronal uptake of [A] in vascular tissue has,
however, been described (Abrahamsen and Nedergaard, 1983).
Although spontaneous release of [A] from the heart was not observed
at any time, abolition of [A] extraction on reperfusion after DMI
and DMI/yohimbine in combination does suggest some release of [A]
from the reperfused area, as complete absence of extraction at this
time is improbable. Release of [A] from the heart during
reperfusion may potentiate [NA] release through its action at
presynaptic beta-adrenoceptors. In this respect, [A] may act as a
functional co-transmitter (Majewski et al, 1983).
Myocardial lactate production was restricted to the ischaemic
area in all studies and was increased following sympathetic
stimulation. Yohimbine and yohimbine/DMI in combination reduced
lactate extraction prior to coronary occlusion and reduced
extraction across the non-ischaemic area during coronary occlusion
(Figures 5.5 and 5.13), but only in combination was release
increased during ischaemia. An increase in myocardial lactate
release with yohimbine/DMI may reflect enhanced catecholamine
mediated stimulation of anaerobic glycolysis in the ischaemic zone.
This study has suggested enhanced activity both of neuronal
reuptake and alpha-adrenoceptor negative feedback in nerve
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terminals within acutely ischaemic myocardium. Both mechanisms act
independently to limit myocardial catecholamine release and the
consequent detrimental effects of released neurotransmitter on
electrophysiological abnormalities and regional blood flow. The
beneficial effects of post-synaptic alpha-adrenoceptor blockade in
acute ischaemia may be offset by enhanced local catecholamine
turnover. Prazosin, for example, appears not to increase
catecholamine levels or myocardial catecholamine release in
conscious dogs (Holtz and Bassenge, 1981). An alternative
approach, worth further investigation, is the possible
antiarrhythmic action of alpha^-adrenoceptor agonists that may
switch off local [NA] release through activation of presynaptic
negative feedback. Preliminary data from three pilot experiments
using clonidine are shown in Figure 5.18. It can be seen that
clonidine acts as a powerful peripheral inhibitor of myocardial
[NA] release in response to sympathetic stimulation. Basal [NA] at
both arterial and venous sampling sites was also decreased by this
drug and heart rate fell by 32, 46 and 52 beats per minute at the
1, 10 and 50 pg/kg doses respectively. Alternative agents without
central sedative effects may be Referable for further evaluation.
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Ansa stimulation frequency (Hz)
Figure 5.18 Myocardial NA release in response to sym¬
pathetic stimulation; effects of clonidine. The ansa
subclavia from the left stellate ganglion was stimulated
at the frequencies shown before and twenty minutes
after intravenous clonidine at three doses-1, 10 and 50
pig/kg (pentobarbitone anaesthetised open-chest dog; n =3).
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6 METABOLIC MODULATION OF SYMPATHETIC NERVE TERMINAL ACTIVITY:
EFFECTS OF REGIONAL HYPERKALAEMIA AND ADENOSINE
m
One of the earliest metabolic changes in the myocardium during
coronary ligation is loss of intracellular potassium from ischaemic
cells. Early attempts to quantify the secondary rise in
extracellular potassium relied on measurement of coronary
arteriovenous differences (Harris et al, 1958; Regan et al, 1967,
1969; Thomas et al, 1970; Ettinger et al, 1973), almost certainly a
considerable underestimate of true changes in the interstitial
space. More recently, however, the use of ion-sensitive electrodes
has permitted direct measurement of extracellular potassium during
myocardial ischaemia (Eill and Gettes, 1980; Hirsche et al, 1980;
Weiss and Shine, 1981). Levels start to rise some ten seconds
after coronary occlusion in the pig model and reach 15-20 mM in the
central ischaemic zone within the first five minutes of ischaemia
at the time of onset of early ventricular arrhythmias (Hirsche et
al, 1980). At this concentration, important electrophysiological
effects on the myocardium have been demonstrated, including
inhibition of the fast inward sodium channel and shortening of the
duration of the action potential (Opie et al, 1979).
In parallel with this evidence, it has been known for over a
decade that potassium concentrations between 5 and 20 mM decrease
the reactivity of blood vessels to sympathetic stimulation in vitro
through inhibition of noradrenaline release while beyond 20 mil, the
transmitter is released directly (Kirkepar et al, 1972; Lorenz and
Vanhoutte, 1975).
The first part of the series presented in this chapter
therefore examines in vivo myocardial release of noradrenaline in
response to sympathetic stimulation during regional intracoronary
infusions of potassium designed to mimic concentrations shown by
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direct measurement during ischaemia. It is hypothesised that
release of potassium from ischaemic myocardium may directly
influence noradrenaline release from adjacent nerve terminals and
hence indirectly modify both myocardial and coronary vascular
reactivity.
Purine release from ischaemic myocardium, especially
adenosine, occurs following coronary occlusion and the altered
levels are paralled by altered flow (Olsson, 1970; Rubio et al,
1974; Olsson et al, 1978). Because adenosine is a potent
vasodilator when injected into the coronary arteries (Drury and
Szent-Gyorgyi, 1929) it has been suggested that it ma3>- play a role
in mediating coronary vasodilatation during ischaemia and hypoxia
and thus act as a determinant of regional myocardial perfusion.
In vitro, however, adenosine also modifies the response of
canine vascular strips to sympathetic nerve stimulation (Verhaeghe
et al, 1977). A dose-dependent inhibition of the contractile
response to electrical stimulation occurs, associated with reduced
efflux of noradrenaline during nerve stimulation. Vasodilatation
during adenosine infusion into the lateral saphenous vein of the
dog is also greater during vasoconstriction from electrical
stimulation of sympathetic nerves than from exogenous
noradrenaline. The effects of adenosine on myocardial
noradrenaline release and coronary vascular resistance during
sympathetic stimulation in-vivo have not been examined.
The second part of this study therefore examined whether basal
or nerve stimulated myocardial noradrenaline release was modified
by regional adenosine infusion and whether the effects of
sympathetic stimulation on coronary vascular reactivity changed as
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a result of adenosine-induced coronary vasodilation.
For both studies, potassium and adenosine were infused
selectively into the LAD with venous sampling from a local coronary
vein in this territory and in the territory of drainage of the
circumflex coronary artery which acted as the control.
METHODS, PROTOCOLS
Adult mongrel dogs of either sex were anaesthetised with
pentobarbitone and prepared surgically as described in Chapter 4
with two modifications:-
Firstly, a fine (1 FG) Portex cannula was inserted into a
small proximal branch of the LAD, usually found running laterally
round the root of the pulmonary artery towards the right ventricle.
The artery (ext. diameter approximately 1—1.5 mm) was carefully
dissected along its length to ensure that small branches were
absent or ligated and the cannula inserted and advanced to the
branch point with the LAD. Preliminary studies had shown that this
method allowed infusion into the LAD without reducing flow in the
parent artery. The length of cannula to be inserted was carefully
measured against the branch vessel (usually 1—1.5 cm) and the
position of the cannula tip checked at the end of each experiment.
Selective infusion into the LAD was also confirmed at the end of
the experimental preparation by observing a selective increase in
LAD (but not circumflex) flow after infusion of 100 pi 10-4 m
adenosine. The position of the cannula was, if necessary, adjusted
and rechecked.
Secondly, both the circumflex and LAD were dissected over
187
approximately one centimetre within three centimetres of their
origin and electromagnetic flow probes (internal diameter 2-3 mm)
placed round each vessel for continuous measurement of flow using a
two-channel flowmeter (Skalar Instruments). The flowmeter zero in
isotonic saline at 37°C was checked at intervals during each
experiment. Zero-drift characteristics were within specification
and checked and if necessary adjusted hourly.
Heart rate was kept constant throughout each experiment by
atrial pacing at a rate of 5-10 beats per minute faster than the
maximum rate during ansa stimulation (the paced rate varied between
142 and 204 beats per minute) but was kept constant throughout each
experiment.
Thirty minutes after completion of the experimental
preparation, intracoronary infusions of isotonic saline or
potassium chloride (10, 25, 75 mM; first series) and isotonic
saline or adenosine (10—5, 10-^, 10-^, 10-^ M; second series) were
established at a rate less than 5 per cent of measured LAD flow and
continued for thirty minutes. The infusion rate of potassium was
adjusted on the basis of the measured basal LAD flow to achieve an
arterial K+ level of +1, +2 and +7.5 mM for each study but was
thereafter kept constant. K+ infusions above 150 mM tended to
cause progressive LAD vasoconstriction preventing the establishment
of a steady state. Blood pressure, LAD and circumflex flow were
measured continuously. After 10 minutes, changes in mean flow,
aortic diastolic pressure and regional myocardial [NA] release from
the anterior (LAD) and lateral (circumflex) surfaces of the heart
were evaluated during graded stimulation of the ansa subclavia from
the left stellate ganglion at supramaximal voltage (8-10 v; 4
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Figure 6,1 Metabolic modulation of sympathetic responsiveness. Protocol
for regional infusion studies (saline, potassium, adenosine; seetext for details)
and graded ansa stimulation (2, 5, 20 Hz).
squares3 arterial/venous sampling, arrows3 aortic diastolic pressure and





Figure 6. 2 Haemodynamic responses (mean t SEM) during and after
graded ansa stimulation (2, 5, 20Hz). Increments in regional myo¬
cardial blood flow (A) and mean aortic diastolic blood pressure (B).
Control experiments (n =6; ? expts).
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msecs) and varying frequency (2, 5, 20 Hz) as shown in Figure 6.1.
A further twenty minute recovery period was allowed before the
protocol was repeated. Coronary vascular resistance was calculated
f rom
aortic diastolic pressure (mmEg)
mean flow (ml/min)
Arterial and coronary venous potassium levels were measured in the
first series at the start and finish of each infusion period.
Changes in regional coronary blood flow and mean aortic
diastolic pressure during six periods of graded ansa stimulation
for one minute in three preliminary experiments are shown in Figure
6.2. Although there was considerable inter-experimental
variability in the responses to sympathetic stimulation, in keeping
with variable noradrenaline release, maximum responses were evident
after one minute of stimulation, and this time period was therefore
selected for this study. Flow increases in the circumflex coronary
artery were greater than the LAD at all stimulation frequencies.
Each of the three potassium or four adenosine dose ranges were
given in random order for each experiment with a saline control
infusion before and at the end of each metabolite study. Control
data have been calculated from the mean of these two saline
responses.
All plasma samples were collected into pre-cooled tubes over
15 seconds before and during the final 15 seconds of ansa
stimulation. Plasma was immediately separated and frozen for
subsequent analysis in duplicate as described previously.
Differences in regional myocardial catecholamine release,
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blood flow and corona^ vascular
stimulation, were evaluated by ana
modified t-statistic for pair
considerable inter-experimental
haemodynamic data have been
measurements before and at the
stimulation. All data are expr
cent level of confidence was consi
resistence at each level of ansa
lysis of variance and computed
differences. In view of the
variability in basal flow,
normalised to mean baseline
end of each sequence of ansa




Stimulation of the left ansa subclavia at increasing frequency
resulted in progressive [NA] release from both anterior and lateral
surfaces of the heart. Release was greater from the lateral
(circumflex) territory at all levels of ansa stimulation as noted
previously (at 20 Hz, [NA] release 10.2 + 2.9 pmol/ml anterior;
21.2 + 6.9 pmol/ml lateral; p < 0.005).
Spontaneous release of [NA] from the heart did not occur with
intracoronary potassium infusion. During low dose potassium
infusions (10 mmol/ml) despite a minor and statistically
insignificant rise in anterior venous K+, [NA] release was
significantly reduced at both 5 and 20 Hz stimulation (peak release
at 5 Hz 4.8 + 1.1 pmol/ml control and 2.7 + 0.8 pmol/ml 10 mM
KC1, p < 0.05; peak release at 20 Hz 10.2 + 2.6 pmol/ml control
and 2.9 + 1.8 pmol/ml 10 mil KC1, p < 0.01; Figure 6.3a). During
75 mil potassium infusion [NA] release was potentiated at high
frequency stimulation (10.2 + 2.6 pmol/ml control, 13.3 + 2.7










































* p < 0.03
** p < 0.01
2 Hz 5 Hz 20 Hz
wrt saline infusion
Figure 6.3 Myocardial NA release during graded ansa stimulation
-effects of regional potassium infusion (n=6; mean + SEM). Insets
show venous K in anterior (LAD; A) and lateral (circumflex; B) veins.
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3.6 + .4 to 9.7 + 3.4 minol/1 (p < 0.01). The trend for a
biphasic action of potassium on regional [NA] release from the
heart (inhibition at low dose and potentiation at high dose) was
evident at all stimulation frequencies, as shown in Figure 6.3a.
In contrast, no significant dose related differences in [NA]
release from the lateral (circumflex) territory were noted during
ansa stimulation. Coronary venous K+ was not significantly
increased at this site (Figure 6.3b).
Basal coronary artery flow was not significantly changed by
intracoronary potassium at any of the three concentrations (46 + 8
ml/min saline; 44+9 ml/min 10 mM KC1; 42+5 ml/min 25 mM KC1
and 41+4 ml/min 75 mM KC1). Similarly, arterial pressure
remained constant. Changes in coronary flow and coronary vascular
resistance during ansa stimulation and regional potassium infusion
are summarised in Figure 6.4. Control studies showed no
significant changes in LAD coronary vascular resistance during
sympathetic stimulation. During 75 mM potassium infusion, however,
the increase in LAD flow was significantly less than control at 5
and 20 Hz ansa stimulation (Figure 6.4a and Table 6.1) with a
corresponding increase in coronary vascular resistance at these
stimulation frequencies (Figure 6.4b and Table 6.1). Mean
circumflex coronary flow and coronary vascular resistance were not
significantly altered by the infusions. As noted in the
preliminary experiments, increases in flow tended to be greater in
the circumflex than the LAD territory.
Self terminating ventricular tachycardia was noted on two
occasions during high frequency ansa stimulation with 75 mM
potassium. Ventricular fibrillation did not occur. In all
194
* d < 0 05
**
p < o! 01 wrt contro1 (C)
Figure 6.4 Mean haemodynamic responses to graded ansa stimulation (2, 5,
20 Hz). Effects of regional potassium infusion (10, 25, 75 mM) into LAD on flow
(A) and coronary vascular resistance (CVR; B) in LAD and circumflex (CIRC)
territories (n=6).
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2 Hz 5 Hz 20 Hz
Flow CVR Flow CVR Flow CVR
CONTROL
LAD x 7 -1 13 3 26 0
SEM 3 6 5 7 11 8
CIRC x 8 -1 25 -8 35 -8
SEM 3 5 8 7 14 8
I KC1
LAD x 2 5 3 21 5 25
SEM 1 6 5 11 6 10
CIRC x 7 -7 18 -1 23 6
SEM 3 5 9 10 12 10
■ 6.1: Chang e s in regional mean coronary blood flow (flow)
and coronary vascular resistance (CVR) during graded
ansa stimulation. Effects of high dose KC1 into LAD.
Results are expressed as per cent change from basal
(pre- stimulation) values.
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experiments, the surface PR interval remained constant, although in
both experiments with ventricular tachycardia, some slurring of the
ventricular electrogram was observed, suggesting delayed
ventricular activation.
Lactate extraction was maintained across the heart throughout
with the exception of high frequency ansa stimulation during the 75
mM potassium infusion when lactate release from the myocardium
averaged 60 + 52 per cent (0.01 > p > 0.05 wrt basal A-V
difference). Arterial lactate increased slightly during the
infusions from 0.8 + 0.3 iamol/1 during the initial to 1.3 + 0.5
mmol/1 during the final saline infusion (0.1 > p > 0.05).
Series II: Adenosine
Prior to sympathetic stimulation, intracoronary adenosine at
the two highest doses resulted in significant spontaneous release
of small amounts of [NA] from the LAD territory (-0.1 + 0.4
pmol/ml control; 0.6 + 0.7 pmol/ml 10~%! adenosine; 1.0 + 0.6
pmol/ml 10~2 M adenosine; p for both < 0.05; Figure 6.5a). [NA]
release at 2 and 5 Hz ansa stimulation was similar for all doses of
adenosine. At 20 Hz, however, release was inhibited at the two
highest doses (3.8 + 1.4 pmol/ml control; 0.4 + 0.7 pmol/ml 10-^
—9
M adenosine; 0.7 + 0.6 pmol/ml 10 M adenosine; p for both <
0.05; Figure 6.5a). Thus at these two infusion rates, [NA] release
was independent of ansa stimulation. No significant differences in
[NA] release from the lateral circumflex territory were observed
during adenosine infusion (Figure 6.5b).
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* p<0.05 wrt saline infusion
5 Hz 20 Hz
Figure 6.5 Myocardial NA release from anterior (A) and lateral (B)
veins during graded ansa stimulation; effects of regional adenosine
infusion (n=5; mean ± SEM) into LAD territory.
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vasodilation with a rise in basal LAD flow from 29+3 ml/min
during the saline infusion to 87 + 13 ml/min during the highest
dose of adenosine (Table 6.2), corresponding with an approximately
four-fold reduction in vascular resistance. Blood pressure was
unchanged at all except the highest dose of adenosine which caused
a small fall (Table 6.2). Coronary vascular resistance in the
circumflex territory remained unchanged.
Changes in LAD and circumflex blood flow (Figure 6.6a) and
coronary vascular resistance (Figure 6.6b) during ansa stimulation
were not significantly modified by adenosine, despite major
alteration in coronary vascular tone.
Lactate extraction was maintained across both areas of
myocardium during intracoronary infusions and ansa stimulation and
averaged 26 + 11 per cent. Arterial levels remained constant
during the infusions (0.9 + 0.2 mmol/1 during the initial and 1.1
+ 0.4 mmol/1 during the final saline infusion).
Discussion
The main finding of this investigation is the demonstration
that both potassium and adenosine, metabolites that accumulate in
ischaemic myocardium, can modify local sympathetic nerve terminal
activity, as measured by regional myocardial [NA] release. Thus
the local control of myocardial catecholamine release in acute
ischaemia may involve both 'adrenergic' and 'metabolic' feedback.
Extracellular accumulation of potassium in ischaemic dog
myocardium proceeds rapidly during the first five minutes after




































































Table 6.2: Regional myocardial blood flow, aortic diastolic
pressure and coronary vascular resistance during





2 Hz 5 Hz 20 Hz Basal 2 Hz 5 Hz 20 Hz
30 r- CIRC
20 -
Basal 2 Hz 5 Hz 20 Hz Basal 2 Hz 5 Hz 20 Hz
Figure 6.6 Mean haemodynamic responses to graded ansa stimulation (2,3, 20 Hz).
Effects of regional adenosine infusion (10~5,10~4,10"3, ?0~2M) into LAD on flow (A)
and coronary vascular resistance (CVR.-B) in left anterior descending (LAD) and
circumflex (C IRC) territories (n=5).
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1972; Wiegand et al, 1979). Early studies evaluating the effects
of regional hyperkalaemia on conduction delay and arrhythmias
reproduced many of the electrophysiological abnormalities seen
during acute ischaemia, including ventricular fibrillation (Logic
1972, 1973). Furthermore, non-uniform distribution of potassium
increments within epicardial and endocardial layers was observed
(Ettinger et al, 1973), similar to the heterogeneous distribution
of ischaemic metabolites during coronary occlusion (Russell, 1982).
It is likely, however, that the concentrations of infused potassium
in these studies were greater than the extracellular levels found
during acute ischaemia especially in the dog model.
Thus, the infusion rates and concentrations selected in this
study attempted to mirror the concentration ranges likely to occur
across an ischaemic area in the dog model. Plasma levels in the
local venous drainage of the perfused territory increased by 0.1,
1.3 and 6.1 mM respectively at the three concentrations, certainly
an underestimate of the extracellular concentration, although this
was not measured. Potassium levels in the unperfused territory
were unchanged.
At these infusion rates, a biphasic action of regional
hyperkalaemia on nerve stimulated [NA] release was observed;
inhibition of release at the lowest concentration with potentiation
of release at the highest concentration. No significant effects of
potassium on [NA] release were observed before or during low
frequency sympathetic stimulation (although the trend was similar)
possibly because of relatively small changes in [NA] at these
times. By contrast, [NA] release from the lateral circumflex
territory remained unchanged throughout the periods of
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hyperkalaemia, so that variability in effectiveness of sympathetic
stimulation or deterioration in tbe preparation could not bave
explained the results.
The ability of regional hyperkalaemia to have disparate
effects on sympathetic nerve terminal [NA] release in vivo
illustrates the complexities of predicting the likely responses
during acute ischaemia. However, it may be readily envisaged that
areas of enhanced [NA] release resulting from potassium induced
nerve terminal depolarisation or inhibition of neuronal reuptake
(Shore 1972) adjacent to areas of inhibited [NA] release (from
milder hyperkalaemia) will intensify the heterogeneous effects of
the hyperkalaemia on regional activation times and repolarisation
and increase the likelihood of arrhythmias. An increase in [NA]
release may itself increase extracellular potassium accumulation
and initiate a cycle of catecholamine release and
electrophysiological abnormality. Enhanced beta-adrenoceptor
stimulation of myocytes in a milieu of high extracellular potassium
is conducive to re-entrant arrhythmias, possibly by facilitating
slow response action potentials (Wit and Bigger, 1975).
Beta-adrenoceptor blockade attenuates the initial rise in
extracellular potassium independent of changes in heart rate
(Wiegand et al, 1979). Thus, the possibility of combined effects
of hyperkalaemia and myocardial [NA] release as triggers of early
ventricular arrhythmias has both theoretical basis and experimental
support (Hirsche et al, 1982). The changes in [NA] release shown
in this study are analogous to in vitro studies in a variety of
preparations (Haddy 1975; Verhaeghe et al, 1978).
The second interaction between changes in extracellular
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potassium and neurosympathetic responsiveness centres round changes
in coronary vascular resistance. At the highest infusion rate,
sjnnpathetic stimulation at 5 and 20 Hz resulted in significant
increases in coronary vascular resistance and attenuated the rise
in regional flow (Figure 6.4). Basal coronary flow was not
affected, thus it is unlikely that the vasoconstriction occurred as
a direct effect of hyperkalaemia on coronary vasculature. Indeed,
in most vascular beds an increase in potassium causes local
vasodilation (Kjellmer 1965; Haddy et al, 1968; Mellender and
Johannson, 1968).
It is more likely that the vasoconstrictor response during
sympathetic stimulation represents an interaction between
hyperkalaemia and the responsiveness of the coronary vasculature to
released [NA]. Vasoconstriction during sympathetic stimulation has
been shown at several points within the range of coronary vascular
reserve, including reactive hyperaemia (Schwartz and Stone, 1977)
exercise (Murray and Vatner, 1979), adenosine infusion (Johannson
et al, 1982) and in the presence of a coronary stenosis (Buffington
and Feigl, 1981). Recently, Heusch and Deussen (1983) showed a
progressive change in the effect of left cardiac sympathetic nerve
stimulation on the resistance of the coronary vascular bed distal
to an increasingly severe coronary stenosis. Sympathetic
stimulation decreased the diastolic coronary resistance of intact
coronary arteries but increased the resistance in the presence of a
severe stenosis, resulting in lactate production and spontaneous
ventricular fibrillation. The increase was blocked by post
junctional alpha 2-adrenoceptor blockade. Although the mechanism
of the increase in coronary vascular resistance during
hyperkalaemia is speculative, enhanced alpha-adrenoceptor mediated
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vasoconstriction seems possible, although impaired
beta-adrenoceptor mediated or metabolic vasodilatation is not
excluded. The potassium-induced increase in coronary vascular
resistance during sympathetic activation provides one mechanism to
explain vasoconstriction in the presence of myocardial ischaemia,
although it remains contraversial whether such an effect could
overwhelm vasodilation from accumulation of powerful vasodilator
metabolites (Mudge et al, 1979; Gewirtz et al, 1982).
Tissue adenosine increases rapidly during acute myocardial
ischaemia, with a seven fold increase in one study after only 15
seconds coronary occlusion (Olsson, 1978). Sympathetic stimulation
further increases adenosine production which closely parallels
changes in myocardial oxygen demand (Killer et al, 1979). The
concentration of adenosine in the interstitial space during
myocardial ischaemia has not been accurately determined, partly
because of uncertainty as to whether adenosine formation in the
heart is sarcolemmal (based on the activity of 5' nucleotidase) and
hence close to the interstitial space (Rubio et al, 1977) or
whether it is formed intracellularly by a cytoplasmic enzyme
(5-adenosyl homocysteine hydrolase) and transported across the
sarcolemmal membrane (Schutz et al, 1981). Nonetheless,
concentrations of between 10-6 and 10-^ have been suggested in the
interstitial space. Despite the rapid inactivation of adenosine,
(Fredhold and Hedqvist, 1978), this should have been achieved by
the higher infusion concentrations in this study.
The effects of intracoronary adenosine on myocardial [NA]
release were different to those of potassium. Under basal
conditions, high dose adenosine (10-3 and lO-^ M) increased [NA]
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release selectively from the infused territory (Figure 6.5). The
mechanism of this enhanced release is uncertain, since washout of
released transmitter would also be enhanced from the increase in
flow, thus reducing exposure to neuronal and extraneuronal uptake
and metabolism. Adenosine-induced coronars7 vasodilatation does not
appear to increase arteriovenous shunting in the coronary
circulation (Downey et al, 1979). However, enhanced neuronal
leakage of [NA] from storage vesicles in the nerve terminal is an
alternative explanation for which there is experimental support
from in vitro studies (Verhaeghe et al, 1977) and indirect support
from the observation that adenosine releases cAMP into coronarj7
venous blood (Buynh-Thu and Lammerant, 1980).
During sympathetic stimulation, however, myocardial [NA]
release was inhibited during high frequency ansa stimulation at the
two highest concentrations of adenosine, analogous to the
dose-dependent inhibition of neurotransmission shown in a variety
of tissues in vitro (Enero and Saidman, 1977; Fredholm and
Hedqvist, 1978; Hedqvist and Fredhold, 1979). This presynaptic
action of adenosine will be complementary to post synaptic
inhibition of the inotropic and chronotropic responses to
catecholamines (Schrader et al, 1977, 1982), and may explain
suppression of sinus node automaticity and prolongation of
atrioventricular nodal conduction (Di Marco et al, 1983).
Despite inhibition of regional [NA] release during ansa
stimulation, changes in coronary blood flow and coronary vascular
resistance were unaffected at all adenosine concentrations. A
trend for reduction in coronary vascular resistance was evident
during sympathetic stimulation in both the LAD and circumflex
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territories but this did not achieve statistical significance.
Thus, these investigations have shown that the profile of
sympathetic nerve terminal activity in acutely ischaemic myocardium
appears to be very complex, involving heterologous (metabolite) as
well as homologous (catecholamine) regulation of activity. Only
two potentially active metabolites were chosen for study although
it is likely that many others (such as pH, adenine nucleotides,
5-hydroxytryptamine lactate etc.) may be active in determining [NA]
release from different areas of ischaemic heart.
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7 INFLUENCE OF BETA-ADRENOCEPTOR ANTAGONISM ON
NERVE TERMINAL RESPONSIVENESS, BLOOD FLOW AND
ACTIVATION ABNORMALITIES DURING ACUTE ISCHAEMIA:
THE IMPORTANCE OF HEART RATE
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A variety of beta-adrenoceptor antagonists have been evaluated
and shown to be variably effective in the prevention of ventricular
arrhythmias during experimental myocardial ischaemia and infarction
(Corr and Gillis, 1978; Meesman 1982). However, controversy
remains as to whether the differing pharmacological profiles of
these drugs, namely selectivity, intrinsic sympathomimetic activity
and membrane-stabilising activity are of relevance in any
antiarrhythmic or anti-ischaemic action. The mechanism of action
of beta-adrenoceptor antagonists in protecting ischaemic myocardium
is incompletely understood and may involve presynaptic effects,
antiplatelet effects and peripheral effects in addition to
classical postsynaptic myocardial catecholamine antagonism. Some
but not all of the metabolic actions of beta-adrenoceptor
antagonists are dependent on haemodynamic changes (reduction in
heart rate and blood pressure) after drug administration.
Several studies have suggested that intrinsic differences
exist in the efficacy of beta-adrenoceptor antagonists in acutely
ischaemic myocardium. Potassium release from the ischaemic region,
for example, may play an important role in initiating ventricular
arrhythmias (see Chapter 6). Catecholamines have biphasic effects
on potassium release; propranolol and beta^-selective antagonists
block the beneficial decrease in potassium release (Lockwood and
Lum, 1974). Practolol, an antagonist with both beta-selectivity and
intrinsic sympathomimetic activity, has been shown to reduce the
incidence of ventricular fibrillation after coronary artery
occlusion (Sethi et al, 1973; Kelliher et al, 1975). Practolol,
but not propranolol, increases the diastolic period for
subendocardial perfusion and does not unmask alpha-adrenoceptor
mediated coronary vasoconstriction in the ischaemic area (Marshall
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and Parratt, 1976).
In view of the reported anti-arrhythmic actions of low,
non-pressor doses of systemic catecholamines, associated with
reduction in myocardial potassium loss (Regan et al, 1970), it was
hypothesised that the use of a beta-adrenoceptor antagonist with
intrinsic sympathomimetic activity might have the dual actions of
preventing the detrimental effects of heterogeneous noradrenaline
release within the ischaemic area while maintaining low level but
uniform sympathetic tone.
Pindolol is a potent beta-adrenoceptor antagonist, which as a
result of indole substitution of the aromatic ring possesses
partial agonist activity (Kaufmann and Blinks, 1980). Compared to
pure antagonists, the drug causes a relatively modest fall in heart
rate, blood pressure and global left ventricular function in the
anaesthetised dog model (Stephen et al, 1978) and in man (Svendsen
et al, 1979).
This series of experiments has evaluated the effect of
intravenous pindolol on sympathetic nerve terminal activity,
regional myocardial blood flow distribution, arrhythmias and
conduction abnormalities during LAD occlusion in the dog model
previously described.
Methods
The experimental preparation was as described in Chapter 4.
Briefly, in the open chest pentobarbitone anaesthetised dog, the
heart was suspended in a pericardial cradle and sampling catheters
placed in the aorta ,in a vein in the centre of the LAD territory
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and laterally in a vein draining towards the coronary sinus within
the circumflex territory. Regional anterior myocardial ischaemia
was induced by 12 minute periods of LAD ligation using an occlusion
clip. The anterior and posterior ansa from the left stellate
ganglion were stimulated by square wave pulses (4 msecs) at
supramaximal voltage (8-10v) and varying frequency (1-10 Hz),
allowing assessment of minute-to-minute changes in myocardial
catecholamine and lactate overflow from ischaemic and non-ischaemic
myocardium during LAD ligation and reperfusion and during
sympathetic stimulation.
Regional epicardial activation delay across the ischaemic area
was mapped using a flexible 80 point multielectrode grid as
described in Chapter 2.
Detailed mapping of regional myocardial blood flow was
achieved by left atrial injection of large numbers of microspheres
(at least 8 x 10^) labelled either with ^Co or ^^Sn. This
allowed the heart to be sectioned into 80 full thickness tissue
samples of the left ventricular wall (approximately 5 mm square)
and each biopsy to be divided into endocardial and epicardial
halves, while still retaining the minimum number of spheres in each
biopsy for accurate assessment of regional myocardial blood flow
(Buckberg et al, 1971). Previous studies have confirmed the
reproducibility of flow determination with high dose microspheres
labelled with these isotopes and the absence of haemodynamic effect
of the injection itself (Russell et al, 1982).
Regional myocardial catecholamine and lactate release,
epicardial activation delay and blood flow maps were performed
during two twelve minute periods of LAD occlusion and reperfusion
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as shown in Figure 7.1. Ansa stimulation was performed for 30
seconds at low (1 Hz) and high (10 Hz) frequency sequentially on
two occasions 4 1/2 and 9 1/2 minutes after coronary occlusion.
Regional myocardial flow was measured three minutes after coronary
occlusion and activation delay assessed at three and nine minutes
of ischaemia, one minute after coronary reperfusion, and
immediately after each period of high frequency ansa stimulation
(Figure 7.1). At least one hour recovery was allowed between
successive occlusions.
Three experimental groups were evaluated.
(1) A control group (n = 8) without drug administration during
either occlusion and with atrial pacing at constant rate
throughout;
(2) A second group (n = 8) with a control occlusion followed by
intravenous pindolol 0.45 mg/kg i.v. thirty minutes before the
second occlusion, also with atrial pacing at constant rate
throughout and
(3) A third group (n = 8) similar to the second group but without
atrial pacing during either occlusion.
In addition the effects of three doses of pindolol on myocardial
[NA] release during graded ansa stimulation in the absence of
ischaemia were investigated (n = 3).
Dose-response curves (heart rate and pulse pressure) to bolus
injections of isoprenaline (1, 2.5, 5, 10 fig pre and 10, 25, 75,
200 pg post pindolol) were determined in the unpaced group 15
minutes before each period of ischaemia.
Ventricular fibrillation was managed by internal
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Figure 7.1 Experimental protocol. See text for details. Bars indicate
ansa stimulation at low and high frequency.
213
samples obtained after tbe onset of ventricular fibrillation were
excluded from analysis.
Changes in catecholamine and lactate concentrations for the
three groups were evaluated by analysis of variance and computed
modified t statistic. Intraexperimental comparisons (for pair
differences) were validated by reproducible changes in
catecholamine release, blood flow and electrophysiology during two
successive occlusions in the control group. Non-parametric methods
were used for analysis of changes in flow and surface
electrophysiology, although variability in epicardial and
endocardial flow has been expressed by the use of variance. Unless
otherwise stated, data are expressed as mean + SEM. A five per
cent level of confidence was considered statistically significant.
Results
Catecholanines:
Basal [NA] release from the normal (non-ischaemic) heart was
not modified by pindolol at any of the three doses selected (Figure
7.2). However, at the two higher doses (0.15 and 0.45 mg/kg), a
small reduction in peak release was observed during maximal
sympathetic stimulation. No inhibition of [NA] release was
observed at lower stimulation frequencies, although peak
concentrations in anterior and lateral coronary venous effluent
were modest at these frequencies.
Mean changes in [NA] at each of the three sampling sites
during LAD occlusion, ansa stimulation and coronary reperfusion are
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Figure 7. 2 Peak noradrenaline release (mean + SEM) during graded
ansa stimulation for one minute. Effects of intravenous pindolol.
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Figure 7.3 Mean plasma noradrenaline (NA) responses to ansa stimulation during
LAD occlusion and on reperfusion (n =8 each group). Effects of pindolol. Blocks
indicate low (1 Hz) and high (10 Hz) frequency ansa stimulation.
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arterial [NA] and nerve-stimulated increases in venous [NA] at both
sampling sites were similar during the two periods of coronary
occlusion and sympathetic stimulation. Arterial [NA] did not
change following pindolol (1.1 + 0.4 pmol/ml before and 1.5 + 0.7
pmol/ml after drug administration), and the trend for a gradual
rise in arterial [NA] during the experimental period was unaltered.
However, as noted in the earlier studies without coronary
occlusion, pindolol reduced peak [NA] responses in the
non-ischaemic venous effluent. No such trend was observed across
the ischaemic area. Peak [NA] release from the ischaemic and
non-ischaenic areas at low and high frequency ansa stimulation is
shown in Figure 7.4. At 10 Hz, pindolol reduced peak [NA] release
from the non-ischaemic area from 25.3 + 5.4 to 11.0 + 8.9 pmol/ml
(p < 0.02) in the paced series and from 26.1 + 6.1 to 16.9 + 7.6
pmol/ml (p < 0.05) in the unpaced series. No statistically
significant significances in myocardial [NA] release from the
ischaemic area were noted in any of the other three experimental
groups.
As shown in earlier studies, arterial [A] increased
progressively during the experimental period (Figure 7.5),
especially during coronary reperfusion. No significant differences
between the first and second periods of coronary occlusion were
observed in any series. Spontaneous release of [A] from the heart
did not occur.
Lactate:
Myocardial lactate extraction across the non-ischaemic area
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Figure 7.4 Peak myocardial NA release from ischaemic (I) and non-
ischaemic (NI) areas during low (1Hz) and high (10Hz) frequency ansa
stimulation. Effects of pindolol. Data shown (mean + SEM) for both
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Figure 7. 5 Mean plasma A responses during coronary occlusion and on
reperfusion (n=8 each group). Effects of pindolol.
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occlusions in the control series and in the pindolol series at
constant heart rate (Figure 7.6). A significant reduction in
myocardial lactate production (i.e. an increase in extraction) was
however, seen during the second (pindolol) occlusion in the unpaced
group. At three minutes, extraction after pindolol increased in
this group from -133 + 37 to -58 + 32 per cent and during
sympathetic stimulation it increased from -177 + 45 to -77 + 31
per cent (p for both < 0.05). Lactate extraction across the
non-ischaemic area was unchanged. These changes are summarised in
Figure 7.6.
Haesodynamics:
Heart rate for the control group averaged 185 + 12 beats per
minute and for the pindolol (paced) group 191 + 13 beats per
minute. The rate was kept constant throughout each experiment 5-10
beats per minute faster than the peak response during a test period
of ansa stimulation. In the unpaced series, heart rate fell from
183 + 8 beats per minute before to 151 + 7 beats per minute after
pindolol (p < 0.001). In keeping with the known acute effects of
beta-adrenoceptor antagonism, mean blood pressure after pindolol
fell from 103 + 8 to 88 + 8 mmHg in the paced series and from 97
+7 to 85 + 7 in the unpaced series (p < 0.05). A small
reduction in mean blood pressure in the control group between the
first and second occlusions (from 101 + 9 to 95 + 6 mmHg) was not
statistically significant.
The increase in mean systolic pressure during high frequency
ansa stimulation was also attenuated by pindolol, although somewhat
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Figure 7.6 Myocardial lactate extraction (mean -t SEM) across non-
ischaemic and ischaemic areas. Effects of pindolol. Extraction
(art-ven/art &100) was measured firstly three minutes and secondly
immediately after high frequency ansa stimulation (n=8, each group).
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summarised in Table 7.1.
Isoprenaline dose-response curves for heart rate and pulse
pressure before and after beta-adrenoceptor blockade are summarised
in Figure 7.7. It can be seen that fairly complete
beta-adrenoceptor antagonism has been achieved by this dose of
pindolol, evidenced by an approximate 100 fold shift in the
dose-response curves for these two variables.
Pindolol resulted in significant alterations in the pattern of
and variability in blood flow within the central ischaemic and
border ischaemic areas. Details of mean endocardial and epicardial
flow in the non-ischaemic, border ischaemic and central ischaemic
areas are shown in Figure 7.8. No differences in flow during the
first and second occlusions were evident in the control group.
Pindolol reduced flow to both ischaemic and non-ischaemic zones,
although the reduction in the border and central ischaemic zone was
relatively modest in the unpaced group, especially in the
endocardial region.
Redistribution of flow within the central ischaemic area
occurred with pindolol only in the unpaced group. Comparison
between the endocardial:epicardial blood flow ratios in the paced
and unpaced series is shown in Table 7.2. With pacing, the ratio
fell slightly from 0.83 to 0.72 and from 0.77 to 0.59 in the border
and central ischaemic areas respectively. With the reduction in
heart rate in the unpaced group, the ratio increased slightly from
1.23 to 1.31 in the border ischaemic area and increased
significantly from 0.72 to 0.93 in the central ischaemic area (p <
0.05) .
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INCREASE IN MEAN PRESSURE
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p < 0.05 wrt occlusion 1.
Table 7.1: Increments in mean blood pressure (mmHg) during two

































Figure 7. 7 Dose-response curves (semi-log scale) for heart rate
(circles) and pulse pressure (triangles) increments during bolus
intravenous isoprenaline. Closed symbols before and open symbols
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Figure 7.8 Regional myocardial blood flow (RMBF; mean ± SEM) to
non-ischaemic, border ischaemic and central ischaemic areas. Effects
of pindolol. Open histogram-no drug; hatched histogram-pindolol.
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PACED UNPACED
CONTROL PINDOLOL CONTROL PINDOLOL
NON
ISCHAEMIC 0.98 + 0.07 1.02 + 0.10 1.12 + 0.07 1.10 + 0.09
BORDER
ISCHAEMIC 0.83 + 0.19 0.72 + 0.23 1.23 + 0.16 1.31 + 0.32
CENTRAL +
ISCHAEMIC 0.77 + 0.21 0.59 + 0.19 0.72 + 0.15 0.93 + 0.18
+ p < 0.05 Wrt control.
Table 7.2: Endocardial : epicardial blood flow ratios in the
non-ischaemic, border ischaemic and central ischaemic
areas. Effects of pindolol with and without atrial
pacing.
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Intraexperimental variability in regional blood flow was
assessed by comparison of the variance of flow across each
endocardial and epicardial region for each experiment. It can be
seen from Table 7.3 that pindolol reduced flow variance across both
the border and central ischaemic area, the reduction being somewhat
greater in the unpaced compared to the paced series. No
differences in flow variance were seen in the control series.
Profiles of flow variability from one experiment from the unpaced
series are shown in Figure 7.9. In addition to a reduction in
flow, pindolol reduced the variability in regional flow,
particularly in the ischaemic (low flow) region.
Electropbysiology:
Spontaneous ventricular fibrillation occurred four times in
two control experiments. The time of onset of ventricular
fibrillation was similar in these experiments, occurring
respectively at 8 and 10 1/2 minutes after each LAD ligation in the
first and 10 and 10 minutes after each LAD ligation in the second
study. In the paced pindolol series, ventricular fibrillation
developed three times during the control occlusion at 6, 10 and 10
1/2 minutes and twice immediately after coronary reperfusion. The
pattern of arrhythmia development was similar after pindolol in
this series, ventricular fibrillation occurring in the same three
experiments during coronary occlusion (at 7, 5 and 10 minutes
respectively) and three times after coronary reperfusion. In the
unpaced pindolol series, however, spontaneous ventricular
fibrillation developed three times during the control occlusion (at

































Figure 7.9 Patterns of flow variability from one experiment
(unpaced series). Flow values in 50 individual biopsies from
a 5 &10 grid across the ischaemic region.
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but no episodes of ventricular fibrillation occurred during the
second (pindolol) occlusion. Ventricular fibrillation on
reperfusion developed after pindolol on three occasions, two of
these in animals previously fibrillating during the ischaemic
period. Thus an antiarrhythmic action of pindolol on ventricular
fibrillation during acute ischaemia was evident only in the unpaced
group.
Individual and mean epicardial activation delays during each
period of coronary occlusion, sympathetic stimulation and
reperfusion are summarised in Tables 7.4, 7.5 and 7.6 for the
control, pindolol (paced) and pindolol (unpaced) series
respectively. Mean activation delay within the ischaemic area was
derived from those electrodes showing conduction delay equal to or
greater than forty milliseconds at any time during coronary
occlusion and sympathetic stimulation. The number of electrodes in
each experiment (an index of the area of activation abnormality) is
shown in the tables. No significant differences in activation
delay in the first and second periods of ischaemia were seen in the
control (Table 7.4) and in the paced pindolol (Table 7.5) series.
Activation abnormalities were, in general, intensified during
sympathetic stimulation and although the increase in mean
activation delay following ansa stimulation was attenuated somewhat
in the paced pindolol group compared to the corresponding control
(Table 7.5), this was not statistically significant. By contrast,
activation delay was significantly (p < 0.05) less during the
second occlusion in the unpaced pindolol series three minutes after
LAD occlusion and during both periods of ansa stimulation (Table
7.6). This attenuation of conduction abnormality during acute
ischaemia paralleled the lower incidence of spontaneous ventricular
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EXPT ELECTRODES EPICARDIAL ACTIVATION DELAY (msecs)
3min 10Hz 8min 10Hz Reperfusion
(1) CI 13 27 29 27 28 26
2 29 28 28 29 26
(2) CI 9 45 54 49 VF —
2 36 46 VF
(3) CI 10 44 46 46 VF
2 43 44 46 VF —
(4) CI 18 36 39 41 38 28
2 37 40 46 41 26
(5) CI 9 26 26 28 29 25
2 27 28 29 31 25
(6) CI 5 46 51 48 50 34
2 50 55 50 55 37
(7) CI 17 43 41 40 43 —
2 37 38 43 39
(8) CI 17 55 56 51 59 27
2 47 53 55 56 29
Mean + SEM
CI 40+3 43+4 39+6 41+6 28+2
C2 38+4 42+4 42+4 42+5 29+2
Table 7.4: Epicardial activation delay during the first (CI) and
second (C2) periods of LAD ligation and on reperfusion
Control series. Mean values (+ SEM) for paired
data also shown with the number of electrodes within
the ischaemic area (see text for definition).
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EXPT ELECTRODES EPICARDIAL ACTIVATION DELAY (usees)
3min 10Hz 8min lOIIz Reperfusion
(9) C 19 29 49 VF — —
P 29 53 VF — —
(10) C 34 32 35 38 49 VF
p 33 34 44 46 VF
(11) c 23 31 36 33 35 25
p 29 29 31 32 24
(12) c 20 33 53 36 VF —
p 47 VF — — —
(13) c 16 37 40 34 39 32
p 35 38 38 38 VF
(14) c 26 41 45 43 45 28
p 38 40 41 42 28
(15) c 24 42 48 47 VF —
p 41 44 VF — —
(16) c 12 31 39 36 40 31
p 34 36 37 39 31
Mean + SEM
c 35+2 42+2 37+2 42+3 28+-
36+2 39+3 38+2 39+2 28+4
Table 7.5: Epicardial activation delay during first (control)
and second (Pindolol) LAD ligation. Paced series.
Mean values (+ SEM) for paired data also shown.
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EXPT ELECTRODES EPICARDIAL ACTIVATION DELAY (msecs)
3min 10Hz Smin 10Hz Reperfusion
(17) C 51 41 70 64 69 VF
P 35 54 58 65 VF
(18) c 52 56 VF — — —
F 25 48 76 77 VF
(19) C 39 61 VF — — —
P 44 58 49 44 VF
(20) C 13 30 35 30 39 29
P 30 32 32 33 28
(21) C 9 24 29 27 30 24
P 24 25 25 25 24
(22) C 39 42 46 41 45 27
P 37 42 44 41 24
(23) C 21 36 49 39 53 35
P 32 38 36 39 30
(24) C 27 44 69 VF — —
P 42 55 51 46 32
Mean + SEM
C 42+4 50+8 40+7 47+7 29+2
P 34+ +3 41 +5 39+6 41 +6 27+2
+
p < 0.05 wrt control
Table 7.6: Epicardial activation delay during first (control)
and second (Pindolol) LAD ligation. Unpaced series.
Mean values ( + SEM) for paired data also shown.
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fibrillation in this unpaced group.
Detailed analysis of patterns of activation delay from one
experiment from the unpaced and one from the paced pindolol series
is presented in Figure 7.10. It can be seen from this figure that
activation abnormalities were similar in the control and pindolol
groups during pacing at the same heart rate (Figure 7.10a upper
panel) but that activation abnormalities were more intense
(i.e. activation times longer) in the control compared to pindolol
groups without pacing (Figure 7.10a, lower panel). Profiles of
epicardial activation delay during sympathetic stimulation showed
similar variability in activation in the paced pindolol series
(Figure 7.10b, upper panel) but much less variability in activation
in the unpaced pindolol series (Figure 7.10b, lower panel).
DISCUSSION
As demonstrated in the control series, two sequential twelve
minute periods of regional myocardial ischaemia were associated
with reproducible patterns of sympathetic responsiveness, lactate
release, regional myocardial blood flow, activation abnormalities
and spontaneous arrhythmias. Thus, comparison of changes in these
parameters as a result of intervention before the second period of
ischaemia is valid and has the advantage of allowing paired data
analysis thus avoiding inter-experimental variability.
The main finding of this investigation is the almost complete
dependence of the beneficial effects of pindolol on
electrophysiological abnormalities, blood flow distribution and
lactate release on reduction in heart rate. In the absence of
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Figure 7.10 A Patterns of epicardial activation delay from one experiment
in the paced and unpaced series. Activation delay is plotted against num¬
ber of electrodes with that delay. Data are shown before and after pindolol
prior to and three minutes after LAD ligation and during ansa stimulation.
B Profiles of activation delay across the ischaemic zone from the same
expt during ansa stimulation Data from 5 rows of 10 electrodes traversing
the ischaemic area.
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parameters. It is probable that bradycardia protects the acutely
ischaemic myocardium by reduction in myocardial oxygen demand and
hence acts as an ' anti-ischaemic' rather than an 'anti-arrhythmic'
intervention.
Reduction in flow to the non-ischaemic area following
beta-adrenoceptor blockade has been shown for virtually all
beta-adrenoceptor antagonists (Becker et al, 1971, 1975; Gross and
Winbury, 1973; Berdeaux et al, 1978). Redistribution of flow
within the ischaemic region with an increase in the endo-epi flow
ratio has been shown previously for several antagonists including
pindolol (Flameng et al, 1975; Berdeaux et al, 1978) and has been
variably attributed to combined beta^- and beta2~adrenoceptor
blockade, unmasking of alpha-adrenoceptor mediated vasoconstriction
in the epicardial zone and prolongation of diastolic perfusion
time. The results of the present study suggest that it is the
latter action, that predominates in this effect as the increase in
the flow ratio was prevented by maintenance of a constant heart
rate. In this respect the results are in agreement with the study
by Gross and Winberg (1973) who noted that increasing the heart
rate to control levels abolished the increase in endo-epi flow
ratio following propranolol, practolol and bunolol. Since the
major portion of subendocardial flow occurs during diastole, and
since subendocardial flow is nearly always less than epicardial
flow within the ischaemic area, it might be expected that
prolongation of diastolic perfusion would enhance subendocardial
perfusion. In a study by Warltier et al (1976) in the isolated
canine heart, increases in heart rate alone were sufficient to
decrease the endo-epi flow ratio, an observation supported by data
from Neill et al (1973, 1975) in unaesthetised dogs and those with
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a proximal coronary stenosis and from Flannery et al (1975a) during
coronarj' vasodilatation. Although the effect of bradycardia alone
was not studied, it is, however, unlikely that the increase in flow
ratio with pindolol could be exclusively attributed to the fall in
rate since Gross and Winberg showed that reduction in heart rate
(SA node crush) within the range seen in the study presented here
did not significantly modify the endo-epi ratio, a difference
possibly explained by the different effects of these two manoeuvres
on diastolic pressure - time index per minute.
A second action of pindolol on patterns of blood flow within
the ischaemic territory was the reduction in flow variance within
the border and central ischaemic areas. Measurement of variance of
flow provides an index of the heterogeneity of flow distribution.
Significant reductions in flow variance were seen after pindolol in
both the paced and unpaced groups, although the reduction was more
marked in the latter. Thus, beta-adrenoceptor blockade with this
drug may reduce gradients of flow within the ischaemic area, an
effect likely to promote more uniform changes in myocardial
metabolism and possibly in electrophysiological disturbance. The
combination of sympathetic stimulation and tachycardia is most
likely to promote non-homogenous flow distribution in the heart
(Flannery et al, 1975). However, absence of reduction in
epicardial activation delay or spontaneous arrhythmias in the paced
group suggests that this phenomenon may not be of primary
importance in determining the electrophysiological abnormality.
The reduction in activation delay in the unpaced group after
pindolol was reflected in a reduced incidence of spontaneous
arrhythmias. No protective effects were observed in the paced
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group during coronary occlusion or in either group during
reperfusion. Several studies have shown that heart rate is a major
determinant of myocardial electrical stability during ischaemia
(Scherlag et al, 1970; Redwood et al, 1972; Kent et al, 1973). The
protective effect of pindolol in this study is most likely to
operate through this mechanism.
Reduction in lactate production across the ischaemic area with
pindolol was also restricted to the unpaced group. Arteriovenous
lactate gradients provide a fairly crude index of the extent of
anaerobic myocardial metabolism and do not necessarily equate with
the severity of ischaemic injury. During severe ischaemia, for
example, lactate production may decrease because of acidaemia
(Gevers,1977) but the venous concentration may be maintained
because of a reduction in flow. Furthermore, the assumption that
arteriovenous lactate differences equate with tissue concentrations
can lead to important errors (Al Makdessi et al, 1982). However,
in view of concomitant reduction in heart rate, spontaneous
arrhythmias, conduction abnormalities and improvements in blood
flow distribution, it seems probable that the reduction in lactate
production in this group is a reflection of less severe derangement
of myocardial metabolism, especially as the difference was evident
by three minutes of ischaemia.
Reduction of peak [NA] release from the heart by pindolol
during high frequency ansa stimulation supports the existance of
presynpatic facilitatory beta-adrenoceptors in dog myocardium. The
subclassification of these receptors has not been conclusively
determined. Stjarne and Brundin (1975) and Westfall et al (1979)
have suggested they are of the beta^-subtype on the basis of the
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action of selective agonists and antagonists, but Majewski et al
(1980, 1981) have shown that metoprolol readily blocks the
facilitatory action of adrenaline on catecholamine efflux from rat
and guinea pig atria. A qualitatively similar reduction in [NA]
release from dog heart was noted by Yamaguchi et al (1977) who
studied the effects of sotalol on [NA] release during right
cardio-accelerator nerve stimulation. Inhibition of release was
greatest at lower stimulation frequencies, although marked
increases in heart rate during high frequency stimulation during
control studies may have influenced this result. The identity of
the facilitatory transmitter during sympathetic stimulation is
unknown but in vitro studies suggest that adrenaline is a more
likely candidate that [NA] (Marjewski et al, 1981) as the former is
much more effective at increasing [NA] release and can do so at a
physiological concentration range (below 10 nil), close to that
measured in arterial plasma in the pindolol experiments. It is
also known that adrenaline may be taken up into sympathetic nerve
terminals and released during sympathetic stimulation (Iversen and
Whitby, 1962; Anden, 1964).
Although reduction in [NA] release during sympathetic
stimulation may have theoretical benefits for the heart during
regional ischaemia, a reduction in epicardial activation delay
after pindolol was seen only in the unpaced group. Thus, at
constant heart rate, no beneficial action was evident despite
similar reduction in [NA] release. It may be important, however,
that basal release of [NA] and release at lower (physiological)
stimulation frequencies was not reduced by pindolol and that
responses across the ischaemic area were unaffected at all
stimulation frequencies.
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8 QUANTITATIVE ANALYSIS OF MYOCARDIAL ADRENOCEPTORS -
PROSPECTS AND LIMITATIONS
2lt0
The classical pharmacological approach to the definition of
receptor taxonom}', initiated by Dale in 1906, has been to compare
rank order potencies of agonists and antagonists for a variety of
physiological activities. Subtypes of beta-adrenoceptors were
first suggested by Lands in 1967 but receptors remained a
physiological concept until the mid 1970's when high specific
activity radioligands were introduced permitting direct study of
receptor binding sites in a variety of membrane fractions. Since
methodology for studying beta-adrenoceptors was developed in 1974
(Aurbach et al, 174; Lefkowitz et al, 1974; Levitzki et al, 1974)
and applied to the canine heart in 1975 (Alexander et al, 1975),
there has been an explosion of information concerning molecular
mechanisms of agonist-receptor interactions (Watanabe et al, 1982)
and receptor modulation by physiological and pathophysiological
processes (Lefkowitz, 1979; Matulsky and Insel, 1982).
Receptor modulation may provide an important mechanism for
altered adrenergic responsiveness of the heart in disease and may
result from homologous or heterologous interactions. Recognised
homologous modulatory effects are increased beta-adrenoceptor
density in rat ventricle after denervation with 6-hydroxydopamine
(Yamada et al, 1980) and decreased receptor binding after exposure
to isoprenaline (Mickey et al, 1976; Marsh et al, 1980). Among the
latter may be included increases in cardiac beta-adrenoceptor
density and decreases in alpha-adrenoceptor density in experimental
hyperthyroidism (Williams et al, 1977; Ciaraldi and Marinetti,
1977; Williams and Lefkowitz, 1979) with decreases in
beta-adrenoceptor binding in hypothyroidism (Stiles and Lefkowitz,
1982). Furthermore, in the hyperthyroid state, changes in the
ratio of high to low affinity binding sites of the
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beta-adrenoceptor for agonists suggest an enhanced ability of the
agonist to stabilise the high affinity state of the receptor, in
keeping with an increase in receptor coupling to the adenylcyclase
system (Stiles and Lefkowitz, 1981).
The concept of a change in the density or functional
characteristics of beta-adrenoceptors on sarcolemmal membranes in
ischaemic myocardium as a means of altered adrenergic
responsiveness has not been extensively investigated, yet is one
theoretical explanation of absence of spontaneous catecholamine
release shown in Chapter 3. Furthermore, the concept has the
advantage of not requiring the synthesis of new receptors as a
prerequisite for modulation (unlikely in acutely ischaemic tissue),
since altered binding characteristics, unmasking of latent receptor
sites by membrane-active enzymes or variable reductions in
functional receptor units may all theoretically lead to
heterogeneous catecholamine action within the heart and hence an
arrhythmogenic effect.
High specific activity radioligands with high affinity have
advantages of allowing assay of small receptor populations at low
ligand concentrations hence minimising the problem of non-specific
binding (Maguire et al, 1977). (+)
125 125
[I ]-Iodohydroxybenzylpindolol (I -IHYP) has been widely used
in a variety of tissues employing both saturation and competition
binding techniques (Charness et al, 1976; Harden et al, 1976). Its
high specific activity (>2,000 Ci/mmol), relatively high affinity
particular advantages for study in myocardium that outweigh its
disadvantages of fairly rapid radiochemical decomposition and
approx 10
-10
M) and ease of assay in biological tissue confer
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existance only as a racemate. Towards the end of the studies
described here, an even more specific radioligand (-)
125 125
[I )-iodopindolol (I -IP) was described (Barowsky and Brooker,
1980) and was used to investigate the possibility of direct
receptor quantification in vivo.
In vitro receptor quantification from equilibrium binding
studies has generally been performed using microsomal membrane
preparations, because the use of unfractionated membranes yielded
excessive non-specific binding. As a result, up to 95 per cent of
the total receptor population was discarded (Baker and Potter,
1980), limiting considerably the biological usefulness of any
observed change in receptor activity. Furthermore, serious
difficulties may arise in the isolation of subcellular fragments
from ischaemic myocardium. The process of ischaemia can itself
influence membrane recovery. For these reasons, the first part of
125
this study has investigated the use of I -IHYP in assay of
ventricular beta-adrenoceptors in a 'crude' membrane preparation
and identified an unexpected source of error using low ligand
concentrations as a consequence of endogenous catecholamines. This
may result in important underestimation of receptor numbers at
single low-dose ligand concentrations. Secondly, the applicability
125 125
of I -IHYP and I -IP to in vivo receptor mapping in normal and
acutely ischaemic myocardium has been explored. Such an approach
would avoid some of the difficulties mentioned above and allow





HeEbrane preparation: Adult male Wistar rats (weight 200 - 350 g)
were killed by cervical dislocation and the ventricles minced with
scissors and homogenised on ice in 0.25 M sucrose, 5 mM Tris-HCl
and mM MgCl^ at pll 7.4 ('homogenate'). The homogenate was filtered
through two layers of nylon gauze ('crude cell membranes'),
centrifuged at low speed (480 g) for 10 minutes and the pellet
consisting mainly of cell debris and fibrous tissue separated.
Potassium chloride was added to the supernatant (final
concentration 0.5 M) to facilitate dissolution of contractile and
other proteins (Baker et al, 1980) and the suspension centrifuged
at 48000 g (4°C) for ten minutes. The pellet was resuspended in 50
mM Tris-HCl, 10 mM MgCl^, pH 7.5 at a protein concentration between
0.5 and 1.5 mg/ml ('cell membrane') or resuspended and
recentrifuged twice at 48000 g (4°C) for ten minutes ('washed cell
membranes'). 'Microsomes' were prepared by recentrifugation of the
supernatant from the first 48000 g spin at 140,000 g (4°C) for one
hour and resuspension in Tris buffer. 'Cell water' was the
supernatant from this spin. Protein concentrations above 1 mg/ml
were measured by the Biuret method (Mokrasch and McGilvery, 1956)
and below this by the method of Lowry et al, (1951). Aliquots of
the membrane suspensions (50 pi) were assayed for noradrenaline,
adrenaline and dopamine as described in Chapter 2.
Denervation: Cardiac denervation was achieved by four doses of
intraperitoneal 6-hydroxydopamine (6-OHDA) as the bromide salt
dissolved in one per cent (w/v) ascorbic acid. Two doses of 50
mg/kg were given at 24 hour intervals with two further doses of 100
mg/kg nine and ten days after the first dose. Animals were
2U
sacrificed ten da3rs after the last 6-OHDA injection.
Incubations, separation of bound ligand: For saturation binding,
ventricular membranes (300 pi) were incubated in polypropylene
tubes for one hour at 37°C with 5-1600 pM I125-IHYP (Radiochemical
Centre, Amersham, specific activity 2000 Ci/mmol) in the presence
and absence of 200 pM (+) isoprenaline. The total assay volume
125
per tube was 500 pi. Bound and free I -IHYP was separated by
vacuum filtration (30 mmllg) through glass fibre filters (Whatman
GF/C) presoaked in 200 pM isoprenaline to minimise non-specific
binding to the filter. After washing (3 x 10 ml Tris-buffer), the
bound ligand was assayed directly using a gamma counter (NE 1600).
125
Specific binding of I -IHYP was defined as the amount of
radioactivity displaced by 200 pM (+) isoprenaline and varied
between 50 and 85 per cent of total binding over the range of
ligand concentrations used. At least ten different ligand
concentrations were used for each saturation isotherm. For kinetic
binding experiments, bound and free ligand were separated at
intervals during one hour incubation as described above. For
dissociation experiments, bound and free ligand were separated at
intervals after the addition of 200 pM (+) isoprenaline to
membranes previously incubated for one hour with the radioligand.
Total binding to ventricular membranes was kept at less than 10 per
cent of the ligand concentration for all studies to avoid errors
from the use of excessive receptor concentrations (Chang et al,
125





I -IHYP: Adult mongrel dogs were anaesthetised with
pentobarbitone and prepared surgically as described in Chapter 3.
Thirty minutes after completion of surgery, approximate!y 100 pCi
125
I -IHYP was injected intravenously.According to the extent of
125
radiochemical decay, the specific activity of I -IHYP was reduced
3-5 fold with hydroxybenzylpindolol to achieve a final plasma
concentration of approximately 50 pM. At this concentration
significant functional beta-adrenoceptor antagonism is unlikely.
125
Sixty minutes after injection of I -IHYP (at steady state),
the LAD was occluded for thirty minutes (n = 4) and the area of
cj^anosis and systolic bulging carefully noted. The heart was then
excised with the occlusion clip in situ and suspended in a cradle
to facilitate coronary perfusion with 500 ml isotonic saline at
4°C. The saline was infused into the aortic root by roller pump at
100 ml per minute, the occlusion clip being removed immediately
prior to the perfusion. Perfusate was collected from the coronary
sinus at intervals during the infusion. Epicardial fat and
coronary vessels were removed from the left ventricle and the free
wall was then cut into a matrix of 80 biopsies including the whole
of the ischaemic and border-ischaemic area. Each biopsy was
further divided into endocardial and epicardial segments by midline
dissection before weighing and direct counting in a gamma counter.
125
Non-specific binding of I -IHYP was defined in separate
experiments by the relationship between arterial and myocardial
125
concentrations of I -IHYP in the presence of a saturating amount
(1 mg/kg) of propranolol (ICI Pharmaceuticals) given 30 minutes
125
before radioligand injection. Incremental doses of I -IHYP were
injected intravenously and 60 minutes after each increment, a
2 46
biopsy of the front wall of the left ventricle was taken
(approximately 100 mg), washed, weighed and counted.
125
Simultaneously, arterial plasma was assayed for I -IHYP. Sixty
125
minutes after the highest dose of I -IEYP, the heart was excised,
perfused and the free left ventricular wall biopsied as described
above. In two of the four experiments in which non-specific tissue
binding was determined, the LAD was occluded for 30 minutes after
125
the final dose of I -IIIYP. The dose of (-) propranolol was
calculated to saturate 99 per cent of the total myocardial
beta-adrenoceptor population, in association with at least a 100
fold shift in the isoprenaline dose-response curve.
125
I -IP: The ligand was prepared by iodination of (-) pindolol
essentially as described by Barowsky and Brooker (1980), originally
modified from Maguire et al (1976). Briefly, 10 pi of 13.5 mil I1C1
containing 20 pg (-) pindolol, 20 pi 0.3 M KH^PO^ (pH 7.6), ImCi
125
Nal (as the carrier-free compound) and 20 pi aqueous solution
of chloramine T were combined in that order and the iodination
allowed to proceed for 5 minutes at room temperature. The reaction
was stopped by addition of 300 pi ^a2^2^5 ^ acetic
acid. Iodinated products were extracted x4 with 300 pi portions
of ethylacetate containing 0.01 per cent phenol. Phase separation
was carried out using a Pasteur pipette. The 4 washes were
combined, spotted on to a 25 x 40 cm strip of Whatman 3 MM paper
and chromatographed for 4 hours at 4°C in 1M ammonium formate (pH
125
8.5) containing 0.01 per cent phenol. The I -IP band was located
(narrow peak approx. 7 cm from origin), cut into 1 cm strips and
125
the ligand eluted with 5 ml methanol. I -IP separated well from
125
pindolol. The peak I -IP bands were combined, evaporated to 1 ml
under nitrogen and stored at -20°C.
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As preliminary studies in both, rat and guinea pig ventricle
had suggested that non-specific binding with this ligand was
extremely low (< 10 per cent of total binding at 50 - 100 pM) with
a Kd of approximately 200 pM, studies were undertaken to determine
whether in vivo beta-adrenoceptor binding could be achieved without
coronary perfusion as described above and the assumptions implicit
in the use of this procedure to remove unbound ligand (see below).
The experimental preparation was the same open-chest
pentobarbitone anaesthetised dog described above. Because of the
125
increased affinity of I -IP for cardiac beta-adrenoceptors, lower
concentrations of ligand were injected to avoid functional
beta-adrenoceptor antagonism. Coronary occlusion was hence
continued for one hour (n = 6) rather than 30 minutes to increase
the prospects for steady state bindng in ischaemic tisse, the time
to which is directly dependent on ligand concentration. Arterial
and coronary venous sampling was continued during the period of
ischaemia. In the two control experiments without ischaemia,
125
changes in coronary venous I -IP were measured during and after
supramaximal stimulation of the ansa from the left stellate
ganglion. Non-specific binding was measured as described above
using 1 mg/kg (-) propranolol given intravenously 30 minutes before
radioligand injection. At the end of the period of coronary
occlusion the heart was removed, washed (4°C) and biopsied directly
without coronary perfusion. Biopsies from the ischaemic and
non-ischaemic areas were also assayed for NA and A. Tissue for
catecholamine assay was immediately frozen on dry ice.
Statistical analysis of changes in adrenoceptor binding to
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Figure 8.1 Binding of 1125-1HYP to rat ventricular membranes: validation studies.
Specific binding is saturable (A) and Scatchard analysis (B) suggests a single binding
site. Competition for specific binding is stereospecific (C) and conforms to known
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As shown previously (Harden et al, 1976) , binding of I " -II1YP
to cardiac membranes at concentrations between 100 and 1600 pM was
saturable, stereospecific, of high affinity and inhibited by
agonists according to their known affinities (Figure 8.1).
Scatchard analysis (Scatchard, 1949) suggested a single class of
binding sites (Figure 8.1b). Equilibrium was achieved within 60
125
minutes of incubation at 50 and 200 pM I -IHYP concentrations
(Figure 8.2a) with no tendency for reduction in the free 1igand
concentration (Figure 8.2b) or change in non-specific binding
(Figure 8.2c) over a two hour period under the incubation
conditions studied. The 'cell membrane' preparation appeared most
suitable for in vitro study as it was the least purified
preparation combining the highest specific binding with reasonable
non-specific binding at 50 per cent receptor occupancy (Figure
8.3a). Specific binding of pindolol was linear over the range of
protein concentration used in this study (Figure 8.3b).
The calculated maximum number of binding sites (Bmax) from six
experiments was 61+7 fmol/mg protein (mean + SEM) and affinity
(Kd) 460 + 70 pM. Kinetic analysis of the association and
125
dissociation of I -IHYP to the cell membrane preparation also
suggested a single binding site. The calculated pseudo first order
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Figure 8.2 Binding of 1125-1HYP to rat ventricular membranes*,
validation studies. Equilibrium is achieved within 60 minutes at
50 and 200 pM l-^-IHYP (A). Total radioactivity per tube (B) and
binding (C) are independent of incubation time at various concentrations




Figure 8.3 A Specific (open bars) and non-specific (shaded bars) 1125-1hYP
binding to rat ventricular membranes (see text for definitions). The "cell
membrane" preparation combined maximum specific binding with acceptably
low non-specific binding. Mean data from two experiments in duplicate.
B Linear relationship between specific l125-IHYP binding and measured
total protein concentration. "Cell membrane" preparation (mean ± SEM;
3 expts).
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second order dissociation rate constant (k , -k,) 0.021 per minute.
obs 1
The derived Kd from kinetic studies was thus 80 pM, significantly
lower than the dissociation constant from equilibrium binding as
noted in previous analyses of adrenergic receptors in a variety of
tissues (Greenberg and Snyder, 1978; U'Pritchard et al, 1978;
Earliner et al, 1979). Mean data from which the association and
dissociation rate constants were derived are shown in Figue 8.4.
125
At lower concentrations of I -IHYP in the range 5-100 pM, a
progressive reduction in expected specific binding to the cell
membrane preparation occurred, producing a sigmoid saturation
isotherm, an example of which is shown in Figure 8.5. A Hill plot
of this data (Hill, 1910) showed a Hill coefficient of 1.4.
Scatchard analysis produced a curvilinear line with upwards
convexity (Figure 8.6a) suggesting positive cooperativity between
ligand binding sites (Boeynaems and Dumont, 1975) i.e. an increase
in drug affinity for the receptor with increasing receptor
occupancy. The reduction in specific binding was most readily
demonstrated in membranes used within two hours of preparation.
Since [NA] containing synaptosomes were expected to be present in
the membrane fraction, the hypothesis was tested that this
non-linear relationship was due to endogenous catecholamines in the
125
membrane fraction interacting in some way with I -IHYP for
receptor sites. In four experiments, the concentration of
125
I -IHYP was determined at which specific binding was reduced by
50 per cent from that predicted from the higher part of the
saturation isotherm, assuming binding obeyed the law of mass
action. This concentration (i50, Figure 8.5) was closely related
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Figure 8.4 Association (A) and dissociation (B) of 1125-1hYP from rat ventricular
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Figure 8.5 Saturation isotherm for I125-IHYP binding in low concentration
to rat ventricular cell membranes. The sigmoid saturation curve was repres¬
entative of four experiments , although the concentration of I125-IHYP at
which specific binding was reduced 50 per cent from that predicted from a
higher concentration saturation isotherm (the dashed line), the I50, varied
with each membrane preparation.
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(Figure 8.6b). The [NA] concentration theoretically required to
give equivalent membrane binding to I125-IHYP was calculated
according to the Cheng and Prusoff equation (Cheng and Prusoff,
1973) using a Kd for (-) NA of 2 |iM derived from competition
binding experiments with the same membrane preparation. The
endogenous [NA] concentration of the membrane suspension was
approximately four fold lower than that predicted from the Cheng
and Prusoff equation. Concentrations of [A] in the membrane
suspension varied between 1 and 2.6 nM and [DA] varied between 2
and 19 nM, both orders of magnitude too low to significantly modify
ligand binding.
When endogenous catecholamines were removed in vitro by
repeated washing of the 'cell membrane' preparation or in vivo by
chemical sympathectomy withn 6-OHDA, a linear Scatchard plot was
obtained with no evidence of cooperativity (Figure 8.6a). The
calculated Kd (mean + SEM) was similar in three experiments
between washed (300 + 90 pM) and denervated (380 + 90 pM)
membranes. Bmax, however, increased from 52 + 15 to 68 + 12
fmol/mg protein with denervation. Membrane [NA] content was
substantially reduced in the washed preparation with further
reduction after 6-OHDA (Figure 8.7a).
It has been suggested that deterioration of membrane receptor
proteins during equilibrium binding might be different in the
presence and absence of a non-saturating amount of radioligand
producing curvilinear Scatchard analysis. This was investigated by
125
the addition of a saturating concentration of I -IHYP to washed
membranes previously incubated for 120 minutes with 10 pM
125
I -IHYP. The maximum specific binding obtained after a further
256
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Figure 8.6 A Scatchard analysis of |125-|HYP binding to rat
ventricular membranes. "Cell membrane" preparation (open
circles); "washed cell membranes" (closed circles); "cell mem¬
branes" from denervated animals (triangles). Data from 10
denervated and 10 control (sham-injected) rats. B The relat¬
ionship between NA content in the cell membrane fraction and
l125-IHYP concentration at which specific binding was reduced
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Figure 8. 7 A Comparison of endogenous NA content in the
three membrane fractions. B Kinetic analysis of 125. IHYP
binding to ventricular membranes. After incubation at lOpM
for two hours (circles), the addition of a saturating concentration
of radioligand (arrow) resulted in similar binding to that obtained
with a saturating concentration throughout (triangles). Data
mean ± SEM, three experiments.
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60 minutes was the same in four experiments as that obtained with a
saturating concentration throughout (Figure 8.7b).
In vivo:
125 125
I —IHYP: Non-specific binding of I -IHYP to ventricular
myocardium was linear over a range of ligand concentrations with no
evidence of saturability (Figure 8.8a). The slope factor relating
125
arterial I —IHYP (pM) and non-specific tissue binding to
ventricle (fmol/g wet weight) averaged 0.41 over four experiments.
No systematic differences between non-specific binding to ischaemic
and non-ischaemic areas was observed. Washout of free radioligand
during coronary reperfusion was monoexponential and rapid (Figure
8.8b) suggesting removal predominantly from a single compartment.
125
Changes in specific I -IHYP binding to ischaemic,
non-ischaemic and border ischaemic areas from four experiments are
shown in Table 8.1. Considerable interexperimental variability in
binding, related principally to variable arterial ligand
concentrations, was observed. However, non-specific binding,
125
derived from the arterial I -IHYP concentration at the end of
each experiment and the slope factor from the experiments with (-)
propranolol, averaged 47+6 per cent of total counts. Just over
half of the total counts in each biopsy therefore represented
binding to the beta adrenoceptor population. No significant
changes in adrenoceptor binding were observed in the border
ischaemic endo- or epicardial layers. Indeed binding increased in
two, decreased in one and was unchanged in the fourth study.
However, a small increase in receptor binding (6+2 per cent) was
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Figure 8.8 A Non-specific radioligand binding to dog myocardium
in vivo; relationship to arterial ligand concentration at steady state.
Circled points from ischaemic myocardium. Individual data from
four experiments. B Effluent l125-IHYF during coronary perfusion
with 500ml saline. Monoexponential washout is evident from one
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Table8.1:
I -IHYPbinding(fmol/weteight)toischa micandnon-ischaemicdyocardiumiviv .F re h ofthef urexperiments,pcentontributionn -specificalbi dingisgiv(deri d fromfigure8.8A)to eth rwithhen bfbiopsies( )ieacr g onnt r st.
while binding to the corresponding epicardial zone was unchanged.
The increase in binding was statistically significant at the 5 per
cent level for the second experiment and at the 1 per cent level
for the third and fourth experiments. The increase for grouped
data however, did not achieve statistical significance at the 5 per
cent level. The endocardial : epicardial binding ratio increased
in the central ischaernic area in all four experiments from 1.02 +
0.02 to 1.11 + 0.02 (p < 0.05).
An example of the variability in binding across the left
ventricle is shown in Figure 8.9. Profiles of endocardial and
epicardial binding from one experiment are shown for 50 biopsies
including the ischaemic area. Greater variability in binding is
evident within the ischaemic region particuarly in endocardium.
125
I —IP: The criteria for identification of beta-adrenoceptors
were not met by the results using the experimental protocol
described above for this series. It is probable that the major
reason for this lay in failure to differentiate specific from
non-specific binding across the heart. This is illustrated in
125
Figure 8.10 which compares arterial and tissue levels of I -IP in
six experiments using the radioligand alone and in four where
beta-adrenoceptors were initially saturated with 1 mg/kg (-)
propranolol. It can be seen from this figure that the ratio of
plasma to tissue counts was not importantly lower in the
propranolol treated group, preventing the assessment of the true
receptor population. In keeping with this finding, the
125
concentration of I -IP in arterial, ischaemic and non-ischaemic
coronary venous plasma did not significantly change with systemic







Figure 8. 9 Profiles of 1|HYP binding to canine myocardium
in vivo. Data from one experiment shows binding across 5 rows
each of 10 sequential biopsies traversing the ischaemic area.






















Figure 8.10 Total and non-specific binding of l125-|p to
dog myocardium in-vivo; relationship to arterial ligand
concentration at steady state. No important reduction in
tissue binding is evident in the propranolol experiments
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supramaximal stimulation of the left stellate ganglion (Table 8.2).
The [NA] content of left ventricular muscle was similar from
the iscliaemic (0.51 + 0.05 pg/g wet weight) and non-ischaemic
(0.51 + 0.06 pg/g wet weight) regions.
DISCUSSION
In vitro assessment of myocardial beta-adrenoceptors:
This study has demonstrated an important pitfall in the
inference of site-site receptor interactions namely that during
apparently steady state binding of a high specific activity ligand
endogenous tissue hormones can interact with the labelled ligand at
the receptor site. Other explanations of the curvilinear Scatchard
plot with upwards convexity, including ligand inactivation during
incubation, incomplete separation of bound and free forms of the
ligand or failure to reach equilibrium (Chamness and McGuire,
1975), seem unlikely because of the relationship between the
reduction in specific binding and measured endogenous
catecholamines and the demonstration of linear Scatchard analysis
after catecholamine depletion both by in vivo and in vitro
techniques. This phenomenon may result in significant errors in
the estimation of both affinity and receptor density, high
affinity, low density receptor populations would not be identified.
It is of interest that the endogenous [NA] concentration of
the membrane fraction was lower than that predicted to compete
125
equally with I -IHYP binding to the membrane receptor population,
derived from direct measurement of the affinity of (-) NA under the
same experimental conditions. The difference between measured and
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TIME (Minutes)
Basal 1 2 4 6 10
ANSA STIMn
(20 Hz x 2min)
A 1940 2000 1950 1930 1950 1890
LV 1820 1790 1760 1810 1440 1600
cs 1880 1890 1810 1880 1720 1890
PROPRANOLOL
(1 mg/kg iv)
A 1820 1800 1810 1790 1780 17 80
LV 1570 1580 1600 1560 1550 1560
CS 1560 1570 1590 1550 1550 1540
125
Table 8.2: Plasma I -IP (cpm/ml) in arterial and coronary-
venous plasma before and after supramaximal stimulation
of the ansa subclavia from the left stellate ganglion
and the systemic injection of a saturating amount of
propranolol. Representative data from one of three
experiment s.
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predicted [NA] may relate to non-homogenous distribution of
endogenous catecholamines close to receptor binding sites. Thus,
the effective [NA] concentration at the receptor site may be higher
than the average concentration in the membrane fraction.
Alternatively, synaptosome formation in the fraction may have
prevented uniform distribution of endogenous neurotransmitter.
Equally, the contribution of catecholamine metabolites to ligand
displacement has not been quantified.
The discrepancy between the predicted and measured [NA]
concentration and the curvilinear nature of the saturation isotherm
before removal of endogenous neurotransmitter suggest that, under
these incubation conditions, the effect of endogenous
catecholamines at low radioligand concentrations does not conform
to the law of mass action. One possible explanation for these
findings may be that at low concentrations of radioligand,
endogenous catecholamines modulate radioligand access to the
receptor site and prevent establishment of true equilibrium with
the receptor population. Further kinetic studies would be
necessary to examine this. A further problem concerns the
125
contribution of the (+) and (-) isomers of I -IHYP to total
binding at low radioligand concentrations. Theoretical
considerations predict that a significant proportion of the (+)
isomer will bind at low receptor occupancy whereas the (-) isomer
(with higher affinity) predominates towards receptor saturation
(Burgisser et al, 1981). The effect of endogenous catecholamines
with mixed ligand binding is unknown.
False-positive cooperativity may be a more general problem of
125
tissue-ligand sj'-stems than that of the rat myocardium-I -IHYP
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system described here. The artefact may be avoided in several
ways. Firstly, ligand concentrations sufficient to minimise the
endogenous hormone effect (in this case > 100 pM), secondly choice
of a ligand with lower affinity for the receptor or thirdly
reduction of the endogenous hormone concentration in the membrane
fraction (for example by repeated washing) should all prevent
curvilinear Scatchard analysis. It is not necessarily correct to
assume that endogenous hormone concentrations are negligible,
particularly in a crude membrane preparation.
In vivo beta—adrenoceptor quantification in ischaemic myocardium:
Although the possibility of directly assaying
beta-aarenoceptor populations in vivo has many theoretical
attractions, particularly the avoidance of preparation of
sarcolemmal membrane fractions, this study has identified several
practical difficulties in the application of radioligand binding
techniques with conventional antagonists.
The most important drawback relates to the high proportion of
non-specific binding to myocardial tissue and the extracellular
space, such that coronary perfusion is required to washout unbound
and albumin-bound ligand and allow the identification of the
receptor population. It is unlikely that specifically bound ligand
will be removed by coronary perfusion because of the latter's short
duration (five minutes) and the high affinity of the ligand for the
receptor and hence slow rate of dissociation. However, there can
be no guarantee that washout from the ischaemic area will be the
same as from the non-ischaemic area, particularly since after a
thirty minute, and to a greater extent after a sixty minute period
of acute ischaemia, the water content of ischaemic tissue will have
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increased by up to 30 per cent (Kloner et al, 1974). However, no
125
significant differences in I -IHYP binding to ischaemic and
non-ischaemic myocardium were observed in the propranolol treated
animals, suggesting that differential washout of ligand from these
two areas would not account for the results.
A second limitation of this in vivo technique is that binding
is assessed at only one ligand concentration and not over a range
of receptor saturation. Hence, an increase in specific binding may
occur either from an increase in receptor density or an increase in
receptor affinity for the ligand. Non-specific binding is
minimised by the use of low ligand concentrations but too low a
concentration prolongs the time required for requilibration of
binding following coronary occlusion and may risk errors due to the
presence of endogenous neurotransmitter described above.
Equilibration of the ligand with the receptor after coronary
occlusion would result in reduced ligand availability to the
ischaemic receptor pool, or at least in prolongation of the time to
equilibration and would preclude its quantitative analysis.
Despite these important limitations, however, the technique
125
for beta adrenoceptor labelling in vivo using I -IHYP did appear
to label a myocardial receptor pool and demonstrated small
increases in binding within the receptor pool, associated with a
significant increase in endo-epicardial binding ratio, the latter
possibly a consequence of more intense ischaemic injury in the
subendocardial layers. In addition, variability in ligand binding
was enhanced across the ischaemic zone. This technique, however,
will require further refinement and in vivo validation before
observed changes in receptor binding can be considered to be
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relevant to changes in catecholamine sensitivity.
The mechanism or mechanisms responsible for a change in
receptor binding within 30 minutes of LAD occlusion are unknown.
Theoretically, an increase in receptor binding sites could reflect
increased de novo receptor synthesis, translocation of a cytosolic
receptor pool to the sarcolemma or unmasking of latent receptors by
membrane-active enzymes. In view of the 30 minute time period and
the presence of ischaemic injury, de novo synthesis of new membrane
receptors seems most unlikely, in contrast to changes in receptor
density as a result of thyroid hormone administration (Kempson et
al, 1978). Changes in ligand binding to isolated membrane
fractions have been described in reticulocyte ghosts incubated with
S-adenosylmethionine (Strittmatter et al, 1979) in sarcolemmal
membranes treated with detergents or ionophores (Shutt et al, 1977)
and in frog erythrocytes treated with phospholipase (Limbard and
Lefkowitz, 1976). Thus, membrane active enzymes may unmask cryptic
binding sites, possibly by uncovering receptors in a more fluid
membrane environment. This does not necessarily imply enhanced
adrenergic responsiveness unless the receptors remain coupled to
intracellular readout systems. Part of the desensitization of
chick ventricle by exposure to isoprenaline for example, may
involve GTP-sensitive reduction in adenylate cyclase responsiveness
without change in receptor binding (Marsh et al, 1980).
Natural variations in the density of beta-adrenoceptors across
the left ventricle is an unlikely explanation of the findings,
since the diaphragmatic surface of the heart and interventricular
septum, were not included in the assay. Although beta-adrenoceptor
density varies significantly in different chambers of the canine
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heart, increasing progressively from atrium to right ventricle,
interventricular septum and left ventricle (Baker et al, 1980) and
is lower in the diaphragmatic surface of the left ventricle (Burman
et al, 1981), no differences within the anterolateral free wall of
the left ventricle have been noted (Mukherjee et al, 1979).
Mukherjee et al, (1979) using in vitro binding techniques with
3
(E )- dihydroalprenolol noted a significant increase in
beta-adrenoceptor density in canine ischaemic myocardium after one
hour of LAD occlusion. This increment, however, was maintained
over eight hours, beyond the period of irreversible cell injury and
at a time when tissue catecholamine depletion had developed, thus
raising doubts about the physiological significance of the
observation. Binding of a muscarinic cholinergic antagonist,
3
(H )-quinuclidynl benzilate, did not change with ischaemia. In a
follow-up study, these authors (Mukherjee et al, 1982) noted
enhanced catecholamine stimulated cyclic AMP formation and
phosphorylase b to a conversion in canine left ventricle after one
hour of ischaemia and fifteen minutes reperfusion, providing one
biochemical measure of the functional responsiveness of the
receptor increase noted earlier. Down regulation of
beta-adrenoceptors in non-ischaemic myocardium following regional
infarction has also been demonstrated (Baumann et al, 1981) and
postulated as an adaptive mechanism to enhanced catecholamine
stimulation at this site.
Alteration in alpha-adrenoceptor density in ischaemic and
reperfused myocardium has also been described (Corr et al, 1981)
and advanced as a possible explanation for enhanced alpha
adrenergic activity at these times (Sheridan et al, 1980). In the
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study by Corr et al, alpha^-adrenoceptor density , assessed by
3
H -prazosin, doubled after 30 minutes ischaemia from LAD occlusion
in the anaesthetised cat model, and remained elevated during early
(2 minutes) but not late (15 minutes) reperfusion. Na -K+-ATPaS6
activity remained unaltered during occlusion and reperfusion.
Alterations in cardiac membrane adrenoceptor activity as a
result of acute ischaemia requires considerable further evaluation
before it can be established as a mechanism for altered sympathetic
responsiveness in vivo and before its importance in the genesis of
early ventricular arrhythmias in man can be appreciated.
Nonetheless, the development of in vivo binding techniques is of
critical importance in avoiding possible artefacts due to tissue
fractionation and destruction or removal of a functionally
important receptor population. The use of ligands with lower
affinity for adrenoceptors requires further study for two reasons.
Firstly, requilibration as a result of changes in the receptor
population will be achieved more rapidly and secondly, changes in
ligand distribution or washout in vivo may reflect local release of
endogenous neurotransmitter at post-synaptic sites. The
development of immunological probes for adrenoceptor binding may be
a promising alternative approach (Wrenn and Haber, 1979).
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9 SUMMARY AND CONCLUSIONS
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The mechanism of ventricular fibrillation in acutely ischaemic
myocardium remains poorly understood. Much clinical and
experimental evidence suggests a central role for the sympathetic
nervous system in the genesis of early ventricular arrhythmias. A
combined biochemical, neuropharmacological and electrophysiological
approach has been used in the studies reported here to investigate
the activity of the sympathetic neuroeffector junction in ischaemic
myocardium at the time of onset of early ventricular arrhythmias.
A simple animal model has been developed with the aim of increasing
understanding of the role of myocardial catecholamines in the
development of arrhythmias and their potential relevance to sudden
cardiac death in man.
Acute myocardial ischaemia was created by clip occlusion of
the left anterior descending coronary artery in the open chest,
anaesthetised dog. Coronary venous effluent (draining ischaemic
and non-ischaemic myocardium), regional myocardial blood flow
(using radiolabelled microspheres) and epicardial activation
abnormalities (multielectrode epicardial electrograms) were
monitored on a minute-to-minute basis before and during sympathetic
stimulation and pharmacological and metabolic manipulation of
sympathetic nerve terminals and post synaptic junctions.
Endogenous [NA] concentrations in local venous effluent were
not modified by a ten minute period of LAD ligation but myocardial
[NA] release was observed to occur from the previously ischaemic
area during the first two minutes of coronary reperfusion. It is
unlikely that spontaneous [NA] release during ischaemia was masked
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by enhanced [NA] metabolism as increased efflux of radioactivity
was not observed when the heart was prelabelled by
IP-no radrenaline. Furthermore, failure to sample from the
ischaemic area, insensitivity of the preparation to changes in
myocardial [NA] release, or the use of a specific anaesthetic agent
did not explain absence of spontaneous [NA] release. In occasional
individual experiments, sudden increases in [NA] in ischaemic
venous effluent were observed coincident with spontaneous
ventricular arrhythmias. Spontaneous ventricular fibrillation was
associated with marked increases in [NA] in arterial and coronary
venous plasma, probably a secondary response to circulatory arrest.
Arterial [A] and, to a lesser extent [NA] rose progressively
during coronary occlusion and reperfusion. Extraction of [A] was
increased selectively across the ischaemic area during coronary
occlusion and was abolished during the first 3-5 minutes of
reperfusion, compatible with some release of [A] from the heart at
this time.
Thus, as a result of these studies showing absence of
sponteneous release of [NA] into coronary venous effluent during
acute ischaemia- in contrast with the widely held view- further
studies investigated the activity of the sympathetic nerve terminal
at varying times after coronary occlusion and its modification by
neuronal reuptake and alpha^-adrenoceptor blockade.
The relationship between the duration of ischaemia and
responsiveness of cardiac sympathetic nerves has been examined by
electrical stimulation of the ansa subclavia from the left stellate
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ganglion and measurement of epicardial activation abnormalities and
[NA] release from ischaemic and non-ischaemic areas at intervals
following LAD ligation. In normal myocardium, sequential one
minute periods of ansa stimulation over three hours resulted in
reproducible, frequency dependent regional myocardial [NA] release
without tachyphylaxis. Two successive ten minute periods of
ischaemia did not modify peak myocardial [NA] release from the
predominantly ischaemic (I) or non-ischaemic (NI) areas during low
(1 Hz) and high (10 Hz) frequency ansa stimulation. Peak [NA]
release from the anterior local vein at 1 Hz was 1.1 + 0.8 pmol/ml
before and 2.2 + 1.9 pmol/ml during ischaemia and at 10 Hz was 7.5
+ 4.3 pmol/ml before and 7.8 + 5.0 pmol/ml during ischaemia (p =
NS). Reperfusion induced a 30 fold increase in [NA] output
(pmol/ml) from I while output from NI was unchanged.
In a second experimental group, myocardial catecholamine
release was related to changes in epicardial activation delay
during repeated ansa stimulation on four occasions during 75
minutes of ischaemia. Stimulation at the two periods of peak
spontaneous phase I arrhythmias 5 and 17 minutes after coronary
occlusion resulted in [NA] release from the ischaemic area of 2.8
+ 1.3 and 3.0 + 1.6 pmol/ml respectively and a significant
increase in mean activation delay in I of 12+4 msecs at 5
minutes and 9 +4 msecs at 17 minutes (p < 0.05). In contrast,
stimulation 30 and 60 minutes after coronary occlusion, when
spontaneous arrhythmias are rare, was not associated with [NA]
release from I (0.3 + 0.3 and 0.9 + 0.5 pmol/ml respectively) and
resulted in a minor reduction in mean activation delay in I of 2 +
3 msecs at 30 minutes and 3+4 msecs at 60 minutes. [NA] release
from NI, and increases in blood pressure and myocardial lactate
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release were similar during each of these four periods of ansa
stimulation. Coronary reperfusion at 75 minutes induced massive
release of [NA] (peak 11.8 + 2.8 pmol/ml) and abolished extraction
of [A] from I, with a time course similar to the development of the
reperfusion arrhythmias which are recognised to occur in this
model. Thus, stimulation-evoked release of [NA] from ischaemic
myocardium is maintained during the early periods of enhanced
vulnerability to arrhythmias but is inhibited after 30 minutes.
This temporal variability may be a factor in the time course of
spontaneous arrhythmias.
The influence of presynaptic alpha-adrenoceptor and neuronal
reuptake blockade, singly and in combination, on basal and nerve
stimulated catecholamine responses during coronary occlusion has
been investigated using the alpha 2-adrenoceptor antagonist
yohimbine and reuptake blockers desmethylimipramine and viloxazine.
Spontaneous [NA] release from I did not occur after yohimbine
(1 mg/kg) but release was significantly potentiated during low and
high frequency ansa stimulation (at 10 Hz, [NA] release increased
from 4.3 + 0.4 to 11.8 + 5.4 pmol/ml; p < 0.005), associated with
enhanced release on reperfusion. Arterial [NA] changed little
after yohimbine but [A] rose 2-3 fold. Extraction of [A] across
the heart was enhanced after yohimbine and enhanced extraction was
maintained (across I and NI) during coronary occlusion. Mean
arterial blood pressure fell after yohimbine but the increment in
blood pressure with ansa stimulation was unaffected. Blood flow to
the ischaemic endocardium and epicardium fell significantly by 24
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and 36 per cent respective^ while flow to the non-ischaemic area
was unaffected. Regional epicardial activation abnormalities in I
were intensified by yohimbine both before and during ansa
stimulation (control 41+2 msecs, yohimbine 54+5 msecs at 3
minutes; control 57+7 msecs, yohimbine 73 + 10 msecs during 10
Hz SNS; p < 0.01) with in particular an increase in variability of
regional activation as assessed by multielectrode grid mapping
within the ischaemic area. The incidence of spontaneous
ventricular fibrillation increased from 22 to 56 per cent with this
drug.
Changes in regional myocardial catecholamine release and blood
flow were qualitatively similar after desmethylimipramine (2.5
mg/kg). Spontaneous [NA] release from I or NI was not observed
during LAD occlusion, but release during ansa stimulation and
reperfusion was substantially increased. Expressed as the increase
in [NA] release, potentiation with reuptake blockade following
desmethylimipramine was greater across I compared to NI at 1 Hz
ansa stimulation and on reperfusion suggesting that there was
selective enhancement of reuptake in I prior to drug
administration. Despite absence of change in arterial pressure,
flow to the ischaemic endocardium and epicardium fell significantly
by 44 and 35 per cent respectively, somewhat greater than the fall
to the respective non-ischaemic areas. The incidence of
spontaneous ventricular fibrillation increased from 17 to 50 per
cent.
Given in combination, yohimbine and desmethylimipramine
resulted in a 15 fold rise in arterial catecholamines, much greater
than that seen with either drug given alone. In the non-ischaemic
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heart spontaneous release of [NA] was not seen. During LAD
occlusion, however, small but significant spontaneous release of
[NA] from I and NI was observed, contrasting with responses to
either drug given alone. Increments in coronary venous [NA] (from
the higher basal level) with ansa stimulation were modest. [A]
extraction across I and NI was maintained with the drug combination
and abolished on reperfusion. Epicardial activation abnormalities
and their variability were further intensified by the drug
combination with a 59 per cent increase in mean activation delay at
3 minutes (from 42 + 2 to 67 + 6 msecs; p < 0.01) and a 55 per
cent increase during 10 Hz ansa stimulation (from 56 + 5 to 87 +
9 msecs; p < 0.01). The incidence of spontaneous ventricular
fibrillation increased from 14 to 57 per cent.
Myocardial lactate production occurred throughout all periods
of ischaemia and remained restricted to I with yohimbine,
desmethylimipramine and the combination. Lactate production tended
to increase during sympathetic stimulation and with the drug
combination was greater than control during sympathetic stimulation
and immediately prior to coronary reperfusion.
Selective enhancement of [NA] extraction across I during LAD
occlusion (from 42 + 6 to 51 + 7 per cent; p < 0.05) was
confirmed in control studies, prior to viloxazine by pulse
labelling the myocardium with 1-H^-noradrenaline. Viloxazine (5
and 25 mg/kg) reduced myocardial extraction of ^noradrenaline
across both I and NI but the percentage reduction was significantly
greater across NI (45 + 8 per cent) than across I (20 + 4 per
cent), despite enhanced extraction of [NA] across I before
viloxazine. Prelabelling studies with desmethylimipramine showed a
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similar trend. The incidence of spontaneous ventricular
fibrillation increased from 22 to 44 per cent after viloxazine. In
individual experiments, differential reduction in [NA] extraction
across I and NI increased the incidence of spontaneous arrhythmias.
These observations on the effects of yohimbine,
desmethylimipramine and viloxazine show that presynaptic mechanisms
(reuptake and alpha-adrenoceptor negative feedback) are important
and are active in controlling [NA] release from acutely ischaemic
myocardium at the time of onset of early ventricular arrhythmias.
Local neuronal [NA] reuptake is seen to be enhanced in acute
ischaemia and this, combined with alpha-adrenoceptor mediated
negative feedback limits [NA] release from the heart. Blockade of
both processes is necessary to unmask spontaneous release of [NA]
from the heart following LAD occlusion. This occurs although the
activity of neuronal reuptake blocking drugs, as indicated above
may be limited in ischaemic myocardium. While extraction of [A] is
enhanced across the ischaemic area, probably secondary to a
flow-dependent increase in extraneuronal uptake, extraction of [A]
is abolished during early coronary reperfusion. Post-synaptic
alpha-adrenoceptor mediated coronary vasoconstriction may limit
collateral coronary perfusion to the ischaemic area and is
potentiated by alpha^-adrenoceptor antagonism and reuptake
blockade. Spontaneous ventricular arrhythmias, and spontaneous and
nerve stimulated epicardial activation abnormalities are increased
by all the drugs studied, singly and in combination, in parallel
with their potentiation of catecholamine output from the heart.
Furthermore, heterogeneity of activation delays within the
ischaemic area is increased.
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The effects of intracoronary infusion (LAD) of potassium and
adenosine, both vasoactive and neurogenically active metabolites
known to accumulate in ischaemic myocardium, have been assessed by
measurement of [NA] release and changes in blood pressure and
coronary blood flow during graded sympathetic stimulation.
Potassium infusion produced biphasic effects on nerve stimulated
regional [NA] release from the heart. At low dose infusions, [NA]
release during ansa stimulation was inhibited (peak release at 20
Hz 10.2 +2.6 pmol/ml control and 2.9 + 1.8 pmol/ml with 10 mM
KC1; p < 0.01), while at high dose, release during ansa stimulation
was potentiated (peak release at 20 Hz 13.3 + 2.7 pmol/ml with 75
mM KC1; p < 0.05). Potassium concentrations in the local coronary
venous effluent increased from 3.6 to 9.4 mmol/1 during the highest
infusion rate. [NA] release from and potassium content of the
circumflex coronary territory did not change with the LAD infusion.
High dose potassium infusion did not increase coronary vascular
resistance in the LAD territory but in that territory was
associated with a 25 + 10 per cent increase in coronary vascular
resistance during maximal ansa stimulation.
Intracoronary adenosine caused progressive local coronary
vasodilatation and fall in coronary vascular resistance. At high
—3 —2
dose (10 and 10 M), adenosine potentiated basal release of [NA]
from the heart but inhibited release during maximal ansa
stimulation. The changes normally seen in local blood flow and
coronary vascular resistance during ansa stimulation were not
modified by adenosine, despite major alteration in basal coronary
vascular tone.
Thus, both these metabolites of myocardial ischaemia are
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theoretically capable
heart in vivo and may
[NA] release at nerve
of modifying nenrosympathetic activity in
act diversely as metabolic determinants
terminals during acute ischaemia.
the
of
Intravenous pindolol (0.45 mg/kg), a beta-adrenoceptor
antagonist with partial agonist activity, reduced [NA] release from
NI during maximal ansa stimulation but did not modify release from
I during a twelve minute period of LAD occlusion and reperfusion.
[A] extraction across the heart was unchanged. Following a
reduction in heart rate of 32+6 beats per minute with pindolol,
LAD occlusion was associated with reduced lactate production from
I, reduction in blood flow to I and NI, an increase in the
endo-epicardial blood flow ratio in the central ischaemic area, and
a reduction in regional blood flow variance in the border and
central ischaemic areas. Epicardial activation abnormalities in I,
responses to ansa stimulation and the frequency of spontaneous
ventricular fibrillation were also reduced by pindolol. In a
separate series in which heart rate was held constant by atrial
pacing, pindolol did not modify lactate production, the
endo-epicardial blood flow ratio, basal activation delays or
spontaneous arrhythmias, compared to a control occlusion. Blood
flow variance within the border and central ischaemic areas was,
however, reduced.
Thus, the beneficial actions of pindolol on metabolic,
haemodynamic and electrophysiological parameters during acute
ischaemia depend principally on reduction in heart rate, primarily
an anti-ischaemic rather than an anti-arrhythmic effect.
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Reductions in regional variability in blood flow may, however,
provide additional protection against re-entrant arrhythmias,
although the contribution of partial agonist acitivty to this
action remains uncertain.
Adrenergic receptor modification has been recognised as an
important mechanism of altered sympathetic responsiveness in
several disease states, although changes in receptor binding in
ischaemia have not been systematically investigated. A high
affinity, high specific activity radioligand,
I^^-Iodohydroxybenzylpindol ol (I^-^^-IHYP), was used to assess
beta-adrenoceptor populations in rat myocardium in vitro and in dog
myocardium in vivo.
During validation studies using a rat heart crude heart
membrane preparation, it was found that at low concentrations of
jl25-IHYP (below 100 pM), variable and unexpected reduction in
specific binding of this radioligand ccurred, suggesting positive
cooperativity between receptor sites. The reduction in specific
binding paralleled the competition from catecholamines predicted
from direct measurement of the concentrations of these in the
membrane fraction. Following depletion of endogenous
catecholamines by in vivo and in vitro techniques, a simple
receptor population of uniform affinity was demonstrated. At low
ligand concentrations, therefore, endogenous hormones may interfere
with receptor analysis and suggest false receptor site
int e ractions.
In vivo beta-adrenoceptor labelling with tracer doses of
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-IEYP, subsequent washout of free ligand by coronarji- perfusion
and separate determination of non-specific binding after receptor
saturation with 1-propranolol was validated and applied to assess
regional changes in radioligand binding after 30 minutes coronary
occlusion in the open chest anaesthetised dog. High non-specific
binding and uncontrolled ligand washout limited considerably the
sensitivity of the technique. Nonetheless, small increases in
1 9 S
specific IAiJ-IHYP binding to endocardium from the central
ischaemic area were observed, with greater variability in ligand
binding at this site. Unfortunately, despite promising in vitro
results with (-) I^"*-Iodopindolol (I^^-IP), an isomer with,
i 25
apparently, less non-specific binding than I -IHYP, in vivo
studies with I^^-IP did not allow direct labelling of the heart
with this ligand. The possible reasons for this and potential
applicability of the technique to define receptor and
neurotransmitter activity in the heart have been discussed.
These studies indicate the important role of catecholamines in
acute myocardial ischaemia at the time of spontaneous ventricular
arrhythmias. The release of these catecholamines is determined by
complex interactions at sympathetic nerve terminals. The
neuro—effector junction is modified by changes in neuronal
reuptake, local feedback mechanisms, release of ischaemic
metabolites from the myocardium, changes in regional coronary blood
flow and post synaptic adrenoceptor activity. Difficult although
these studies are, models of this type show promise of gradually
elucidating the multifactorial determinants of ventricular
fibrillation during acute myocardial ischaemia, a prerequisite for
the rational application of therapeutic measures to prevent sudden
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